Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
CONF IDENT IAL  AND  PROPR IETARY ,  UN ITED  THERAPEUT ICS  
CORPORAT ION 
A l l  c o n t e n t  c o n t a in e d  h e r e in  i s  c o n f id e n t i a l  a n d  p r o p r i e t a ry  in fo rm a t io n  o f  U n i t e d  
Th e r a p e u t i c s  C o rp o r a t io n  a n d  s h a l l  n o t  b e  d i s c lo s e d  in  w h o l e  o r  in  p a r t  e x c e p t  a s  p e rm i t t e d  b y  
a  s ig n e d  c o n t r a c t  w i th  U n i t e d  Th e r a p e u t i c s  C o rp o r a t io n .  ©  2 0 1 9  U n i t e d  Th e r a p e u t i c s  
C o rp o r a t io n  
 Pa g e  1   
S tudy  P r o to c o l  
Numb e r : APD 8 1 1- 0 0 7  
S tudy  T i t l e : A n  O p e n- l a b e l  Ex t e n s io n  S tu d y  o f  APD 8 1 1 - 0 0 3  in  P a t i e n t s  w i th  
Pu lmo n a ry  A r t e r i a l  H y p e r t e n s io n 
S tudy  Pha s e : 2  
P r odu c t  N am e : R a l in e p a g  (APD 8 1 1 ) 
IND  Numb e r :  1 0 9 0 2 1  
Ind i c a t ion :  Pu lmo n a ry  A r t e r i a l  H y p e r t e n s io n 
Inv e s t ig a to r s :  M u l t i c e n t e r 
Spon s o r : U n i t e d  Th e r a p e u t i c s  C o rp o r a t io n   
Spon s o r  C on ta c t : U n i t e d  Th e r a p e u t i c s  C o rp o r a t io n   
5 5  T .W .  A l e x a n d e r  D r iv e   
R e s e a r c h  T r i a n g l e  P a rk ,  NC  2 7 7 0 9 
USA 
 
 
 
 D a t e 
O r ig ina l P r o to c o l:  1 7  J u n e  2 0 1 4  
Am endm en t  0 1 : 1 5  A u g u s t  2 0 1 4  
Am endm en t  0 2:  0 9  O c to b e r  2 0 1 7  
Am endm en t  0 3:  0 4  J u n  2 0 1 8  
Am endm en t  0 4 : 1 5  M a y 2 0 1 9  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  2  L IST  OF  CONTACTS  FOR  THE  STUDY 
C on t r a c t  R e s e a r ch  
O r g an i z a t ion s  
  
 
 
 
S tudy  Spon so r  Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion 5 5  TW  A l e x a n d e r  D r  R e s e a r c h  T r i a n g l e  P a r k ,  NC  2 7 7 0 9   USA 
SAE  R ep o r t ing Un i t ed  Th e r ap eu t i c s  G loba l  D rug  Sa f e t y 
G lo b a l  F a x   
em a i l :    
 
C l in i c a l  Labo r a t o r y  
 
 
 
ECG   
 
 
 
 
 
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  3  INVEST IGATOR ’S  AGREEMENT 
I  h a v e  r e a d  th e  a t t a c h e d  p ro to c o l  e n t i t l e d  “A n  O p e n - l a b e l  Ex t e n s io n  S tu d y  o f  APD 8 1 1 - 0 0 3  in  
P a t i e n t s  w i th  Pu lmo n a ry  A r t e r i a l  H y p e r t e n s io n ”  Am e n dm e n t  4  d a t e d  1 5  M a y 2 0 1 9 ,  a n d  a g r e e  
to  a b id e  b y  a l l  p ro v i s io n s  s e t  fo r th  th e r e in .  
I  a g r e e  to  c omp ly  w i th  th e  In t e rn a t io n a l  C o u n c i l  fo r  H a rmo n i s a t io n  G u id e l in e  fo r  G o o d  
C l in i c a l  P r a c t i c e  a n d  a p p l i c a b l e  Fo o d  a n d  D ru g  A dm in i s t r a t io n  r e g u l a t io n s /g u id e l in e s  s e t  
fo r th  in  2 1  C o d e  o f  F e d e r a l  R e g u l a t io n s  P a r t s  5 0 ,  5 4 ,  5 6 ,  a n d  3 1 2  a n d  lo c a l  r e g u l a t io n s  p e r  
c o u n t ry .  
I  a g r e e  to  e n s u r e  th a t  th e  c o n f id e n t i a l  in fo rm a t io n  c o n t a in e d  in  th i s  d o c um e n t  w i l l  n o t  b e  u s e d  
fo r  a n y  p u rp o s e  o th e r  th a n  th e  e v a lu a t io n  o r  c o n d u c t  o f  th e  c l in i c a l  in v e s t ig a t io n  w i th o u t  th e  
p r io r  w r i t t e n  c o n s e n t  o f  U n i t e d  Th e r a p e u t i c s  C o rp o r a t io n .  
I  a l s o  h a v e  r e a d  th e  c u r r e n t  In v e s t ig a to r ’ s  B ro c h u r e  fo r  r a l in e p a g  a n d  a c k n ow l e d g e  th a t  
r e v i ew  o f  th e  in fo rm a t io n  c o n t a in e d  in  th e  In v e s t ig a to r ’ s  B ro c h u r e  i s  a  r e q u i r em e n t  fo r  In v e s t ig a to r s  b e fo r e  u s in g  r a l in e p a g  in  a  c l in i c a l  s t u d y .  
Th i s  p ro to c o l  h a s  b e e n  r e c e iv e d  fo r  in fo rm a t io n  o n ly  a n d  mu s t  n o t  b e  imp l em e n t e d  b e fo r e  a l l  
n e c e s s a ry  r e g u l a to ry  a g e n c y  a n d  e th i c s  a p p ro v a l  d o c um e n t s  h a v e  b e e n  o b t a in e d .  
 
   
S ig n a tu r e  o f  P r in c ip a l  I n v e s t ig a to r  D a t e 
   
   
P r in t e d  N am e  o f  P r in c ip a l  I n v e s t ig a to r   
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  5  Ob j e c t iv e s : P r ima r y : 
To  e v a lu a t e  th e  lo n g- t e rm  s a f e ty  a n d  to l e r a b i l i ty  o f  r a l in e p a g  in  
s u b j e c t s  w i th  W o r ld  H e a l th  O rg a n i z a t io n  (WHO )  G ro u p  1  
p u lmo n a ry  a r t e r i a l  h y p e r t e n s io n  (PAH )  w h o  h a v e  c omp l e t e d  S tu d y  
APD 8 1 1- 0 0 3 .  
S e c onda r y : To  e v a lu a t e  th e  e f f e c t  o f  r a l in e p a g  in  s u b j e c t s  w i th  WHO  G ro u p  1  
PAH  w h o  c omp l e t e d  S tu d y APD 8 1 1- 0 0 3 ,  a s  d e t e rm in e d  b y  th e  in c id e n c e  o f  c l in i c a l  w o r s e n in g .   C l in i c a l  wo r s e n in g  i s  d e f in e d  a s  
fu l f i l lm e n t  o f  a n y  1  o f  th e  fo l low in g  c r i t e r i a  ( a s  a s s e s s e d  b y  c h a n g e  f rom  b a s e l in e  in  S tu d y  APD 8 1 1 - 0 0 3 ) :  
•  D e a th ,  o r  o n s e t  o f  t r e a tm e n t- em e rg e n t  a d v e r s e  e v e n t  ( AE)  
w i th  a  f a t a l  o u t c om e  o c c u r r in g  l e s s  th a n  o r  e q u a l  t o  1 4  d a y s  
a f t e r  s tu d y  t r e a tm e n t  d i s c o n t in u a t io n  
•  H o s p i t a l i z a t io n  fo r  w o r s e n in g  PAH ,  h e a r t- lu n g  o r  l u n g  
t r a n s p l a n t ,  o r  a t r i a l  s e p to s tomy  
•  Th e  s u b j e c t r e q u i r e s  th e  a d d i t io n  (o r  c h a n g e  in  d o s e  i f  
a p p l i c a b l e )  o f  a n y  o f  th e  fo l low in g  PAH - s p e c i f i c  
m e d i c a t io n s : 
•  P ro s t a c y c l in /p ro s t a c y c l in  a n a lo g u e  ( in t r a v e n o u s [ IV ] ,  
s u b c u t a n e o u s  [SC ] ,  o r a l ,  o r  in h a l e d )   
•  Ph o s p h o d i e s t e r a s e  ty p e 5  in h ib i to r (PDE5 - I )  
•  So lu b l e  g u a n yl a t e  c y c l a s e  s t imu l a to r  ( sGC )  
•  En d o th e l in  r e c e p to r  a n t a g o n i s t 
•  Th e  c omb in e d  o c c u r r e n c e  o f  th e  e v e n t s  l i s t e d  b e low:   
•  A  d e c r e a s e  in  6 - M in u t e  W a lk  D i s t a n c e  (6MW D )  b y  a t  
l e a s t  2 0%  f rom  b a s e l in e ,  c o n f i rm e d  o n  tw o  6 -M in u t e  
Wa lk  Te s t s  (6 MWT s) ,  o n  d i f f e r e n t  d a y s  
•  In c r e a s e  (w o r s e n in g )  in  WHO / N ew  Y o rk  H e a r t  
A s s o c i a t io n  (NYHA)  Fu n c t io n a l  C l a s s  (FC)  f rom  
b a s e l in e  
•  A p p e a r a n c e  o f  o r  w o r s e n in g  o f  s ig n s / s ymp tom s  o f  r ig h t  
h e a r t  f a i lu r e  th a t  d id  n o t  r e s p o n d  to  o p t im i z e d  o r a l  
d iu r e t i c  th e r a p y .  
In  c a s e s  o f  c l in i c a l  d e t e r io r a t io n ,  th e  In v e s t ig a to r  mu s t  a s s e s s  c a r e fu l ly  i f  th e  d e t e r io r a t io n  o f  th e  s u b j e c t ’ s  c o n d i t io n  ( e g ,  
w o r s e n in g  FC)  i s  r e l a t e d  to  th e  u n d e r ly in g  PAH o r  c a n  b e  
e x p l a in e d  b y  a n  a l t e rn a t iv e  c a u s e  ( e g ,  t r a n s i e n t  in f e c t io n ,  
mu s c u lo s k e l e t a l  d i s e a s e ,  s u rg i c a l  o r  m e d i c a l  in t e rv e n t io n  o th e r  th a n  
p u lmo n a ry  h y p e r t e n s io n  (PH)  r e l a t e d ,  e x a c e rb a t io n  o f  a  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  6  c o n c om i t a n t  lu n g  d i s e a s e ,  l a c k in g  c omp l i a n c e  o f  m e d i c a t io n  
in t a k e ) .   O n ly  p e r s i s t e n t  c l in i c a l  d e t e r io r a t io n s  c a u s e d  b y  th e  
u n d e r ly in g  PAH a n d  c o n f i rm e d  a s  p e r  th e  a b o v e  c r i t e r i a ,  w i l l  b e  
c o n s id e r e d  c l in i c a l  w o r s e n in g .  
In  s u b j e c t s  w i th  WHO  G ro u p  1  PAH  w h o  h a v e  c omp l e t e d  S tu d y  
APD 8 1 1- 0 0 3 ,  to  e v a lu a t e  c h a n g e s  f rom  B a s el in e  fo r  th e  fo l low in g  e f f i c a c y  e n d p o in t s  w i th  r a l in e p a g  t r e a tm e n t  
•  6 MWD 
•  WHO /NYHA  FC •  H emo d y n am i c s  
S tudy  D e s ign : Th i s  p ro to c o l  d e s c r ib e s  a n  o p e n- l a b e l  e x t e n s io n  s tu d y  to  d e t e rm in e  
th e  lo n g - t e rm  s a f e ty  a n d  to l e r a b i l i ty  o f  r a l in e p a g  in  s u b j e c t s  w i th  
WHO  G ro u p 1  PAH  w h o  h a v e  c omp l e t e d  th e  Ph a s e  2  s tu d y ,  
APD 8 1 1- 0 0 3 .   Su b j e c ts  mu s t  h a v e  c omp l e t e d  S tu d y APD 8 1 1- 0 0 3  
a n d  mu s t  m e e t  e l ig ib i l i ty  c r i t e r i a  fo r  S tu d y  APD 8 1 1- 0 0 7 .   
A d d i t io n a l ly ,  p l a c e b o- t r e a t e d  s u b j e c t s  w h o  d i s c o n t in u e  r a l in e p a g  
t r e a tm e n t  d u e  to  c l in i c a l  w o r s e n in g  in  S tu d y  APD 8 1 1- 0 0 3  w i l l  b e  
p e rm i t t e d  to  e n ro l l  in  S tu d y  APD 8 1 1- 0 0 7  u p o n  a p p ro v a l  o f  th e  
m e d i c a l  mo n i to r ,  p ro v id e d  th a t  a l l  En d  o f  Stu d y  p r o c e d u r e s ,  
in c lu d in g  r ig h t  h e a r t  c a th e t e r i z a t io n  (RHC ) ,  a r e  p e r fo rm e d  p e r  
p ro to c o l .  
Th e  W e e k  2 5  Vi s i t  in  Stu d y  APD 8 1 1 - 0 0 3  w i l l  s e rv e  a s  th e  Ba s e l in e  
Vi s i t  fo r  S tu d y  APD 8 1 1- 0 0 7 .   I f  t h e  W e e k  2 5  Vi s i t  fo r  S tu d y  
APD 8 1 1- 0 0 3  s e rv e s  a s  th e  in i t i a l  v i s i t  fo r  S tu d y  APD 8 1 1 - 0 0 7 ,  
s u b j e c t s  s h o u ld  b e  c o n s e n t e d  fo r  S tu d y  APD 8 1 1- 0 0 7  p r io r  to  th e  f in a l  p ro c e d u r e s  b e in g  p e r fo rm e d  fo r  S tu d y  APD 8 1 1- 0 0 3 .  
A l l  s u b j e c t s  e n ro l l e d  in  S tu d y  APD 8 1 1- 0 0 7  w i l l  r e c e iv e  o p e n - l a b e l  
t r e a tm e n t  w i th  r a l in e p a g .   Th e  s t a r t in g  d o s e  a n d  t i t r a t io n  s c h e d u l e  
w i l l  b e  in d iv id u a l ly  d e t e rm in e d  a n d  in  a c c o rd a n c e  w i th  th e  s t a r t in g  
d o s e  a n d  t i t r a t io n  s c h e d u l e  o p t im i z e d  f rom  S tu d y  APD 8 1 1- 0 0 3 .   
A d ju s tm e n t s  in  th e  d o s e  a n d  t i t r a t io n  s c h e d u l e  m a y  b e  m a d e  a c c o rd in g  to  s u b j e c t  to l e r a b i l i ty .  
A f t e r  a n  in d iv id u a l  s u b j e c t  c omp l e t e s  Stu d y  APD 8 1 1 - 0 0 3  a n d  th a t  
s u b j e c t ’ s  d a t a b a s e  i s  lo c k e d ,  s u b j e c t  u n b l in d in g  w i l l  o c c u r.   
Su b j e c ts  o n  a c t iv e  t r e a tm e n t  ( r a l in e p a g )  w i l l  r em a i n  o n  c u r r e n t  d o s e  
a n d  h a v e  o n s i t e  c l in i c a l  a s s e s sm e n t s  p e r fo rm e d  e v e ry  3  mo n th s  
u n t i l  th e  s u b j e c t  i s  d i s c o n t in u e d  f rom  th e  s tu d y .  
Su b j e c ts  in  th e  p l a c e b o  t r e a tm e n t  g ro u p  w i l l  u n d e r g o  a  Do s e  
Ti t r a t io n  Pe r io d  u n t i l  a  s t a b l e ,  m a x imum  to l e r a t e d  d o s e  (MTD )  i s  
r e a c h e d  (u p  to  9  w e e k s ) ,  fo l low e d  b y  a  Tr e a tm e n t  Pe r io d  a f t e r  th e  
MTD  is  d e t e rm in e d ,  d u r in g  w h i c h  mo n th ly  o n s i t e  c l in i c  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  7  a s s e s sm e n t s  w i l l  b e  p e r fo rm e d  fo r  th e  f i r s t  3  mo n t h s  a n d  th e n  e v e ry  
3  mo n th s  u n t i l  th e  s u b j e c t  i s  d i s c o n t in u e d  f rom  th e  s tu d y  o r  th e  s tu d y  i s  t e rm in a t e d .   
D i s c o n t in u a t io n  o f  th e  s tu d y  m a y  a l s o  o c c u r  a t  th e  Sp o n s o r ’ s  
d e c i s io n  to  t e rm in a t e  th e  s tu d y .   D o s e  r e d u c t io n s  m a y  b e  m a d e  a t  
a n y  t im e  fo r  s a f e ty  r e a s o n s .  
In c r em e n t a l  d o s e  in c r e a s e s  w i l l  a l s o  b e  a l low e d  d u r in g  th e  
T r e a tm e n t  P e r io d  a t  th e  d i s c r e t io n  o f  th e  In v e s t ig a to r  ( a s  c l in i c a l ly  
in d i c a t e d )  a n d  a c c o rd in g  to  th e  s t e pw i s e  t i t r a t io n  s c h em e .  
Su b j e c ts  w i l l  b e  a s s e s s e d  fo r  c l in i c a l  w o r s e n in g  d u r in g  e a c h  c l in i c  
v i s i t.   I f  c l in i c a l  w o r s e n in g  i s  c o n f i rm e d ,  th e  In v e s t ig a to r  m a y  o p t  
to  e i th e r  c o n t in u e  t r e a tm e n t  w i th  r a l in e p a g  a t  th e  c u r r e n t  d o s e ,  
in c r e a s e  th e  d o s e  o f  r a l in e p a g ,  in t e r ru p t  t r e a tm e n t ,  o r  d i s c o n t in u e  th e  s u b j e c t  a t  h i s /h e r  d i s c r e t io n .  
In  a d d i t io n ,  a l l  s u b j e c t s  w i l l  b e  c o n t a c t e d  a t  th e  t im e  o f  S tu d y  
APD 8 1 1- 0 0 7  c lo s u r e  to  a s s e s s  v i t a l  (mo r t a l i ty )  s t a tu s .   Th e  v i t a l  
s t a tu s  fo l low - u p  c o n t a c t  o f  s u b j e c t s  w i l l  d e p e n d  o n  lo c a l  r e g u l a t io n s  o r  s p e c i f i c  a g r e em e n t  w i th  th e  s u b j e c t  a n d  In v e s t ig a to r .  
A f t e r  th e  l a s t  s u b j e c t  e n ro l l e d  in  S tu d y  APD 8 1 1- 0 0 7  h a s  c omp l e t e d  
a p p ro x im a t e ly  6  mo n th s  o f  th e  s tu d y ,  a  c umu l a t iv e  a l l- s u b j e c t  d a t a  
a n a ly s i s  w i l l  b e  p e r fo rm e d  fo r  a l l  s u b j e c t s  w h o  e n t e r e d  th e  s tu d y .   
Su b j e c ts  w i l l  c o n t in u e  to  h a v e  v i s i t s  to  th e  c l in i c  e v e ry  3  mo n th s  
in d e f in i t e ly  to  c o l l e c t  d a t a  u n t i l  m a rk e t in g  a p p ro v a l  o f  r a l in e p a g  i s  
g r a n t e d  o r  u n t i l  th e  Sp o n s o r  d i s c o n t inu e s  th e  s tu d y .   A t  th e  t im e  o f  
m a rk e t in g  a p p ro v a l  o r  th e  Sp o n s o r’ s  d e c i s io n  to  d i s c o n t in u e  th e  
s tu d y ,  a l l  o n g o in g  s u b j e c t s  w i l l  c omp l e t e  a n  En d  o f  S tu d y  Vi s i t .   A  
2 8 - d a y  Fo l low - u p  V i s i t  w i l l  b e  c o n d u c t e d  to  e n s u r e  a p p ro p r i a t e  
s u b j e c t  s a f e ty .   Th i s  v i s i t  m ay  b e  c o n d u c t e d  b y  t e l e p h o n e  o r  in  
p e r s o n  b a s e d  u p o n  th e  In v e s t ig a to r ’ s  d i s c r e t io n .  S u b j e c t s  w h o  
r em a in  o n  r a l in e p a g  a t  s tu d y  t e rm in a t io n  a n d  m e e t  a l l  e l ig ib i l i ty  
c r i t e r i a  a r e  e l ig ib l e  to  ro l l  in to  th e  o p e n - l a b e l  e x t e n s io n  s tu d y  (ROR - PH- 3 0 3 ) .  
C o n c om i t a n t  Me d i c a t io n s  
Su b j e c ts  a r e  p e rm i t t e d  o r a l  d i s e a s e - s p e c i f i c  PAH  t h e r a p y  c o n s i s t in g  
o f  a n  ERA  a n d /o r  a  PDE5 - I  o r  sGC  s t imu l a to r ,  b u t  n o t  a l l  3 .   Th e  
o n - s tu d y  a d d i t io n / s u b s t i tu t io n  o f  a n  ERA ,  PDE 5 - I ,  o r  sGC  
s t imu l a to r ,  i f  o n  a  s in g l e  s u c h  a g e n t  a t  B a s e l in e,  o r  d o s a g e  in c r e a s e  
fo r  s u c h  a g e n t s  i s  p e rm i t t e d .   In  a d d i t io n  to  r a l in e p a g ,  s u b j e c t s  c a n  
b e  p r e s c r ib e d  n o  mo r e  th a n  1  a g e n t  f rom  th e  ERA  c l a s s  a n d  1  f rom  
th e  PDE5 - I / sGC  s t imu l a to r  c l a s s  a t  a n y  1  t im e .   Su b s t i tu t io n  a n d  
d o s e  a d ju s tm e n t  w i th in  e a c h  o f  th e s e  c l a s s e s  i s  p e rm i t t e d .   Su b j e c ts  
s h o u ld  b e  e v a lu a t e d  fo r  th e  p r e s e n c e  o f  c l in i c a l  w o r s e n in g  i f  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  8  a d d i t io n a l  th e r a p y  o r  d o s e  a d ju s tm e n t s  o f  c u r r e n t  t h e r a p i e s  a r e  
r e q u i r e d .  
In  a d d i t io n ,  th e  fo l low in g  th e r a p i e s ,  w h i c h  m a y  a f f e c t  PAH ,  a r e  
p e rm i t t e d  a n d  d o s e s  m a y  b e  a d ju s t e d  a s  n e e d e d :  
•  Va s o d i l a to r s  ( in c lu d in g  c a l c ium  c h a n n e l  b lo c k e r s )  
•  D ig o x in  
•  Sp i ro n o l a c to n e  
•  L -A rg in in e  s u p p l em e n t a t io n 
D iu r e t i c s  m a y  b e  d o s e d  a s  c l in i c a l ly  in d i c a t e d  th ro u g h o u t  th e  s tu d y . 
Su b j e c t s  w h o  r e q u i r e  tr e a tm e n t  w i th  a  p ro s t a c y c l in /p ro s t a c y c l in  
a n a lo g u e  ( IV ,  SC,  o r a l ,  o r  in h a l e d ),  e x c e p t  fo r  a c u t e  v a s o d i l a to r  
t e s t in g  d u r in g  c a rd i a c  c a th e t e r i z a t io n ,  w i l l  b e  d i s c o n t in u e d  f rom  th e  s tu d y .   
S tudy  S i t e : M u l t ip l e  c e n t e r s  in  th e  U n i t e d  S t a t e s ,  Eu ro p e ,  a n d  A u s t r a l i a . 
Sub j e c t Popu la t ion :   Su b j e c ts  w i th  WHO  G ro u p  1  PAH  w h o  h a v e  c omp l e t e d  S tu d y  
APD 8 1 1- 0 0 3  a s  p l a n n e d  a n d  w h o  m e e t  e l ig ib i l i ty  c r i t e r i a  fo r  S tu d y  
APD 8 1 1- 0 0 7 .   A d d i t io n a l ly ,  p l a c e b o- t r e a t e d  s u b j e c t s  w h o  
d i s c o n t in u e d  s tu d y  d ru g  t r e a tm e n t  d u e  to  c l in i c a l  w o r s e n in g  in  
S tu d y  APD 8 1 1- 0 0 3  w i l l  b e  p e rm i t t e d  to  e n ro l l  in  S tu d y  
APD 8 1 1- 0 0 7 ,  u p o n  a p p ro v a l  o f  th e  m e d i c a l  mo n i t o r ,  p ro v id e d  th a t  
a l l  En d  o f  Stu d y  p ro c e d u r e s ,  in c lu d in g  RHC,  a r e  p e r fo rm e d  p e r  
p ro to c o l .  
A l l  w om e n ,  r e g a rd l e s s  o f  c h i ld b e a r in g  p o t e n t i a l ,  m u s t  h a v e  a  
n e g a t iv e  s e rum  p r e g n a n c y  t e s t  a t  B a s e l in e.   
M a l e s  a n d  f em a l e s  o f  c h i ld b e a r in g  p o t e n t i a l  mu s t  u s e  a d e q u a t e  
m e a n s  o f  c o n t r a c e p t io n  a n d  mu s t  a g r e e  n o t  to  p a r t i c ip a t e  in  a  
c o n c e p t io n  p ro c e s s  ( i e ,  a c t iv e  a t t emp t  to  b e c om e  p r e g n a n t  o r  to  
imp r e g n a t e ,  s p e rm  d o n a t io n ,  in  v i t ro  f e r t i l i z a t io n )  d u r in g  th e  s tu d y  a n d  fo r  1  mo n th  a f t e r  th e  l a s t  d o s e  o f  s tu d y  d ru g . 
E l ig ib i l i ty : K e y  In c lu s io n  C r i t e r i a:  
•  Ev id e n c e  o f  a  p e r s o n a l ly  s ig n e d  a n d  d a t e d  in fo rm e d  
c o n s e n t  d o c um e n t  
•  I s  w i l l in g  a n d  a b l e  to  c omp ly  w i th  s c h e d u l e d  v i s i t s ,  
t r e a tm e n t  p l a n ,  l a b o r a to ry  t e s t s ,  a n d  o th e r  s tu d y  p r o c e d u r e s  a n d  i s  d e em e d  a n  a p p ro p r i a t e  c a n d id a t e  fo r  p a r t i c i p a t io n  in  a  lo n g - t e rm  e x t e n s io n  s tu d y  a n d  a dm in i s t r a t io n  o f  r a l in e p a g  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  9  •  Fu l f i l l e d  a l l  e l ig ib i l i ty  c r i t e r i a  fo r  S tu d y  APD 8 1 1- 0 0 3  a n d  
c omp l e t e d  th e  s tu d y  a s  p l a n n e d   
•  Su b j e c ts  w h o  d i s c o n t in u e d  fo r  c l in i c a l  w o r s e n in g  i n  S tu d y  
APD 8 1 1- 0 0 3  a n d  w e r e  a s s ig n e d  to  p l a c e b o  a n d  c omp l e t e d  
a l l  En d  o f  Stu d y  p ro c e d u r e s ,  in c lu d in g  RHC ,  m a y  
p a r t i c ip a t e  a f t e r  th e i r  d a t a  f rom  S tu d y  APD 8 1 1- 0 0 3  a r e  
c l e a n e d  a n d  lo c k e d  
K e y  Ex c lu s io n  C r i t e r i a:  
•  Su b j e c ts  w h o  e n ro l l e d  in  S tu d y  APD 8 1 1- 0 0 3  a n d  w e r e  
w i th d r aw n  f rom  s tu d y  d ru g  t r e a tm e n t  d u e  to  a n y  AE ,  
s e r io u s  a d v e r s e  e v e n t  ( SAE) ,  o r  c l in i c a l  w o r s e n in g  i f  
a s s ig n e d  to  r a l in e p a g ,  o r  s u b j e c t s  w h o  d id  n o t  c om p l e t e  S tu d y  APD 8 1 1- 0 0 3  fo r  o th e r  r e a s o n s . 
•  F em a l e  s u b j e c ts  w h o  w i s h  to  b e c om e  p r e g n a n t  
•  Sy s to l i c  b lo o d  p r e s s u r e  < 9 0  mmH g  a t  Ba s e l in e / Da y  1  
•  O th e r  s e v e r e  a c u t e  o r  c h ro n i c  m e d i c a l  o r  l a b o r a to r y  
a b n o rm a l i ty  th a t  m a y  in c r e a s e  th e  r i s k  a s s o c i a t e d  w i th  
s tu d y  p a r t i c ip a t io n  o r  in v e s t ig a t io n a l  p ro d u c t  
a dm in i s t r a t io n  o r  m a y  in t e r f e r e  w i th  th e  in t e r p r e t a t io n  o f  
s tu d y  r e s u l t s  a n d ,  in  th e  ju d gm e n t  o f  th e  In v e s t ig a t o r ,  
w o u ld  m a k e  th e  s u b j e c t  in a p p ro p r i a t e  fo r  e n t ry  in t o  th i s  
s tu d y .  
Du r a t ion  p e r  
Sub j e c t:  T r e a tm e n t  w i th  r a l in e p a g  w i l l  b e  in d e f in i t e  u n t i l  e i th e r  m a rk e t in g  a p p ro v a l  o f  r a l in e p a g  i s  g r a n t e d  o r  th e  Sp o n s o r  d i s c o n t in u e s  th e  s tu d y .   Su b j e c t s  w h o  r em a in  o n  r a l in e p a g  a t  s tu d y  t e rm in a t io n  a n d  
m e e t  a l l  e l ig ib i l i ty  c r i t e r i a  a r e  e l ig ib l e  to  ro l l  in to  t h e  o p e n- l a b e l  e x t e n s io n  s tu d y  (ROR - PH- 3 0 3 ) .  
Sub j e c t A s s ignm en t : A l l  s u b j e c t s  w i l l  r e c e iv e  r a l in e p a g  
Samp l e  S i z e :   A p p ro x im a t e ly  6 0  s u b j e c t s  
P r ima r y  Ou t c om e  
M e a su r e s : Th e  p r im a ry  e n d p o in t  fo r  th e  s tu d y  i s  lo n g - t e rm  s a f e ty .   Th e  s a f e ty  
o f  r a l in e p a g  w i l l  b e  mo n i to r e d  th ro u g h o u t  th e  s tu d y  w i th  s a f e ty  
e n d p o in t s  b e in g  a s  fo l low s :  
•  T r e a tm e n t- em e rg e n t  AE s  u p  to  2 8  d a y s  fo l low in g  
d i s c o n t in u a t io n  o f  th e  s tu d y  d ru g .  
•  T r e a tm e n t- em e rg e n t  SAE s  u p  to  2 8  d a y s  fo l low in g  
d i s c o n t in u a t io n  o f  th e  s tu d y  d ru g .  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  1 0  E f f i c a c y  A s s e s sm en t s : E f f i c a c y  w i l l  b e  a s s e s s e d  v i a  p e r fo rm a n c e  o f  th e  fo l low in g  
p ro c e d u r e s :  
•  6MWT 
•  WHO /NYHA  FC  a s s e s sm e n t 
•  A s s e s sm e n t  o f  c l in i c a l  w o r s e n in g  
•  V i t a l  s t a tu s 
•  RHC  
E f f i c a c y  Endpo in t s : A s s e s sm e n t  o f  t im e  to  c l in i c a l  w o r s e n in g  a n d  c h a n g e  f rom  b a s e l in e  
in  S tu d y  APD 8 1 1 - 0 0 3  o f  th e  fo l low in g :  
•  6 MWD 
•  WHO /NYHA  FC 
•  H emo d y n am i c s  
Sa f e ty  A s s e s sm en t s : •  C l in i c a l  l a b o r a to ry  t e s t s  ( to  in c lu d e  h em a to lo g y ,  
c o a g u l a t io n  p a r am e t e r s ,  s e rum  c h em i s t ry ,  a n d  u r in a l y s i s )   
•  V i t a l  s ig n s •  Ph y s i c a l  e x am in a t io n s 
•  1 2 - l e a d  e l e c t ro c a rd io g r am s  (ECG s )  •  AEs  
D a ta  Ana ly s e s : L o n g -t e rm  s a f e ty  a n d  to l e r a b i l i ty  o f  r a l in e p a g  w i l l  b e  a s s e s s e d  b y  
c l in i c a l  a n d  s t a t i s t i c a l  r e v i ew  o f  a l l  r e l e v a n t  s a f e ty  p a r am e t e r s ,  
in c lu d in g  AEs ,  l a b o r a to ry  v a lu e s ,  v i t a l  s ig n s ,  a n d  ECG s .   A l l  
s u b j e c t s  w h o  r e c e iv e d  a t  l e a s t  1  d o s e  o f  r a l in e p a g  i n  th i s  e x t e n s io n  
s tu d y  w i l l  b e  in c lu d e d  in  th e  s a f e ty  a s s e s sm e n t .  
Th e  t im e  to  c l in i c a l  w o r s e n in g  w i l l  b e  s umm a r i z e d.   E s t im a t io n  a n d  
9 5%  c o n f id e n c e  in t e rv a l s  fo r  w i th in - t r e a tm e n t  c h a n g e  f rom  
b a s e l in e  in  6MWD  a n d  WHO /NYHA  FC  a s s e s sm e n t  w i l l  a l s o  b e  
p e r fo rm e d .   B a s e l in e  i s  d e f in e d  a s  th e  D a y  1  p r e- d o s e  m e a s u r eme n t  
f rom  S tu d y  APD 8 1 1 - 0 0 3 .   A  s e c o n d a ry  a n a ly s i s  u s in g  a  d e f in i t io n  
o f  B a s e l in e a s  D a y  1  o f  S tu d y  APD 8 1 1 - 0 0 7  w i l l  a l s o  b e  p e r fo rm e d .  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  1 1  TABLE  OF  CONTENTS 
L IST  OF  CONTACTS  FOR  THE  STUDY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2  
INVEST IGATOR ’S  AGREEMENT  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3  
SYNOPS IS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4  
TABLE  OF  CONTENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 1  
L i s t  o f  App end i c e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 4  
T ab l e  o f  In- T e x t  T ab l e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 4  
T ab l e  o f  In- T e x t  F igu r e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 4  
L IST  OF  ABBREVIAT IONS  AND  DEF IN IT IONS  OF  TERMS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 5  
1 INTRODUCT ION  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 7  
1 .1 BACKGROUND  INFORMAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 1  
1 .1 .1 R a t iona l e  fo r  P r opo s ed  C l in i c a l  S tudy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 1  
1 .1 .2 Summa r y  o f  N on c l in i c a l  D a ta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 1  
1 .1 .3 Summa r y  o f  C l in i c a l  D a ta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 2  
1 .2 ETH ICS  AND  REGULATORY  CONS IDERAT IONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 6  
2 STUDY  OB JECT IVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 7  
2 .1 PR IMARY  OB JECT IVE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 7  
2 .2 SECONDARY  OB JECT IVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 7  
3 INVEST IGAT IONAL  PLAN  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 7  
3 .1 OVERALL  STUDY  DES IGN  AND  PLAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 7  
3 .2 RAT IONALE  FOR  STUDY  DES IGN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 0  
4 STUDY  POPULAT ION  SELECT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 5  
4 .1 STUDY  POPULAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 5  
4 .2 INCLUS ION  CR ITER IA  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 5  
4 .3 EXCLUS ION  CRITER IA  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 6  
5 STUDY  TREATMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 6  
5 .1 TEST  ART ICLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 6  
5 .2 TREATMENTS  ADM IN ISTERED . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 7  
5 .3 PACKAGING ,  LABEL ING  AND  STORAGE  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 7  
5 .4 TEST  ART ICLE  ACCOUNTAB IL ITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 7  
5 .5 INVEST IGAT IONAL  PRODUCT  RETENT ION  AT  STUDY  S ITE  . . . . . . . . . . . . . . . . . . .  3 8  
5 .6 DOSAGE  AND  ADM IN ISTRAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 8  
5 .6 .1 Imm ed ia t e - r e l e a s e  C ap su l e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 8  
5 .6 .1 .1 D o s e  T i t r a t ion  P e r iod  (S tudy  APD 8 1 1- 0 0 3  P la c ebo - t r e a t ed  Sub j e c t s )  . . . . . . . . .  3 8  
5 .6 .1 .2 T r e a tm en t  P er iod  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 0  
5 .6 .2 E x t end ed- r e l e a s e  T ab l e t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 1  
5 .6 .2 .1 Fo rmu la t ion  Sw i t ch  and  D o s e  T i t r a t ion  P e r iod . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 1  
5 .6 .2 .2 T r e a tm en t  P e r iod . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 2  
5 .7 METHOD  OF  ASS IGN ING  SUB JECTS  TO  TREATMENT  GROUPS . . . . . . . . . . . . .  4 2  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  1 2  5 .8 RANDOM IZAT ION  AND  BL IND ING . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 2  
6 STUDY  PROCEDURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 2  
6 .1 INFORMED  CONSENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 3  
6 .2 MED ICAL  AND  SOC IAL  H ISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 3  
6 .3 PHYS ICAL  EXAM INAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 3  
6 .4 V ITAL  S IGNS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 3  
6 .5 ELECTROCARD IOGRAPHY  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 4  
6 .5 .1 ECG  Equ ipm en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 4  
6 .5 .2 ECG  A cqu i s i t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 4  
6 .5 .3 ECG  A s s e s sm en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 5  
6 .6 6 -M INUTE  WALK  TEST. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 5  
6 .7 WHO /NYHA  FUNCT IONAL  CLASS  ASSESSMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 6  
6 .8 R IGHT  HEART  CATHETER IZAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 6  
6 .9 ASSESSMENT  OF  CL IN ICAL  WORSEN ING . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 7  
6 .1 0 CL IN ICAL  LABORATORY  TESTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 7  
6 .1 0 .1 L abo r a to r y  Pa r am e t e r s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 8  
6 .1 0 .2 U r ina ly s i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 9  
6 .1 0 .3 Samp l e  C o l l e c t ion ,  S to r a g e ,  and  Sh ipp ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 9  
6 .1 1 BNP /NT- p r oBNP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 9  
6 .1 2 ADVERSE  EVENTS  ASSESSMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 0  
6 .1 2 .1 Adv e r s e  E v en t  R epo r t ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 0  
6 .1 2 .2 S e r iou s  Adv e r s e  E v en t s  and  E xp ed i t ed  R epo r t ing  o f  Adv e r s e  E v en t s . . . . . . . . . . . . .  5 1  
6 .1 2 .3 P r e gnan c y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 2  
6 .1 2 .4 A s s e s sm en t  o f  Adv e r s e  E v en t  S e v e r i ty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 3  
6 .1 2 .5 A s s e s sm en t  o f  Adv e r s e  E v en t  R e la t ion sh ip  to  S tudy  D rug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 3  
6 .1 2 .6 A s s e s sm en t  o f  Adv e r s e  E v en t  Ou t c om e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 4  
6 .1 2 .7 A c t ion  T ak en  fo r  Adv e r s e  E v en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 4  
6 .1 2 .7 .1 A c t ion  T ak en  fo r  S tudy  D rug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 4  
6 .1 2 .8 C o l l e c t ion  o f  E x t r a  L abo r a to r y  Samp l e s / Inv e s t ig a t ion s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 4  
6 .1 2 .9 Fo l low -up  o f  Adv e r s e  E v en t s  P r e s en t  a t  L a s t  S ch edu l ed  S tudy  V i s i t . . . . . . . . . . . . . . .  5 5  
6 .1 3 CONCOM ITANT  MED ICAT ION  ASSESSMENTS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 5  
6 .1 4 REMOVAL  OF  SUB JECTS  FROM  THE  STUDY  OR  STUDY  DRUG . . . . . . . . . . . . . .  5 6  
6 .1 4 .1 Hand l ing  o f  W i thd r aw a l s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 6  
6 .1 5 ALLOWABLE  V IS IT  AND  PROCEDURE  W INDOWS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 7  
7 STUDY  ACT IV IT IES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 7  
7 .1 SCREEN ING  V IS IT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 7  
7 .2 STUDY  PROCEDURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 8  
7 .2 .1 B a s e l in e  S tudy  P r o c edu r e s  –  A l l  Sub j e c t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 8  
7 .2 .1 .1 P r e- ba s e l in e  P r o c edu r e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 8  
7 .2 .1 .2 B a s e l in e  P r o c edu r e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 8  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  1 3  7 .2 .2 S tudy  P r o c edu r e s  –  fo r  Imm ed ia t e - r e l e a s e  D o s e  T i t r a t ion  P e r iod  (S tudy  
APD 8 1 1- 0 0 3  P la c ebo  Sub j e c t s )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 9  
7 .2 .2 .1 P r e- do s e  P r o c edu r e s  fo r  D o s e  T i t r a t ion  P e r iod  V is i t s  (S tudy  APD 8 1 1 -
0 0 3  P la c ebo  Sub j e c t s )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 9  
7 .2 .2 .2 Po s t- do s e  P r o c edu r e s  fo r  D o s e  T i t r a t ion  P e r iod  V i s i t s  (S tudy  APD 8 1 1-
0 0 3  P la c ebo  Sub je c t s )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 0  
7 .2 .3 S tudy  P r o c edu r e s  fo r  th e  T r e a tm en t  P e r iod  –  A l l  Sub j e c t s  (Fo r  B o th  Imm ed ia t e - r e l e a s e  and  E x t end ed - r e l e a s e  Fo rmu la t ion s )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 0
 
7 .2 .3 .1 S tudy  P r o c edu r e s  M 1- M 3  (S tudy  APD 8 1 1- 0 0 3 :  P la c ebo - t r e a t ed  Sub j e c t s )  Q3  M on th s  (S tudy  APD 8 1 1- 0 0 3 :  P la c ebo -  and  R a l in epa g -t r e a t ed  Sub j e c t s ;  Sub j e c t s  who  Sw i t ch ed  to  th e  XR  Fo rmu la t ion )  . . . . . . . . . . . . . . .  6 0
 
7 .2 .3 .2 S tudy  P r o c edu r e s  -  Y e a r  1  o r  Y e a r  2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 0  
7 .2 .3 .3 Sw i t ch  to  XR  R a l in epa g  and  D o s e  T i t r a t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 0  
7 .2 .4 End  o f  S tudy  V i s i t  –  A l l  Sub j e c t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 1  
7 .2 .5 2 8 -da y  Fo l low- up  –  A l l  Sub j e c t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 1  
8 DATA  MANAGEMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 1  
8 .1 DATA  COLLECT ION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 1  
8 .2 DATA  COD ING . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 2  
8 .2 .1 Adv e r s e  E v en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 2  
8 .2 .2 C on c om i tan t  M ed i c a t ion s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 2  
9 PLANNED  STAT IST ICAL  METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 2  
9 .1 ANALYS IS  POPULAT IONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 2  
9 .2 STAT IST ICAL  METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 3  
9 .2 .1 Sa f e ty  Ana ly s i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 3  
9 .2 .1 .1 D emo g r aph i c s  and  B a s e l in e  Cha r a c t e r i s t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 3  
9 .2 .1 .2 Adv e r s e  E v en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 3  
9 .2 .1 .3 Phy s i c a l  E x am ina t ion s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 3  
9 .2 .1 .4 V i ta l  S ign s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 4  
9 .2 .1 .5 C l in i c a l  L abo r a to r y  V a lu e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 4  
9 .2 .1 .6 Sa f e ty  ECG s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 4  
9 .2 .2 S ta t i s t i c a l  Ana ly s e s  o f  E f f i c a c y  M e a su r em en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 4  
1 0 REGULATORY  REQU IREMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 5  
1 0 .1 PRE- STUDY  DOCUMENTAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 5  
1 0 .2 INVES T IGATOR  OBL IGAT IONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 5  
1 0 .3 SUB JECT  CONF IDENT IAL ITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 5  
1 0 .4 INFORMED  CONSENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 6  
1 0 .5 INST ITUT IONAL  REV IEW  BOARD  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 6  
1 1 PROTOCOL  MANAGEMENT  AND  ADM IN ISTRAT IVE  CONS IDERAT IONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 6
 
1 1 .1 STUDY  DOCUMENTAT ION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 6  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  1 4  1 1 .2 PROTOCOL  INTERPRETAT ION  AND  COMPL IANCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 7  
1 1 .3 STUDY  MON ITOR ING . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 7  
1 2 REFERENCE  L IST  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 8  
 
L i s t  o f  App end i c e s 
A p p e n d ix  1 G u id e l in e s  fo r  6- M in u t e  W a lk  T e s t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7 0  
A p p e n d ix  2 Fu n c t io n a l  C l a s s i f i c a t io n  o f  Pu lmo n a ry  H y p e r t e n s i o n  M o d i f i e d  A f t e r  Th e  
N ew  Y o rk  H e a r t  A s s o c i a t io n  Fu n c t io n a l  C l a s s i f i c a t io n  A c c o rd in g  to  th e  WHO  1 9 9 8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7 5
 
 
T ab l e o f  In- T e x t  T ab l e s 
T a b l e 1 S c h e d u l e  o f  P ro c e d u r e s  a n d  V i s i t s :  S tu d y  APD 8 1 1- 0 0 3  Su b j e c t s  T r e a t e d  
w i th  R a l in e p a g  En t e r in g  S tu d y  APD 8 1 1- 0 0 7  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 1  
T a b l e 2 S c h e d u l e  o f  P ro c e d u r e s  a n d  V i s i t s :  S tu d y  APD 8 1 1- 0 0 3  Su b j e c t s  t r e a t e d  w i th  P l a c e b o  e n t e r in g  S tu d y  APD 8 1 1- 0 0 7  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 3
 
T a b l e 3 Po s s ib l e  D o s in g  R e g im e n  d u r in g  9- W e e k  D o s e  T i t r a t io n  P e r io d . . . . . . . . . . . . . . . . . . .  4 0  
T a b l e 4 Po s s ib l e  D o s in g  R e g im e n  d u r in g  th e  T r e a tm e n t  P e r io d. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 1  
T a b l e  5 D o s e  Sw i t c h in g  G u id a n c e  f rom  Imm e d i a t e- r e l e a s e  to  Ex t e n d e d - r e l e a s e  R a l in e p a g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  4 1
 
 
T ab l e o f  In- T e x t  F igu r e s 
F ig u r e  1 Ev id e n c e -b a s e d  T r e a tm e n t  A lg o r i thm  fo r  PAH  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 0  
 
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  1 5  LIST  OF ABBREV IAT IONS AND DEF IN IT IONS OF TERMS 
6MW D  6 -M in u t e  W a lk  d i s t a n c e  
6MWT 6 -M in u t e  W a lk  Te s t  
ADL Ac t iv i t i e s  o f  Da i ly  Liv in g  ADR A d v e r s e  d ru g  r e a c t io n AE Ad v e r s e  e v e n t AUC Ar e a  u n d e r  th e  c u rv e  BP Blo o d  p r e s s u r e  
B ID Tw i c e  d a i ly 
BNP Br a in  n a t r iu r e t i c  p e p t id e  C
m ax Ma x im a l  d ru g  c o n c e n t r a t io n  
CRF Ca s e  R e p o r t  Fo rm  CRO C o n t r a c t  R e s e a r c h  O rg a n i z a t io n EC
50 Me d i a n  e f f e c t iv e  c o n c e n t r a t io n  
ECG El e c t ro c a rd io g r am  ERA En d o th e l in  r e c e p to r  a n t a g o n i s t  FC Fu n c t io n a l  Cl a s s  FDA Fo o d  a n d  D ru g  A dm in i s t r a t io n GCP G o o d  C l in i c a l  P r a c t i c e GLP G o o d  L a b o r a to ry  Pr a c t i c e  
hCG  Hum a n  c h o r io n i c  g o n a d o t ro p in  
hERG  H um a n  E th e r- a - g o - g o - r e l a t e d  g e n e  IC 5 0  H a l f  m a x im a l  in h ib i to ry  c o n c e n t r a t io n  ICF  In fo rm e d  C o n s e n t  F o rm  ICH  In t e rn a t io n a l  C o u n c i l  fo r  H a rmo n i s a t io n  IEC  In d e p e n d e n t  E th i c s  C omm i t t e e  
IP  P ro s t a c y c l in  r e c e p to r 
IR  Imm e d i a t e - r e l e a s e  
IRB  In s t i tu t io n a l  R e v i ew  B o a rd  
IV  In t r a v e n o u s ( ly )  
M e dDRA M e d i c a l  D i c t io n a ry  fo r  R e g u l a to ry  A c t iv i t i e s MTD Ma x imum  to l e r a t e d  d o s e  
NOAEL No - o b s e rv e d- a d v e r s e - e f f e c t  l e v e l  
NT- p roBNP N- T e rm in a l  p ro- b r a in  n a t r iu r e t i c  p e p t id e  NYHA N ew  Y o rk  H e a r t  A s s o c i a t io n 
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  1 6  PAH Pu lmo n a ry  a r t e r i a l  h y p e r t e n s io n  
PAP Pu lmo n a ry  a r t e ry  p r e s s u r e  PCWP Pu lmo n a ry  c a p i l l a ry  w e d g e  p r e s s u r e  PDE5- I  Ph o s p h o d i e s t e r a s e  ty p e  5  in h ib i to r  
PG I
2 Pro s t a g l a n d in  I 2 
PH Pu lmo n a ry  h y p e r t e n s io n  
PK   Ph a rm a c o k in e t i c( s )  PVR Pu lmo n a ry  v a s c u l a r  r e s i s t a n c e  Q 3 Ev e ry  3 QD On c e  d a i ly  
QT cB QT  in t e rv a l  c o r r e c t e d  fo r  B a z e t t ’ s  fo rmu l a 
QT cF QT  in t e rv a l  c o r r e c t e d  fo r  F r id e r i c i a ’ s  fo rmu l a RHC Rig h t  h e a r t  c a th e t e r i z a t io n  RR R e s p i r a to ry  r a t e SAE Se r io u s  a d v e r s e  e v e n t  SC Su b c u t a n e o u s ( ly )  
sGC  So lu b l e  g u a ny l a t e  c y c l a s e  
SOP St a n d a rd  Op e r a t in g  Pro c e d u r e  SVR Sy s t em i c  v a s c u l a r  r e s i s t a n c e TEAE Tr e a tm e n t - em e rg e n t  a d v e r s e  e v e n t  t
m ax Tim e  o f  m a x imum  p l a sm a  c o n c e n t r a t io n 
WHO W o r ld  H e a l th  O rg a n i z a t io n 
XR Ex t e n d e d -r e l e a s e  
 
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  1 7  1  INTRODUCT ION  
R a l in e p a g i s  a n  o r a l ly  a v a i l a b l e  p o t e n t  a n d  s e l e c t iv e ,  n o n p ro s t a n o id ,  p ro s t a g l a n d in  I 2 (PG I2,  
p ro s t a c y c l in ,  IP )  r e c e p to r  a g o n i s t.   Th e  IP  r e c e p to r  i s  a  rh o d o p s in- l ik e  t r a n sm emb r a n e  
s p a n n in g  G  p ro t e in - c o u p l e d  r e c e p to r  w h i c h  i s  e x p r e s s e d  o n  p l a t e l e t s  a n d  o n  th e  smo o th  mu s c l e  c e l l s  o f  s e v e r a l  t i s s u e s,  in c lu d in g  th e  lu n g ,  h e a r t ,  a o r t a ,  l iv e r ,  k id n e y s ,  a n d  b l o o d  v e s s e l s .   A c t iv a t io n  o f  th e  IP  r e c e p to r  r e s u l t s  in  v a s o d i l a t io n  a n d  in h ib i t s  p l a t e l e t  a g g r e g a t io n .
1 
R a l in e p a g i s  b e in g  d e v e lo p e d  to  t r e a t  W o r ld  H e a l th  O rg a n i z a t io n  (WHO )  G ro u p  1  p u lmo n a ry  h y p e r t e n s io n ,  d e s ig n a t e d  a s  p u lmo n a ry  a r t e r i a l  h y p e r t e n s io n  ( PAH) .   E l e v a t e d  p u lmo n a ry  a r t e ry  p r e s s u r e  (PAP )  in  PAH  i s  th o u g h t  to  r e s u l t  f rom  p r im a ry  p a th o lo g i c a l  a l t e r a t io n s  in  p u lmo n a ry  a r t e r io l e s .   PAH  i s  a  r a r e ,  p ro g r e s s iv e  d i s e a s e  c h a r a c t e r i z e d  b y  e l e v a t e d  p u lmo n a ry  
v a s c u l a r  r e s i s t a n c e  (PVR )  th a t  l e a d s  to  r ig h t  v e n t r i c u l a r  f a i lu r e  a n d  u l t im a t e ly  p r em a tu r e  
d e a th .   P r io r  to  th e  d e v e lo pm e n t  o f  e f f e c t iv e  th e r a p i e s  fo r  PAH ,  th e  m e d i a n  s u rv iv a l  o f  s u b j e c t s  w i th  id io p a th i c  PAH  w a s  a p p ro x im a t e ly  2 .8  y e a r s .
2  Th o u g h  th e  m e d i a n  s u rv iv a l  o f  a  
mo r e  r e c e n t ,  l a rg e,  US  c o h o r t  h a s  imp ro v e d  to  a p p ro x im a t e ly  7  y e a r s3 f rom  t im e  o f  d i a g n o s i s ,  
PAH  r em a in s  a  s e v e r e ,  o f t e n  f a t a l  c o n d i t io n.   Pu lm o n a ry  a r t e r i a l  h y p e r t e n s io n  i s  a s s o c i a t e d  w i th  a l t e r a t io n s  in  p ro s t a c y c lin  a n d  th romb o x a n e  A
2 a c t iv i ty ,  th e  b a l a n c e  o f  w h i c h  p l a y s  a  
m a jo r  ro l e  in  m a in t a in in g  n o rm a l  p u lmo n a ry  v a s c u l a r  to n e .2, 4  P ro s t a c y c l in ,  r e l e a s e d  b y  
e n d o th e l i a l  c e l l s ,  p romo t e s  v a s o d i l a t io n  a n d  in h ib i t s  p l a t e l e t  a g g r e g a t io n  b y  b in d in g  to  G  
p ro t e in - c o u p l e d  r e c e p to r s  o n  n e a rb y  v a s c u l a r  smo o t h  mu s c l e  c e l l s  a n d  p l a t e l e t s .   P ro s t a c y c l in  
a l s o  h a s  a n t ip ro l i f e r a t iv e  e f f e c t s  o n  v a s c u l a r  smo o t h  mu s c l e .   In  d i r e c t  o p p o s i t io n ,  th romb o x a n e  A
2 p romo t e s  v a s o c o n s t r i c t io n  a n d  p l a t e l e t  a g g r e g a t io n .   A n  imb a l a n c e  in  th i s  
h om e o s t a s i s  tow a rd s  v a s o c o n s t r i c t io n ,  in  s i tu  th romb o s i s ,  a n d  r emo d e l in g  o f  th e  sm a l l  
p u lmo n a ry  a r t e r i e s  r e s u l t s  in  p u lmo n a ry  h y p e r t e n s i o n  (PH ) .4, 5 
S tu d i e s  in d i c a t e  th a t  s u b j e c t s  w i th  PH  h a v e  d e c r e a s e d  l e v e l s  o f  p ro s t a c y c l in .4, 6  Ep o p ro s t e n o l ,  
a n  in t r a v e n o u s  ( IV )  p ro s t a n o id  w h i c h  b in d s  to  th e  IP  r e c e p to r ,  i s  th e  o n ly  th e r a p y  to  
d emo n s t r a t e  imp ro v e d  s u rv iv a l  c omp a r e d  to  c o n v e n t io n a l  th e r a p y ,  s u p p o r t in g  u t i l i ty  o f  th e  IP  
r e c e p t o r  a s  a  t a rg e t  fo r  PAH  th e r a p y .7  Ep o p ro s t e n o l  r e q u i r e s  c o n t in u o u s  in fu s io n  th ro u g h  a  
p o r t a b l e  p ump ,  i s  u n s t a b l e  a t  ro om  t emp e r a tu r e ,  a n d  i s  a s s o c i a t e d  w i th  c a th e t e r  r e l a t e d  
in f e c t io n s  a n d  th romb o s i s .   Su b s e q u e n t  fo rm s  o f  p r o s t a n o id s  h a v e  b e e n  d e v e lo p e d  to  a d d r e s s  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  1 8  s om e  o f  th e  l im i t a t io n s  o f  e p o p ro s t e n o l  a n d  h a v e  d emo n s t r a t e d  e f f i c a c y  th ro u g h  imp ro v e d  
e x e r c i s e  c a p a c i ty  a n d /o r  d e l a y  in  c l in i c a l  w o r s e n in g .   
Th e  c l in i c a l  d e f in i t io n  o f  PH  r e q u i r e s  c o n f i rm a t io n  b y  r ig h t  h e a r t  c a th e t e r i z a t io n  (RHC )  
d emo n s t r a t in g  a  m e a n  PAP  > 2 5  mmH g.   Th e  d i a g n o s i s  o f  PAH  r e q u i r e s  a  n o rm a l  (≤ 1 5  
mmH g )  p u lmo n a ry  c a p i l l a ry  w e d g e  p r e s s u r e  (PCWP )  a n d  a n  in c r e a s e  in  PVR  in  a d d i t io n  to  a n  e l e v a t e d  m e a n  PAP .   Th e  l a t e s t  c l in i c a l  c l a s s i f i c a t io n  b y  th e  S ix th  W o r ld  Symp o s ium  o n  Pu lmo n a ry  H y p e r t e n s io n  div id e s  PH in to  5  c a t e g o r i e s  b a s e d  o n  s im i l a r i t i e s  in  c l in i c a l  
p r e s e n t a t io n ,  p a th o g e n e s i s ,  a n d  r e s p o n s e  to  t r e a tm e n t s .
8  PAH  i s  th e  f i r s t  c a t e g o ry  (G ro u p  1 )  
a n d  i s  fu r th e r  d iv id e d  in to  s u b g ro u p s  r e f l e c t in g  a s s o c i a t e d  c o n d i t io n s .   A l l  s u b g ro u p s  in  
G ro u p  1  PH  s h a r e  s im i l a r  c l in i c a l  c h a r a c t e r i s t i c s  a n d  v i r tu a l ly  id e n t i c a l  h i s to p a th o lo g y  in  th e  p u lmo n a ry  a r t e rio l a r  c i r c u l a t io n .   
Th e r e  i s  a  w id e  v a r i a t io n  in  th e  r e p o r t e d  p r e v a l e n c e  o f  PAH ;  1 5 to  5 0  c a s e s /m i l l io n  w i th  a  
h ig h e r  f em a l e  p r e p o n d e r a n c e  (~ 3 :1 ) .
9, 1 0, 11  Th e  r a n g e  in  r e p o r t e d  p r e v a l e n c e  i s  l ik e ly  d u e  to  
th e  d i f f i c u l ty  in  d i a g n o s in g  e a r ly  PAH .   P a t i e nt s  a r e  u s u a l ly  a s ymp tom a t i c  in  th e  e a r l i e s t  s t a g e s  o f  th e  d i s e a s e ,  a n d  p r e s e n t in g  s ymp tom s ,  w h i c h  in c lu d e  e x e r t io n a l  d y s p n e a ,  f a t ig u e ,  
p e r ip h e r a l  e d em a ,  a n d  s y n c o p e ,  c a n  b e  in d i s t in g u i s h a b l e  f rom  o th e r  c a rd io r e s p i r a to ry  
d i s e a s e s .   Th e  m a jo r i ty  o f  p a t i e n t s  a r e  n o t  d i a g n o s e d  u n t i l  th e y  h a v e  d e v e lo p e d  s ymp tom s  o f  WHO  ( mo d i f i c a t io n  o f  th e  N ew  Y o rk  H e a r t  A s s o c i a t io n  [ NYHA]  c l a s s i f i c a t io n  fo r  PH ) Fu n c t io n a l  Cl a s s  (FC )  I I I .  
Th e  c u r r e n t  e v id e n c e- b a s e d  r e c omm e n d e d  t r e a tm e n t  a lg o r i thm  em e rg e d  f rom  th e  F i f th  W o r ld  
Symp o s ium  o n  Pu lmo n a ry  H y p e r t e n s io n
1 2 a n d  i s  s umm a r i z e d  in  F ig u r e  1.   Th e  m a jo r i ty  o f  
p a t i e n t s  w h o  u n d e rg o  a c u t e  v a s o r e a c t iv i ty  t e s t in g  a r e  c l a s s i f i e d  a s  n o n r e s p o n d e r s  a n d  a r e  th e r e fo r e  c a n d id a t e s  fo r  t r e a tm e n t  w i th  a n  e n d o th e l in  r e c e p to r  a n t a g o n i s t  (ERA ) ,  a  
p h o s p h o d i e s t e r a s e  ty p e  5  in h ib i to r  (PDE 5 - I)  o r  a  p ro s t a c y c l in  r e c e p to r  a g o n i s t ,  d e p e n d in g  
u p o n  th e  s e v e r i ty  o f  s ymp tom s .   P a t i e n t s  w i th  in a d e q u a t e  r e s p o n s e  to  in i t i a l  m e d i c a l  th e r a p y  m a y  p ro g r e s s  to  c omb in a t io n  d ru g  th e r a p y  o r  u l t im a t e ly  to  s u rg i c a l  p ro c e d u r e s  th a t  c o u ld  in c lu d e  lu n g  t r a n s p l a n t a t io n .  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  1 9  D u e  to  a v a i l a b i l i ty  o f  o r a l  d o s a g e  fo rm s ,  a lmo s t  a l l  p a t i e n t s  in i t i a t e  th e r a p y  w i th  a n  ERA  o r  a  
PDE5- I .   Th e  r e p o r t  f rom  th e  F i f th  W o r ld  Symp o s ium  o n  Pu lmo n a ry  H y p e r t e n s io n  p o in t s  o u t  th a t  th e  c l in i c a l  ro l e  o f  a g g r e s s iv e  e a r ly  th e r a p y  w i th  p ro s t a c y c l in  r e c e p to r  a g o n i s t s  r em a in s  
u n k n ow n  s in c e  in  r a n d om i z e d  c o n t ro l l e d  s tu d i e s ,  t h e  a v a i l a b l e  a g e n t s  w e r e  e v a lu a t e d  
p r im a r i ly  in  s u b j e c t s  w i th  mo r e  a d v a n c e d  d i s e a s e .   M ul t ip l e  a t t emp t s  a t  d e v e lo p in g  a n  IP  r e c e p to r  a g o n i s t  fo r  o r a l  a dm in i s t r a t io n   h a v e  b e e n  l im i t e d  b y  mo l e c u l e s w i th u n f a v o r a b l e  p h a rm a c o k in e t i c  (PK )  p ro p e r t i e s .   T h u s ,  th e r e  i s  a  n e e d  fo r  a d d i t io n a l  e f f e c t iv e  o r a l a g e n t s  
t a rg e t in g  th e  p ro s t a c y c l in  p a thw ay .  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  2 0  F igu r e 1  E v id en c e- ba s ed  T r e a tm en t  A lg o r i thm  fo r  PAH 
 
Ab b r ev i a t i o n s :  APAH,  a s so c i a t e d  p u lm o n a r y  a r t e r i a l  h y p e r t en s i o n ;  BAS ,  b a l l o o n  a t r i a l  s ep t o s t om y ;  CCB,  c a l c i um  
ch an n e l  b l o ck e r s ;  ERA ,  en d o t h e l i n  r e c e p t o r  an t ag o n i s t ;  FC ,  F u n c t i o n a l  C l a s s;  IPAH ,  i d i o p a t h i c  p u lm o n a r y  a r t e r i a l  
h y p e r t e n s i o n ;  IV ,  i n t r av en o u s ;  PAH ,  p u lm o n a r y  a r t e r i a l  h y p e r t e n s i o n ;  PDE5 - I ,  p h o sp h o d i e s t e r a s e  t y p e - 5  i n h i b i t o r ;  
SC,  s u b cu t an eo u s ;  sGC ,  so l u b l e  g u an y l a t e  cy c l a s e ;  WHO,  Wo r l d  H e a l t h  O r g an i z a t i o n 
S o u r c e :  F i f t h  Wo r l d  S ym p o s i um  o n  P u lm o n a r y  Hy p e r t en s i o n12 
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  2 1  1 .1  BACKGROUND INFORMAT ION  
1 .1 .1 R a t iona l e  fo r  P r opo s ed  C l in i c a l  S tudy 
D e s p i t e  r e c e n t  a d v a n c em e n t s  in  t r e a tm e n t  o p t io n s ,  PAH  r em a in s  a  f a t a l  d i s e a s e  w i th  
a p p ro x im a t e ly  1 5%  mo r t a l i ty  w i th in  1  y e a r1 5 a n d  a  3 - y e a r  s u rv iv a l  r a t e  b e tw e e n  3 5 %  to  7 5%  
d e p e n d in g  o n  PAH  e t io lo g y  a n d  c o - mo rb id  c o n d i t i o n s .4, 15 Th e r e  i s  a  s ign i f i c a n t  n e e d  fo r  
a l t e rn a t iv e  t r e a tm e n t s  fo r  th i s  d i s e a s e .   R a l in e p a g,  a n  o r a l  n o n p ro s t a n o id  IP  r e c e p to r  a g o n i s t ,  c o u ld  b e  a n  e f f e c t iv e  a n d  c o n v e n i e n t  t r e a tm e n t  o p t io n .  
R a l in e p a g h a s  b e e n  c h a r a c t e r i z e d  in  b o th  s in g l e  a n d  mu l t ip l e  d o s e  s tu d i e s  in  a  h e a l th y  
v o lu n t e e r  p o p u l a t io n .   Th e  s a f e ty  p ro f i l e  s u g g e s ts  th a t  d o s e - r e l a t e d  p h a rm a c o lo g y  a t  th e  IP  
r e c e p to r  i s  o c c u r r in g  w i th in th e  d o s e  r a n g e  o f  1 0  to  2 0  m c g ,  w i th  a d v e r s e  e f f e c t s  c o n s i s t e n t  
w i th  th o s e  r e p o r t e d  fo r  IP  r e c e p to r  a g o n i s t s .   Th e  p a th o p h y s io lo g y  o f  PAH  m a y  b e  a s s o c i a t e d  w i th  c h a n g e s  in  p ro s t a c y c l in  r e c e p to r s  w i th in  th e  p u lmo n a ry  v a s c u l a r c i r c u l a t io n ,  a n d  l e a d s  to  d i f f e r in g  r e s p o n s e s  th a n  in  h e a l th y  v o lu n t e e r s .   Th i s  s tu d y  i s  b e in g  u n d e r t a k e n  to  e v a lu a t e  th e  
lo n g - t e rm  s a f e ty  a n d  to l e r a b i l i ty  o f  r a l in e p a g  in  s u b j e c t s  w i th  PAH  w h o  h a v e  c omp l e t e d  th e  
Ph a s e  2  s tu d y ,  APD 8 1 1- 0 0 3 ,  o r  s u b j e c t s  w h o  w e r e  a s s ig n e d  to  p l a c e b o  a n d  w e r e  d i s c o n t in u e d  fo r  c l in i c a l  w o r s e n in g .  
1 .1 .2 Summa r y o f  N on c l in i c a l D a ta 
 
 
 
 
 
 
 
 
 
  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  2 2   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
1 .1 .3 Summa r y o f  C l in i c a l  D a ta  
Th e  s t a r t in g  d o s e  o f  1 0 0  m c g  fo r  th e  f i r s t- in - h u m a n  Stu d y  APD 8 1 1 - 0 0 1  w a s  d e t e rm in e d  in  
a c c o rd a n c e  w i th  Fo o d  a n d  D ru g  A dm in i s t r a t io n  (FDA)  G u id a n c e  fo r  In d u s t ry ,  E s t im a t in g  th e  Ma x im um  S a f e  S ta r t in g  D o s e  in  C l in i c a l  T r ia l s  fo r  Th e r a p e u t i c s  in  Ad u l t  H e a l th y  Vo lu n t e e r s  (2 0 0 5 ) ,  a n d  w a s  b a s e d  o n  th e  mo n k e y  NOAEL  o f  1 0 0  m c g /k g /d a y ,  u s in g  a  s a f e ty  f a c to r  o f  2 0 ,  
a n d  a s s um in g  a  6 0 - k g  h um a n  s u b j e c t . 
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  2 3  In  S tu d y  APD 8 1 1 - 0 0 1 ,  u p  to  9  s in g l e  a s c e n d in g  d o s e  c o h o r t s  o f  8  s u b j e c t s  e a c h  (6  a c t iv e ,  
2  p l a c e b o )  w e r e  p l a n n e d .   Th e  a dm in i s t r a t io n  o f  s i n g l e  d o s e s  o f  3 0 ,  5 0 ,  a n d  1 0 0  m c g  w e r e  g e n e r a l ly  to l e r a t e d  in  h e a l th y  m a l e  a n d  f em a l e  s u b j e c t s .   Th e  a dm in i s t r a t io n  o f  a  s in g l e  d o s e  
o f  2 0 0  m c g  r a l in e p a g  w a s  n o t  w e l l  to l e r a t e d  b y  s u b j e c t s  a n d  r e s u l t e d  in  d i s c o n t in u a t io n  o f  
fu r th e r  d o s e  e s c a l a t io n  in  th e  s tu d y  d u e  to  n a u s e a  a n d  v om i t in g  o f  s e v e r e  in t e n s i ty .   Th e  m a x imum  to l e r a t e d  d o s e  in  th i s  c l in i c a l  s tu d y  w a s  th e r e fo r e  1 0 0  m c g.   Th e  a d v e r s e  e v e n t s ( AE s)  mo s t  c ommo n ly  e x p e r i e n c e d  in c lu d e d  h e a d a c h e ,  v om i t in g ,  n a u s e a,  a n d  j aw  p a in .  
N o  c o n s i s t e n t  e f f e c t s  w e r e  s e e n  o n  b lo o d  p r e s s u r e (BP ) ,  b u t  p u l s e  r a t e  a p p e a r e d  to  in c r e a s e  
mo r e  in  r a l in e p a g  s u b j e c t s  th a n  p l a c e b o  s u b j e c t s  (d e l t a  ~ 1 0  b pm )  a t  th e  3  h ig h e s t  d o s e s .   C o n s e q u e n t ly ,  u n c o r r e c t e d  QT  in t e rv a l  d e c r e a s e d ,  b u t  r a t e  c o r r e c t e d  QT  in t e rv a l  fo r  F r id e r i c i a ’ s  fo rmu l a  (QT cF )  w a s  in c r e a s e d  f rom  b a s e l in e  a t  t im e  o f  m a x imum  p l a sm a  
c o n c e n t r a t io n  ( t
m a x)  i n  n o n d o s e  r e s p o n s iv e  f a s h io n ,  b y  m e a n s  a n d  m e d i a n s  r a n g in g  f rom  3  to  9  
m s e c  a t  th e  2  h ig h e s t  d o s e s .   A n  e f f e c t  o n  QT  in t e r v a l  i s  n o t  s u p p o r t e d  b y  p r e c l in i c a l  f in d in g s  
( h um a n  e th e r- à - g o - g o - r e l a t e d  g e n e  [ hERG ]  c o n c e n t r a t io n  th a t  in h ib i t s  5 0%  [ IC 5 0 ]  > 2 0  µM ,  a n d  n o  e f f e c t  o n  QT c  in  a  p r im a t e  c a rd io v a s c u l a r  s tu d y  a t  3  to  4  tim e s  th e  C
m a x a c h i e v e d  in  th e  
Ph a s e  1  s tu d y ).   N o  d o s e  r e s p o n s e  o n  QT  in t e rv a l  w a s  s e e n ,  a n d  th e  s ig n i f i c a n c e  o f  th e  f in d in g s  in  th i s  l im i t e d  s tu d y  i s  u n c l e a r .  
A  s u b s e q u e n t  mu l t ip l e  a s c e n d in g  d o s e  s tu d y  w a s  c o n d u c t e d  in  h e a l th y  v o lu n t e e r s  (S tu d y  
APD 8 1 1- 0 0 2 ) .   Th e  s a f e ty  a n d  to l e r a b i l i ty  o f  2  d i f f e r e n t  d o s in g  r e g im e n s  w a s  e v a lu a t e d :  a  
o n c e - d a i ly  r e g im e n  in  C o h o r t s  1  a n d  2  ( ru n  c o n c u r r e n t ly )  b e g a n  a t  a n  in i t i a l  d o s e  o f  5 0  m c g  
a n d  w a s  e s c a l a t e d  a s  to l e r a t e d  to  d o s e s  o f  1 0 0 ,  2 0 0 ,  3 0 0 ,  a n d  4 0 0  m c g  a t  5 - d a y  in t e rv a l s ,  a n d  a  tw i c e - d a i ly  r e g im e n  in  C o h o r t  3  b e g a n  a t  a n  in i t i a l  d o s e  o f  1 0  m c g  tw i c e  d a i ly  ( B ID)  a n d  w a s  e s c a l a t e d  a s  to l e r a t e d  to  d o s e s  o f  2 0 ,  3 0 ,  4 0 ,  5 0 ,  a n d  7 0  m c g  B ID a t  5 - d a y  in t e rv a l s .   In  
C o h o r t s  1  a n d  2 ,  a  to t a l  o f  3 0  s u b j e c t s  w e r e  d o s e d ,  w i th  20  s u b j e c t s  r e c e iv in g  r a l in e p a g  a n d  1 0  
s u b j e c t s  r e c e iv in g  p l a c e b o .   In  C o h o r t  3 ,  a  to t a l  o f  2 5  s u b j e c t s  w e r e  d o s e d ,  w i th  2 0  s u b j e c t s  r e c e iv in g  r a l in e p a g  a n d  5  s u b j e c t s  r e c e iv in g  p l a c e b o .  
O v e r a l l  to l e r a b i l i ty  fo r  b o th  d o s in g  r e g im e n s  w a s  s im i l a r ;  w h e n  c omp a rin g  th e  to t a l  d a i ly  d o s e  
t a k e n  b y  s u b j e c t s  fo r  a t  l e a s t  3  c o n s e c u t iv e  d a y s ,  4 0%  o f  s u b j e c t s  to l e r a t e d  a  to t a l  d a i ly  d o s e  
o f  1 0 0  m c g  o r  h ig h e r  w i th  e i th e r  QD o r  B ID r e g im e n s .   Th e  s p e c i f i c  AE s o b s e rv e d  w e r e  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  2 4  s im i l a r  fo r  e a c h  o f  th e  d o s in g  r e g im e n s  a n d  in c lu d e d  h e a d a c h e ,  n a u s e a ,  v om i t in g ,  j aw  p a in ,  
a n d  f lu s h in g ;  n a u s e a  a n d  v om i t in g  o c c u r r e d  mo r e  f r e q u e n t ly  w i th  th e  o n c e - d a i ly  d o s in g  r e g im e n .   Th e  AE s o b s e rv e d  in  th e  s tu d y  w e r e  s im i l a r  to  th e  AE  p ro f i l e  s e e n  w i th  o th e r  IP  
r e c e p to r  a g o n i s t s .   A s  th i s  s tu d y w a s  d e s ig n e d  to  t i t r a t e  to  in d iv id u a l  to l e r a b i l i ty ,  i t  w a s  n o t  
s u rp r i s in g  th a t  th e  m a jo r i ty  o f  AE s fo r  s u b j e c t s  o n  a c t iv e  d ru g  w e r e  mo d e r a t e  in  in t e n s i ty  a n d  w e r e  c o n s id e r e d  b y  th e  In v e s t ig a to r  to  b e  p ro b a b ly  r e l a t e d  to  s tu d y  d ru g . 
O n e  s e r io u s  a d v e r s e  e v en t  (SAE ) ,  t r a n s i e n t  a t r i a l  f i b r i l l a t io n ,  o c c u r r e d  in  a  s in g l e  s u b j e c t  
d u r in g  th e  f i r s t  p o r t io n  o f  th e  s tu d y  a f t e r  r e c e iv in g  5  d a y s  o f  5 0  m c g  QD.   S tu d y  d ru g  w a s  
d i s c o n t in u e d .   Th e  s u b j e c t  w a s  a dm i t t e d  o v e rn ig h t  to  a  h o s p i t a l ,  t r e a t e d  w i th  m e to p ro lo l  a n d  s u b c u t a n e o u s  (SC )  h e p a r in  a n d  s p o n t a n e o u s ly  c o n v e r t e d  to  s in u s  rh y thm.   N o  fu r th e r  e p i s o d e s  o f  a t r i a l  f ib r i l l a t io n  o c c u r r e d  a f t e r  s e v e r a l  a d d i t io n a l  d a y s  o f  mo n i to r in g ,  o r  a f t e r  d i s c h a rg e .   
Th e  In v e s t ig a to r  c o n s id e r e d  th e  e v e n t  to  b e  o f  mo d e r a t e  in t e n s i ty  a n d  p o s s ib ly  r e l a t e d  to  s tu d y  
d ru g .   Th e  s u b j e c t  w a s  s u b s e q u e n t ly  e v a lu a t e d  in  a  c a rd io lo g y  c l in i c ,  w i th  n o  e t io lo g y  id e n t i f i e d  fo r  th e  r e s o lv e d  b o u t  o f  a t r i a l  f ib r i l l a t io n .   
Fo r  a l l  c o h o r t s ,  th e  m a jo r i ty  o f  AEs  e x p e r i e n c e d  b y  s u b j e c t s  in  th e  a c t iv e  t r e a tm e n t  g ro u p  
w e r e  th o s e  th a t  c o d e d  to  th e  Sy s t em  O rg a n  C l a s s e s  N e rv o u s  Sy s t em  D i s o rd e r s ,  
G a s t ro in t e s t in a l  D i s o rd e r s ,  a n d  M u s c u lo s k e l e t a l  a n d  C o n n e c t iv e  T i s s u e  D i s o rd e r s  (M e d i c a l  D i c t io n a ry  fo r  R e g u l a to ry  A c t iv i t i e s  [ M e dDRA]  v .  1 3 .1 ) .   H e a d a c h e ,  n a u s e a ,  p a in  in  j aw ,  a n d  v om i t in g  w e r e  th e  mo s t  c ommo n ly  r e p o r t e d  p r e f e r r e d  t e rm s .   Th e r e  w e r e  n o  d e a th s  r e p o r t e d  
in  th e  s tu d y .  
R a l in e p a g a p p e a r s  to  b e  a s s o c i a t e d  w i th  a  v a s o d i l a to ry  e f f e c t  a t  low e r  d o s e s ,  a n d  r e f l e x  
t a c h y c a rd i a  a t  h ig h e r  d o s e s .   Th e s e  h emo d y n am i c  e f f e c t s w e r e  n o t  l im i t in g  fo r  d o s e  e s c a l a t io n .   Th e s e  o b s e rv a t io n s  a r e  c o n s i s t e n t  w i th  th e  e x p e c t e d  p h a rm a c o lo g y  o f  r a l in e p a g  
a n d  a r e  a l s o  c o n s i s t e n t  w i th  o b s e rv a t io n s  fo r  o th e r  IP  r e c e p to r  a g o n i s t s .  
In t e n s iv e  e l e c t ro c a rd io g r am  ( ECG)  mo n i to r in g  w a s  u n d e r t a k e n  in  th i s  s tu d y  to  b e t t e r  
u n d e r s t a n d  p o s s ib l e  e f f e c t s  o f  r a l in e p a g  o n  QT  in t e rv a l  a n d  to  e v a lu a t e  r i s k  fo r  QT  e f f e c t s .   R a l in e p a g in  th e  d o s e  r a n g e  a dm in i s t e r e d  in  th i s  s t u d y  i s  n o t  l ik e ly  to  b e  a s s o c i a t e d  w i th  QT  
p ro lo n g a t io n .   M ea n  ∆∆QT cF  w a s  b e low  5  m s e c  f o r  p l a sm a  l e v e l s  u p  to  th e  h ig h e s t  l e v e l s  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  2 5  a c h i e v e d ,  a p p ro x im a t e ly  1 0  n g /mL ,  w i th  a n  u p p e r  b o u n d  o f  th e  9 0%  c o n f id e n c e  in t e rv a l  
b e low  1 0  m s e c ,  th e  th r e s h o ld  o f  r e g u l a to ry  c o n c e r n .   
R e s u l t s  o f  th e  PK m e a s u r em e n t s  o f  r a l in e p a g  d em o n s t r a t e  th a t  th e  m e d i a n  t im e  o f m a x imum  
p l a sm a  c o n c e n t r a t io n  ( t m ax)  fo r  r a l in e p a g  w a s  s im i l a r  b e tw e e n  d o s e s  a n d  o c c u r r e d  b e tw e e n  1 .0  
to  1 .5  h o u r s  p o s t - d o s e .   Th e  h a l f- l i f e  o f  r a l in e p a g  w a s  c o n s i s t e n t  a c ro s s  d o s e s  a n d  w a s  
b e tw e e n  2 0 .5  to  2 6 .4  h o u r s .   Th e  a pp a r e n t  o r a l  c l e a r a n c e  w a s  low  c omp a r e d  to  h e p a t i c  b lo o d  f low .   Th e  a p p a r e n t  v o lum e  o f  d i s t r ib u t io n  w a s  mo d e r a t e  (~ 2- fo ld  th a t  o f  to t a l  b o d y  w a t e r ) .   
C l e a r a n c e  a n d  v o lum e  o f  d i s t r ib u t io n  w e r e  d o s e  in d e p e n d e n t .    
S tu d y  APD 8 1 1- 0 0 4  w a s  c o n d u c t e d  a s  a n  o p e n - l a b e l ,  r a n d om i z e d ,  s in g l e - d o s e ,  2 - t r e a tm e n t ,  
c ro s s o v e r  s tu d y  to  a s s e s s  th e  PK p ro p e r t i e s  o f  r a l in e p a g  a t  a  d o s e  o f  3 0  m c g  in  th e  f e d  a n d  f a s t e d  s t a t e s .   Th e  t
m ax in  th e  f e d  s t a t e  w a s  d e l a y e d  c omp a r e d  to  th e  f a s t e d  s t a t e  ( f rom  1  to  
~ 4 h ) ,  th e  Cm a x r e d u c e d  ( e s t im a t e d  g e om e t r i c  m e a n  r a t io  ~ 0 .6 ) ,  a n d  th e  AUC  l a rg e ly  
m a in t a in e d  ( e s t im a t e d  g e om e t r i c  m e a n  r a t io  ~ 0 .8 ).   Th e s e  r e s u l t s  s u p p o r t  d o s in g  o f  r a l in e p a g  w i th  fo o d . 
S tu d y  APD 8 1 1- 0 0 3  w a s  a  ra n d om i z e d ,  d o u b l e - b l in d ,  p a r a l l e l- g ro u p ,  p l a c e b o - c o n t ro l l e d ,  
Ph a s e  2  s tu d y  o f  r a l in e p a g  in  s u b j e c t s  w i th  PAH.   I n  th i s  6 1 - s u b j e c t  s tu d y ,  th e  p r im a ry  
e f f i c a c y  a n a ly s i s  d emo n s t r a t e d  a  s t a t i s t i c a l ly  s ig n i f i c a n t  a b s o lu t e  c h a n g e  f rom  B as e l in e  in  PVR  c omp a r e d  to  p l a c e b o.   R a l in e p a g a l s o  d emo n s t r a t e d  n um e r i c a l  imp ro v em e n t  in  6 -M in u t e  Wa lk  Di s t a n c e  (6MWD ) .   R a l in e p a g imp ro v e d  m e d i a n  PVR  b y  1 6 3 .9  d y n . s . cm
- 5 f rom  
b a s e l in e  c omp a r e d  to  a  0 .7  d y n . s . cm- 5 w o r s e n in g  f r om  b a s e l in e  in  th e  p l a c e b o  a rm  ( p= 0 .0 2 ) .   
Su b j e c ts  t r e a t e d  w i th  r a l in e p a g  h a d  a  2 9 .8%  r e d u c t io n  in  PVR  c omp a r e d  to  th e  p l a c e b o  a rm  (p = 0 .0 3 )  a n d  a  2 0 .1%  r e d u c t io n  in  PVR  c omp a r e d  to  b a s e l in e .   A d d i t io n a l ly ,  AE s o b s e rv e d  in  th e  s tu d y  w e r e  c o n s i s t e n t  w i th  o th e r  p ro s t a c y c l in  t r e a tm e n t s  fo r  th e  m a n a g em e n t  o f  PAH ,  
w i th  h e a d a c h e ,  n a u s e a ,  d i a r rh e a ,  j aw  p a in,  a n d  f lu s h in g  b e in g  th e  mo s t  c ommo n ly  r e p o r t e d  
AE s.   Ad d i t io n a l  in fo rm a t io n  i s  b e  p r e s e n t e d  in  th e  In v e s t ig a to r ’ s  B ro c h u r e .  
In  S tu d y  APD 8 1 1- 0 1 1 ,  a n  e x t e n d e d - r e l e a s e  ( XR)  t a b l e t  fo rmu l a t io n  o f  r a l in e p a g  w a s  
e v a lu a t e d  in  a  d o s e  e s c a l a t io n  p a r a d igm  o v e r  a p p ro x im a t e ly  4  w e e k s  (w i th  d a i ly  d o s in g  
s t a r t in g  a t  6 0  m c g  a n d  s low ly  u p - t i t r a t in g ,  d e p e n d in g  u p o n  in d iv id u a l  s u b j e c t  to l e r a b i l i ty ,  b y  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  2 6  a d d i t io n a l  6 0  m c g  d o s e  in c r em e n t s  e v e ry  5  d a y s  u p  to  3 0  m c g )  in  h e a l th y  s u b j e c t s  in  b o th  th e  
f a s t e d  a n d  f e d  s t a t e s .  
Th e  d a t a  f rom  th i s  s tu d y  s h ow e d  th a t  r a l in e p a g  p e a k  a n d  to t a l  p l a sm a  e x p o s u r e  fo r  th e  XR  
t a b l e t  w e r e  d o s e  d e p e n d e n t  ( a p p e a r in g  o n ly  s l ig h t l y  h ig h e r  th a n  d o s e  p ro p o r t io n a l )  a n d  d id  n o t  
a p p r e c i a b ly  v a ry  w h e n  t a k e n  w i th  o r  w i th o u t  fo o d .   L a s t ly ,  th e  XR  t a b l e t  s h ow s  a  h ig h e r  p l a sm a  c o n c e n t r a t io n  a t  2 4  h  c omp a r e d  to  th e  imm e d i a t e - r e l e a s e  ( IR )  c a p s u l e ,  in d i c a t in g  a n  imp ro v e d  p l a sm a  PK p e r fo rm a n c e  o v e r  th e  IR  c a p s u l e  w i th  r e s p e c t  to  o n c e - d a i ly  d o s in g  in  
t e rm s  o f  e x t e n d in g  e x p o s u r e  a n d  m in im i z in g  p e a k - to - t ro u g h  f lu c tu a t io n .  
O v e r a l l ,  th e r e  w e r e  n o  d e a th s  o r  SAE s ,  a n d  a l l  AE s w e r e  m i ld  o r  mo d e r a t e  w i th  th e  e x c e p t io n  
o f  1  G r a d e  3  a d v e r s e  d ru g  r e a c t io n  (ADR) .   In  b o t h  th e  f a s t e d  a n d  f e d  s t a t e s ,  th e  m a jo r i ty  o f  s u b j e c t s  e x p e r i e n c e d  a t  l e a s t  1  AE ,  mo s t  o f  w h i c h  w e r e  ADR s ,  a n d  th e  n umb e r  a n d  
p e r c e n t a g e  o f  AE s a n d  ADR s  w e r e  c omp a r a b l e .   T h e  m a jo r i ty  o f  AEs  w e r e  t r a n s i e n t  in  n a tu r e  
a n d  h a d  r e s o lv e d  b y  th e  e n d  o f  th e  s tu d y .   Th e  p ro f i l e  o f  AE s f rom  b o th  f a s t e d  a n d  f e d  s u b j e c t s  w e r e  c o n s i s t e n t  w i th  th e  r e f e r e n c e  s a f e ty  i n fo rm a t io n  fo r  r a l in e p a g  a n d  o th e r  p ro s t a c y c l in  r e c e p to r  a g o n i s t s ,  w i th  n o t a b l e  e x c e p t io n s o f  th e  AE s o f  G r a d e  3  in c r e a s e d  
t r a n s am in a s e s  a n d  G r a d e  1  v e n t r i c u l a r  e x t r a s y s to l e s .  
1 .2  ETH ICS AND REGULATORY CONS IDERAT IONS 
Th e  s tu d y  w i l l  b e  c o n d u c t e d  in  c omp l i a n c e  w i th  th e  e th i c a l  p r in c ip l e s  th a t  h a v e  th e i r  o r ig in  in  
th e  D e c l a r a t io n  o f  H e l s in k i  o n  b iom e d i c a l  r e s e a r c h  in v o lv in g  h um a n  v o lu n t e e r s  
(2 0 1 3  V e r s io n ) ,  In t e rn a t io n a l  C o u n c i l  fo r  H a rmo n i s a t io n  ( ICH )  o f  T e c h n i c a l  R e q u i r em e n t s  fo r  Ph a rm a c e u t i c a l s  fo r  H um a n  U s e  G u id e l in e s  fo r  G o o d  C l in i c a l  P r a c t i c e  (GCP ) ,  th e  s tu d y  p ro to c o l ,  a n d  w h e r e  a p p l i c a b l e ,  Sp o n s o r  a n d /o r  C o n t r a c t  R e s e a r c h  O rg a n i z a t io n  (CRO )  
S t a n d a rd  O p e r a t in g  P ro c e d u r e s  (SOP s ).   Th e  p ro to c o l  a n d  in fo rm e d  c o n s e n t  w i l l  b e  s u bm i t t e d  
fo r  c o n s id e r a t io n  b y  th e  a p p ro p r i a t e  In d e p e n d e n t  R e v i ew  B o a rd  ( IRB ) / In d e p e n d e n t  E th i c s  C omm i t t e e  (IEC )  a n d  w r i t t e n  a p p ro v a l  f rom  th e  C h a i r  o r  d e s ig n a t e d  d e p u ty  o f  th e  IRB / IEC  i s  r e q u i r e d  b e fo r e  c l in i c a l  a c t iv i t i e s  o f  th e  s tu d y  c a n  c omm e n c e .  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  2 7  Th e  IRB/ IEC  mu s t  b e  n o t i f i e d  p romp t ly  b y  th e  In v e s t ig a to r  o f  th e  fo l low in g :  
•  D e v i a t io n s  f rom ,  o r  c h a n g e s  in ,  th e  p ro to c o l  to  e l imin a t e  imm e d i a t e  h a z a rd s  to  th e  
s tu d y  s u b j e c t s  
•  C h a n g e s  in c r e a s in g  th e  r i s k  to  s u b j e c t s  a n d /o r  s ig n i f i c a n t ly  a f f e c t in g  th e  c o n d u c t  o f  
th e  s tu d y  
•  A l l  AE s th a t  m e e t  th e  d e f in i t io n  o f  a n  SAE 
•  N ew  in fo rm a t io n  th a t  m a y  a f f e c t  a d v e r s e ly  th e  s a f e ty  o f  th e  s u b j e c t s  o r  th e  c o n d u c t  o f  
th e  s tu d y  
A n y  c h a n g e s  to  th e  p ro to c o l  w i l l  b e  m a d e  b y  m e a n s  o f  a  fo rma l  w r i t t e n  p ro to c o l  am e n dm e n t .   
A l l  am e n dm e n t s  w i l l  r e q u i r e  IRB/ IEC  a p p ro v a l  b e fo r e  imp l em e n t a t io n ,  e x c e p t  w h e n  c h a n g e s  to  th e  p ro to c o l  a r e  r e q u i r e d  imm e d i a t e ly  to  e l im in a t e  h a z a rd s  to  th e  s u b j e c t s .  
2  STUDY  OB JECT IVES 
2 .1  PR IMARY OB JECT IVE 
To  e v a lu a t e  th e  lo n g- t e rm  s a f e ty  a n d  to l e r a b i l i ty  o f  r a l in e p a g  in  s u b j e c t s  w i th  WHO  G ro u p  1  
PAH  w h o  h a v e  c omp l e t e d  S tu d y  APD 8 1 1- 0 0 3 .  
2 .2  SECONDARY OB JECT IVES 
•  To  e v a lu a t e  th e  e f f e c t  o f  r a l in e p a g  in  s u b j e c t s  w i th  WHO  G ro u p  1  PAH  w h o  
c omp l e t e d  S tu d y  APD 8 1 1- 0 0 3 ,  a s  d e t e rm in e d  b y  t h e  in c id e n c e  o f c l in i c a l  w o r s e n in g .  
•  To  e v a lu a t e  c h a n g e s  f rom  b a s e l in e  in  th e  fo l low in g  e f f i c a c y  e n d p o in t s :   
•  6 MWD 
•  WHO /NYHA  FC 
•  H emo d y n am i c s  
3  INVEST IGAT IONAL  PLAN 
3 .1  OVERALL STUDY DES IGN AND PLAN 
Th i s  i s  a  Ph a s e  2 ,  mu l t i c e n t e r ,  o p e n - l a b e l ,  e x t e n s io n  s tu d y  to  d e t e rm in e  th e  lo n g - t e rm  s a f e ty  
a n d  to l e r a b i l i ty  o f  r a l in e p a g  in  s u b j e c t s  w i th  WHO  G ro u p  1  PAH  w h o  h a v e  c omp l e t e d  t h e  
Ph a s e  2  s tu d y ,  APD 8 1 1- 0 0 3 ,  o r  w h o  w e r e  a s s ig n e d  to  p l a c e b o  a n d  w e r e  d i s c o n t in u e d  fo r  
c l in i c a l  w o r s e n in g .   Su b j e c ts  mu s t  a l s o  m e e t  e l ig ib i l i ty  c r i t e r i a  fo r  p a r t i c ip a t io n  in  th i s  lo n g -t e rm  e x t e n s io n  s tu d y .   Th e  D a y  1  (B a s e l in e )  v i s i t  i n  S tu d y  APD 8 1 1- 0 0 7  w i l l  c o in c id e  w i th  th e  W e e k 2 5  V i s i t  in  S tu d y  APD 8 1 1- 0 0 3 .   Fo r  th i s  r e a s o n ,  s u b j e c t s  s h o u ld  b e  c o n s e n t e d  to  S tu d y  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  2 8  APD 8 1 1- 0 0 7  p r io r  to  th e  W e e k  2 5  p ro c e d u r e s  b e in g  p e r fo rm e d  fo r  S tu d y  APD 8 1 1- 0 0 3 .   
B a s e l in e /Da y  1  e v a lu a t io n s  w i l l  in c lu d e  m e d i c a l  h i s to ry  u p d a t e ,  a s s e s sm e n t  o f  d i s e a s e  s t a t e ,  a n d  d e t e rm in a t io n  o f  e l ig ib i l i ty  fo r  e a c h  p o t e n t i a l  s u b j e c t .    
A l l  s u b j e c t s  e n ro l l e d  in  S tu d y  APD 8 1 1- 0 0 7  w i l l  r e c e iv e  o p e n - l a b e l  t r e a tm e n t  w i th  r a l in e p a g .   
Th e  s t a r t in g  d o s e  a n d  t i t r a t io n  s c h e d u l e  w i l l  b e  in d iv id u a l ly  d e t e rm in e d  in  a c c o rd a n c e  w i th  th e  s t a r t in g  d o s e  a n d  t i t r a t io n  s c h e d u l e  o p t im i z e d  f rom  S tu d y  APD 8 1 1- 0 0 3 .   A d ju s tm e n t s  in  th e  d o s e  a n d  t i t r a t io n  s c h e d u l e  m a y  b e  m a d e  a c c o r d in g  to  s u b j e c t  to l e r a b i l i ty .   A f t e r  th e  
c omp l e t io n  o f  S tu d y  APD 8 1 1- 0 0 3 ,  o n g o in g  s a f e ty  r e v i ew  o f  s u b j e c t  d a t a  w i l l  b e  c o n d u c t e d  
b y  th e  Sp o n s o r  to  mo n i to r  fo r  d ru g  s a f e ty .  
A f t e r  a n  in d iv id u a l  s u b j e c t  c omp l e t e s  Stu d y  APD 8 1 1 - 0 0 3  a n d  th a t  s u b j e c t ’ s  d a t a b a s e  i s  
lo c k e d ,  s u b j e c t  u n b l in d in g  w i l l  o c c u r .   Su b j e c ts  w h o  w e r e  o n  a c t iv e  t r e a tm e n t  (r a l in e p a g )  in  
S tu d y  APD 8 1 1- 0 0 3  w i l l  r em a in  o n  c u r r e n t  d o s e  a n d  h a v e  o n s i t e  c l in i c a l  a s s e s sm e n t s  
p e r fo rm e d  e v e ry  3  mo n th s  u n t i l  th e  s u b j e c t  i s  d i s c o n t in u e d  f rom  th e  s tu d y  ( s e e  T a b l e 1 ) .   
Su b j e c ts  in  th e  p l a c e b o  t r e a tm e n t  g ro u p  o f  S tu d y  APD 8 1 1- 0 0 3  w i l l  u n d e rg o  a  Do s e  Ti t r a t io n  
Pe r io d  u n t i l  a  s t a b l e  m a x imum  to l e r a t e d  d o s e  (MTD )  i s  r e a c h e d  (u p  to  9  w e e k s ) ;  th i s  w i l l  b e  
fo l low e d  b y  a  Tr e a tm e n t  Pe r io d  in  w h i c h  mo n th ly  o n s i t e  c l in i c  a s s e s sm e n t s  w i l l  b e  p e r fo rm e d  
fo r  th e  f i r s t  3  mo n th s  a n d  th e n  e v e ry  3  mo n th s  u n t i l  th e  s u b j e c t  i s  d i s c o n t in u e d  f rom  th e  s tu d y  o r  th e  s tu d y  i s  t e rm in a t e d  ( s e e  T a b le  2 ) .   
Su b j e c ts  w i l l  c o n t in u e  to  h a v e  v i s i t s  to  th e  c l in i c  e v e ry  3  mo n th s  in d e f in i t e ly  to  c o l l e c t  d a t a  a s  
s p e c i f i e d  in  T a b l e 1  a n d  T a b l e 2  u n t i l  m a rk e t in g  a p p ro v a l  o f  r a l in e p a g  i s  g r a n t e d  o r  u n t i l  th e  
Sp o n s o r  d i s c o n t in u e s  th e  s tu d y .   
D u r in g  th e  c o n d u c t  o f  th e  s tu d y ,  s u b j e c t s  w i l l  sw i t c h  f rom  th e  IR  fo rmu l a t io n  o f  r a l in e p a g  ( a s  
s tu d i e d  in  ADP8 1 1 - 0 0 3 )  to  a n  XR  fo rmu l a t io n  th a t  w i l l  b e  u s e d  in  Ph a s e  3  s tu d i e s .   
Fo r  b o th  IR  a n d  XR fo rmu l a t io n s ,  d o s e  r e d u c t io n s  m a y  b e  m a d e  a t  a n y  t im e  fo r  
s a f e ty / to l e r a b i l i ty  r e a s o n s .   In c r em e n t a l  d o s e  in c r e a s e s  w i l l  a l s o  b e  a l low e d  d u r in g  th e  T r e a tm e n t  P er io d  ( T a b l e 1  a n d  T a b l e 2 )  a t  th e  d i s c r e t io n  o f  th e  In v e s t ig a to r  ( a s  c l in i c a l ly  in d i c a t e d )  a n d  a c c o rd in g  to  th e  s t e pw i s e  t i t r a t io n  s c h em e  o u t l in e d  in  T a b l e 4 .  
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  2 9  Su b j e c ts  w i l l  b e  a s s e s s e d  fo r  c l in i c a l  w o r s e n in g  d u r in g  e a c h  c l in i c  v i s i t .   I f  c l in i c a l  w o r s e n in g  
i s  c o n f i rm e d ,  th e  In v e s t ig a to r  m a y  o p t  to  e i th e r  c o n t in u e  t r e a tm e n t  w i th  r a l in e p a g  a t  th e  c u r r e n t  d o s e ,  in c r e a s e  th e  d o s e  o f  r a l in e p a g ,  in t e r ru p t  t r e a tm e n t ,  o r  d i s c o n t in u e  th e  s u b j e c t  a t  
h i s /h e r  d i s c r e t io n .   A d d i t io n /d o s e  in c r e a s e s / s u b s t i tu t io n s  o f  1  d ru g  w i th in  th e  ERA  c l a s s  a n d  1  
w i th in  th e  PDE5- I / s o lu b l e  g u a n y l a t e  c y c l a s e  ( s GC)  s t imu l a to r  c l a s s  a r e  a l s o  p e rm i s s ib l e .  
In  a d d i t io n ,  a l l  s u b j e c t s  w i l l  b e  c o n t a c t e d  a t  th e  t im e  o f  S tu d y  APD 8 1 1- 0 0 7  c lo s u r e  to  a s s e s s  
v i t a l  (mo r t a l i ty )  s t a tu s .   Th e  v i t a l  s t a tu s  fo l low- u p  c o n t a c t  o f  s u b j e c t s  w i l l  d e p e n d  o n  lo c a l  
r e g u l a t io n s  o r  s p e c i f i c  a g r e em e n t  w i th  th e  s u b j e c t  a n d  In v e s t ig a to r .  
U p o n  t e rm in a t io n  o f  th e  s tu d y ,  s u b j e c t s  w i l l  c omp l e t e  a n  En d  o f  S tu d y  Vi s i t .   A  2 8- d a y  
Fo l low - u p  Vi s i t  w i l l  b e  c o n d u c t e d  to  e n s u r e  a p p ro p r i a t e  s u b j e c t  s a f e ty .   Th i s  v i s i t  m a y  b e  c o n d u c t e d  b y  t e l e p h o n e  o r  in  p e r s o n  b a s e d  u p o n  th e  In v e s t ig a to r ’ s  d i s c r e t io n .   S u b j e c t s  w h o  
r em a in  o n  r a l in e p a g  a t  s tu d y  t e rm in a t io n  a n d  m e e t  a l l  e l ig ib i l i ty  c r i t e r i a  a r e  e l ig ib l e  to  ro l l  in to  
th e  o p e n - l a b e l  e x t e n s io n  s tu d y  (ROR - PH- 3 0 3 ) .  
C o n c om i t a n t  M e d i c a t io n s:  
Su b j e c ts  a r e  p e rm i t t e d  o r a l  d i s e a s e - s p e c i f i c  PAH  t h e r a p y  c o n s i s t in g  o f  a n  ERA  a n d /o r  a  
PDE5 - I  o r  sGC  s t imu l a to r ,  b u t  n o t  b o th .   Th e  o n- s tu d y  a d d i t io n / s u b s t i tu t io n  o f  a n  ERA ,  PDE5 - I /sGC  s t imu l a to r ,  i f  o n  a  s in g l e  s u c h  a g e n t  a t  B a s e l in e,  o r  d o s a g e  in c r e a s e  fo r  s u c h  a g e n t s  i s  p e rm i t t e d .   In  a d d i t io n  to  r a l in e p a g ,  s u b j e c t s  c a n  b e  p r e s c r ib e d  n o  mo r e  th a n  1  a g e n t  
f rom  th e  ERA  c l a s s  a n d  1  f rom  th e  PDE5 - I / sGC  s t imu l a to r  c l a s s  a t  a n y  1  t im e .   Su b s t i tu t io n  
a n d  d o s e  a d ju s tm e n t  w i th in  e a c h  o f  th e s e  c l a s s e s  i s  p e rm i t t e d .   Su b j e c ts  s h o u ld  b e  e v a lu a t e d  fo r  th e  p r e s e n c e  o f  c l in i c a l  w o r s e n in g  i f  a d d i t io n a l  th e r a p y  o r  d o s e  a d ju s tm e n t s / s u b s t i tu t io n s  o f  c u r r e n t  th e r a p i e s  a r e  r e q u i r e d .  
In  a d d i t io n ,  th e  fo l low in g  th e r a p i e s ,  w h i c h  m a y  a f f e c t  PAH ,  a r e  p e rm i t t e d  a n d  m a y  b e  
a d ju s t e d  in  d o s e  a s  n e e d e d :    
•  Va s o d i l a to r s  ( in c lu d in g  c a l c ium  c h a n n e l  b lo c k e r s )  
•  D ig o x in  
•  Sp i ro n o l a c to n e  
•  L -A rg in in e  s u p p l em e n t a t io n 
Un i t ed  Th e r ap eu t i c s  C o rp . ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  3 0  D iu r e t i c s  m a y  b e  d o s e d  a s  c l in i c a l ly  in d i c a t e d  th ro u g h o u t  th e  s tu d y . 
Su b j e c t s  w h o  r e q u i r e  t r e a tm e n t  w i th  a  p ro s t a c y c l in /p ro s t a c y c l in  a n a lo g u e  ( IV ,  SC ,  o r a l ,  o r  
in h a l e d ) ,  e x c e p t  fo r  a c u t e  v a s o d i l a to r  t e s t in g  d u r in g  c a rd i a c  c a th e t e r i z a t io n ,  w i l l  b e  
d i s c o n t in u e d  f rom  th e  s tu d y .   
3 .2  RAT IONALE FOR STUDY DES IGN 
Thi s  s tu d y  i s  d e s ig n e d  to  e v a lu a t e  th e  lo n g - t e rm  s a f e ty  a n d  to l e r a b i l i ty  o f  r a l in e p a g  in  s u b j e c t s  
w i th  PAH.  
In c lu s io n  o f  a  p l a c e b o  a rm  in  S tu d y  APD 8 1 1- 0 0 3  a n d  th e  r e q u i r em e n t  to  m a in t a in  th e  b l in d  in  
th a t  s tu d y  n e c e s s i t a t e s  th e  r e - t i t r a t io n  o f  a l l  s u b j e c t s  e n t e r in g  S tu d y  APD 8 1 1- 0 0 7 .   Th u s ,  th e  d o s e  t i t r a t io n  s c h em e  f rom  S tu d y  APD 8 1 1 - 0 0 3  w i l l  b e  emp lo y e d  in  th i s  s tu d y  fo r  s u b j e c t s  
w h o  w e r e  p r e v io u s ly  t r e a t e d  w i th  p l a c e b o  in  S tu d y  APD 8 1 1- 0 0 3 .  
O p t im a l d o s in g  o f  IP  r e c e p to r  a g o n i s t s  in  PAH  s u b j e c t s  r e q u i r e s  d o s e  t i t r a t io n  o n  a n  
in d iv id u a l i z e d  b a s i s ;  fu r th e rmo r e ,  to l e r a b i l i ty  m a y  imp ro v e  w i th  c o n t in u e d  e x p o s u r e .
1 5  I t  i s  
a n t i c ip a t e d  th a t  th e  s t a r t in g  d o s e  o f  1 0  m c g  B ID w i l l  b e  to l e r a t e d  b y  mo s t ,  i f  n o t  a l l,  s u b j e c t s .   
D a t a  f rom  th e  p r e v io u s  Ph a s e  1  d o s e  t i t r a t io n  s tu d y  s u g g e s t s  th a t  th e r e  a r e  in d iv id u a l  
d i f f e r e n c e s  in  to l e r a b i l i ty  o f  r a l in e p a g  in  h e a l th y  v o lu n t e e r s ,  c o n s i s t e n t  w i th  f in d in g s  f rom  o th e r  s tu d i e s  o f  p ro s t a c y c l in  r e c e p to r  a g o n i s t s  in  PAH  s u b j e c t s .   
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  3 1  T ab le  1  S ch edu l e o f  P r o c edu r e s  and  V i s i t s :  S tudy  APD 8 1 1-0 0 3  Sub j e c ts  Tr e a t ed  w i th  R a l in epa g  En t e r ing  S tudy  APD 8 1 1 -
0 0 7  
Ev a lua t i ona Ba s e l in eb 
(APD 8 1 1 - 0 0 3  
W e ek  2 5  V i s i t ) T r e a tm en t  P e r iod End  o f  S tudy  
(EOS )  2 8 - D a y 
F o l low -Upc Q3  M on th s 1  o r  2  Y e a r s 
±5  da y s  ± 3  mon th s ± 3  da y s  ± 3  da y s  
I n f o rm e d  c o n s e n t  X     
M e d i c a l  h i s to r y X     
Ph y s i c a l  e x am X   X  
ECG  ( 1 2- l e a d )d X X  X  
C l in i c a l  l a b o r a to r y  t e s t se X X  X  
P r e g n a n c y  t e s tf  X X  X  
V i t a l  s ig n sg X X  X  
S tu d y  d r u g  a dm i n i s t r a t io n  Xh X    
6MWT  X X  X  
BNP /NT- p r oBNPk X X    
A s s e s sm e n t  o f  c l in i c a l  w o r s e n in g X X  X X 
WHO /NYHA  FC  a s s e s sm e n ti X X  X X 
RHCl   X   
D o s e  e s c a l a t io n /d e- e s c a l a t io n  a s s e s sm e n t   Xj    
A d v e r s e  e v e n t  mo n i to r in g X X  X X 
Co n c om i t a n t  m e d i c a t io n  mo n i to r in g X X  X X 
Ab b r ev i a t i o n s :  6MWT ,  6 -M i n u t e  W a l k  T e s t ;  BNP ,  b r a i n  n a t r i u r e t i c  p ep t i d e ;  ECG ,  e l e c t r o c a r d i o g r am ;  FC ,  F u n c t i o n a l  C l a s s ;  hCG ,  h um an  c h o r i o n i c  g o n ad o t r o p i n ;  NT -
p r oBNP ,  N- t e rm i n a l  p r o - b r a i n  n a t r i u r e t i c  p ep t i d e ;  NYHA ,  N ew  Yo r k  H e a r t  A s so c i a t i o n ;  Q3 ,  e v e r y  3 ;  QT cB ,  QT  i n t e r v a l  co r r e c t ed  f o r  B a z e t t ’ s  f o rm u l a ;  QT cF ,  QT  
i n t e r v a l  co r r e c t ed  f o r  F r i d e r i c i a ’ s  f o rm u l a ;  RHC ,  r i g h t  h e a r t  c a t h e t e r i z a t i o n ;  RR ,  r e s p i r a t i o n  r a t e ;  WHO ,  Wo r l d  H e a l t h  O r g a n i z a t i o n  
a R e f e r en c e  t o  p r e- d o s e  a n d  p o s t - d o s e  a c t i v i t i e s  i n  t h i s  s ch e d u l e  a p p l y  t o  t h e  m o r n i n g  d o s e  o f  s t u d y  d r u g .   S t u d y  d r u g  sh o u l d  b e  t a k en  w i t h  f o o d .  
b  Th e  W e ek  2 5  (D ay  1 7 5 )  V i s i t  f r om  S t u d y  APD 8 1 1 - 0 0 3  w i l l  s e r v e  a s  t h e  B a s e l i n e /D ay  1  V i s i t  f o r  S t u d y  APD8 1 1 - 0 0 7 .  
c  Th i s  v i s i t  m a y  b e  co n d u c t ed  b y  t e l ep h o n e  o r  i n  p e r so n  b a s e d  u p o n  t h e  I n v e s t i g a t o r ’ s  d i s c r e t i o n .  
d  S a f e t y  ECG s  sh o u l d  b e  com p l e t ed  p r e - d o s e .   A f t e r  t h e  l a s t  su b j e c t  en r o l l ed  i n  S t u d y  APD8 1 1 - 0 0 7  c om p l e t e s  ap p r o x im a t e l y  6  m o n t h s  o f  t r e a tm en t  an d  a  cum u l a t i v e  a l l -
su b j e c t  d a t a  an a l y s i s  i s  p e r f o rm e d ,  a s  o u t l i n ed  i n  S e c t i o n  9  (P l an n ed  S t a t i s t i c a l  M e t h o d s ) ,  ECG s  w i l l  su b s eq u e n t l y  b e  co n d u c t ed  l o c a l l y  a t  t h e  d i s c r e t i o n  o f  t h e  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  3 2  I n v e s t i g a t o r  ( a s  c l i n i c a l l y  i n d i c a t ed )  d u r i n g  t h e  Q3  m o n t h l y  v i s i t s .   Th e  ECG  w i l l  b e  p e r f o rm ed  a t  t h e  E n d  o f  S t u d y  V i s i t .   L o c a l l y  co l l e c t ed  ECG  v a l u e s  f o r  RR ,  PR ,  
QRS ,  QT ,  QT c ,  QT cB ,  a n d  QT cF  w i l l  b e  co l l e c t ed  i n  t h e  S p o n s o r ’ s  c l i n i c a l  d a t ab a s e .  
e  C l i n i c a l  l ab o r a t o r y  t e s t s  w i l l  i n c l u d e  h em a t o l o g y ,  s e r um  c h em i s t r y ,  co a g u l a t i o n ,  an d  u r i n a l y s i s .   C l i n i c a l  l a b o r a t o r y  t e s t s  w i l l  b e  com p l e t ed  p r e- d o s e .   A f t e r  t h e  l a s t  s u b j e c t  
en r o l l ed  i n  S t u d y  APD 8 1 1 - 0 0 7  com p l e t e s  ap p r o x im a t e l y  6  m o n t h s  o f  t r e a tm e n t  an d  a  cum u l a t i v e  a l l - s u b j e c t  d a t a  a n a l y s i s  i s  p e r f o rm ed ,  a s  o u t l i n e d  i n  S e c t i o n  9 ,  c l i n i c a l  
l ab o r a t o r y  t e s t s  w i l l  s u b s eq u en t l y  b e  c o n d u c t ed  l o c a l l y  a t  t h e  d i s c r e t i o n  o f  t h e  I n v e s t i g a t o r  ( a s  c l i n i c a l l y  i n d i c a t ed )  d u r i n g  t h e  Q3  m o n t h l y  v i s i t s .   A  co m p l e t e  c l i n i c a l  
l ab o r a t o r y  t e s t  w i l l  b e  c o n d u c t ed  l o c a l l y  a t  t h e  E n d  o f  S t u d y  V i s i t .   L o c a l l y  co l l e c t ed  l ab o r a t o r y  v a l u e s  t h a t  a r e  ab n o rm a l  a n d  c l i n i c a l l y  s i g n i f i c an t  w i l l  b e  co l l e c t ed  i n  t h e  
S p o n so r ’ s  c l i n i c a l  d a t a b a s e  a l o n g  w i t h  t h e  r e f e r en c e  r an g e s .  
f  S e r um  hCG  p r eg n a n cy  t e s t s  w i l l  b e  com p l e t e d  p r e - d o s e  a t  e a c h  v i s i t  d u r i n g  t h e  T r e a tm en t  P e r i o d .   A f t e r  t h e  l a s t  su b j e c t  en r o l l ed  i n  S t u d y  APD8 1 1 - 0 0 7  com p l e t e s  
ap p r o x im a t e l y  6  m o n t h s  o f  t r e a tm en t  an d  a  cum u l a t i v e  a l l - su b j e c t  d a t a  an a l y s i s  i s  p e r f o rm ed ,  a s  o u t l i n ed  i n  S e c t i o n  9 ,  p r eg n a n c y  t e s t i n g  ( e i t h e r  s e r um  o r  u r i n e )  w i l l  
su b s eq u en t l y  b e  co n d u c t e d  l o c a l l y  d u r i n g  e a ch  Q3  m o n t h l y  an d  t h e  E n d  o f  S t u d y  V i s i t .   L o c a l l y  co l l e c t ed  p o s i t i v e  v a l u e s  f o r  h CG  w i l l  b e  co l l e c t ed  i n t h e  S p o n s o r ’ s  
c l i n i c a l  d a t ab a s e  a l o n g  w i t h  t h e  r e f e r en c e  r a n g e .  
g  V i t a l  s i g n  m e a su r em en t s  ( b l o o d  p r e s su r e ,  h e a r t  r a t e ,  r e sp i r a t i o n s ,  an d  b o d y  t em p e r a t u r e  t ak e n  i n  su p i n e  p o s i t i o n  a f t e r  5  m i n u t e s  o f  r e s t )  w i l l  b e  t ak e n  p r e - d o s e .  
h S u b j e c t s  t r e a t ed  w i t h  r a li n ep ag  i n  S t u d y  APD8 1 1 - 0 0 3  s t u d y  w i l l  co n t i n u e  o n  cu r r en t  d o s e .  
i WHO /NYHA  F u n c t i o n a l  C l a s s  w i l l  b e  a s s e s s e d  p r e- d o s e  a t  a l l  v i s i t s .  
j  An  a s s e s sm en t  f o r  f u r t h e r  d o s e  e s c a l a t i o n  o r  d e - e s c a l a t i o n  w i l l  b e  co n d u c t ed  d u r i n g  t h e  Q3  m o n t h s .  
k A f t e r  t h e  l a s t  su b j ec t  en r o l l ed  i n  S t u d y  APD8 1 1 - 0 0 7  c om p l e t e s  ap p r o x im a t e l y  6  m o n t h s  o f  t r e a tm en t  an d  a  cum u l a t i v e  a l l- su b j e c t  d a t a  an a l y s i s  i s  p e r f o rm ed ,  a s  o u t l i n ed  i n  
S e c t i o n  9  (P l an n ed  S t a t i s t i c a l  M e t h o d s ) ,  p r o - BNP  an d  NT- p r oBNP  t e st i n g  w i l l  su b s eq u en t l y  b e  co n d u c t ed  l o c a l l y  a t  t h e  d i s c r e t i o n  o f  t h e  I n v e s t i g a t o r  ( a s  c l i n i c a l l y  
i n d i c a t ed )  d u r i n g  t h e  Q3  m o n t h l y  v i s i t s .   L o c a l l y  co l l e c t ed  v a l u e s  w i l l  b e  e n t e r e d  i n t o  t h e  S p o n so r ’ s  c l i n i c a l  d a t a b a s e  a l o n g  w i t h  t h e  r e f e r en c e  r an g e s . 
l  A t  1 y e a r  (±3  m o n t h s )  a f t e r  t h e  su b j e c t  e n r o l l s  i n t o  S t u d y  APD8 1 1 - 0 0 7 ,  an  RHC  a s s e s sm e n t  w i l l  b e  co n d u c t ed .   I f  t h e  su b j e c t  h a s  b e en  i n  S t u d y  APD8 1 1 - 0 0 7  b ey o n d  1  
y e a r  (±3  m o n t h s )  a t  t h e  t im e  o f  r eg u l a t o r y / e t h i c s  ap p r o v a l  o f  t h i s  am en dm en t ,  an  RHC  a s s e s sm en t  w i l l  b e  co n d u c t e d  a t  2  y e a r s  (±3  m o n t h s )  i n s t e ad .   I f  a  su b j e c t  h a s  b e en  
en r o l l ed  i n  S t u d y  APD 8 1 1 - 0 0 7  m o r e  t h an  2  y e a r s  a t  t h e  t im e  o f  r eg u l a t o r y / e t h i c s  ap p r o v a l  o f  Am en dm en t  # 0 2 ,  an  RHC  w i l l  b e  p e r f o rm ed  a t  t h e  t im e  o f  t h o s e  a p p r o v a l s .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  3 3  T ab l e 2  S ch edu l e  o f  P r o c edu r e s  and  V i s i t s:  S tudy  APD 8 1 1-0 0 3  Sub j e c ts  t r e a t ed  w i th  P la c ebo  en t e r ing  S tudy  APD 8 1 1 -0 0 7  
Ev a lua t i ona Ba s e l in eb  
(APD 8 1 1 - 0 0 3  
F o l low -up  
V i s i t ) D o s e  T i t r a t ion  P e r iod T r e a tm en t  P e r iod End  o f  
S tudy  
(EOS )  2 8 - D a y 
F o l low -
Upc 9 - W e ek  P e r iod M 1- M 3 Q3  M on th s 1  o r  2  Y e a r s  
1  2  3  4  5  6  7  8  9  ± 3  da y s ±5  da y s  ± 3  mon th s ± 3  da y s  ± 3  da y s  
I n f o rm e d  c o n s e n t  X               
M e d i c a l  h i s to r y X               
Ph y s i c a l  e x am X             X  
ECG  ( 1 2- l e a d )d X X X X X X X X X X X X  X  
C l in i c a l  l a b o r a to r y  t e s t se X  X   X    X X X  X  
S e r um  p r e g n a n c y  t e s tf  X     X     X X  X  
V i t a l  s ig n sg X X X X X X X X X X X X  X  
S tu d y  d r u g  a dm i n i s t r a t io n  X X X X X X X X X X X    
6MWTh X          X X  X  
BNP /NT- p r oBNPk X           X    
WHO /NYHA  f u n c t io n a l  c l a s s  
a s s e s sm e n ti X  X  X  X  X  X  X X  X  X  X  X   X  X  
A s s e s sm e n t  f o r  c l i n i c a l  w o r s e n in g X  X  X  X  X  X  X X  X  X  X  X   X  X  
RHC
l             X   
D o s e  e s c a l a t io n /d e- e s c a l a t io n  a s s e s sm e n t             X
j    
A d v e r s e  e v e n t  mo n i to r in g X X X X X X X X X X X X  X X 
Co n c om i t a n t  m e d i c a t io n  mo n i to r in g X  X  X  X  X  X  X X  X  X  X  X   X  X  
Ab b r ev i a t i o n s :  6MWT ,  6 -M i n u t e  W a l k  T e s t ;  BNP ,  b r a i n  n a t r i u r e t i c  p ep t i d e ;  ECG ,  e l e c t r o c a r d i o g r am ;  hCG ,  h um a n  ch o r i o n i c  g o n ad o t r o p i n ;  MTD ,  m ax im um  t o le r a t ed  d o s e ;  
NT- p r oBNP ,  N- t e rm i n a l  p r o - b r a i n  n a t r i u r e t i c  p ep t i d e ;  NYHA ,  N ew  Yo r k  H e a r t  A s so c i a t i o n ;  Q3 ,  ev e r y  3 ;  QT cB ,  QT  i n t e r v a l  c o r r e c t ed  f o r  B a z e t t ’ s  f o rm u l a ;  Q T cF ,  QT  
i n t e r v a l  co r r e c t ed  f o r  F r i d e r i c i a ’ s  f o rm u l a ;  RHC ,  r i g h t  h e a r t  c a t h e t e r i z a t i o n ;  RR ,  r e s p i r a t o r y  r a t e ;  WHO ,  W o r l d  H e a l t h  O r g an i z a t i o n  
a  R e f e r en c e  t o  p r e- d o s e  a n d  p o s t - d o s e  a c t i v i t i e s  i n  t h i s  s ch e d u l e  a p p l y  t o  t h e  m o r n i n g  d o s e  o f  s t u d y  d r u g .   S t u d y  d r u g  sh o u l d  b e  t a k en  w i t h  f o o d .  
b  Th e  W e ek  2 5  V i s i t  f r om  S t u d y  APD8 1 1 - 0 0 3  w i l l  s e r v e  a s  t h e  B a s e l i n e /D ay  1  V i s i t  f o r  S t u d y  APD8 1 1 - 0 0 7 . 
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  3 4  c  Th i s  v i s i t  m a y  b e  co n d u c t ed  b y  t e l ep h o n e  o r  i n  p e r so n  b a s e d  u p o n  t h e  I n v e s t i g a t o r ’ s  d i s c r e t i o n . 
d  S a f e t y  ECG  m e a su r em en t s  t o  b e  com p l e t ed  a t  B a s e l i n e  an d  a t  W e ek s  1  t o  9 ,  u n l e s s  t h e  su b j e c t  r e a ch e s  a  s t a b l e  MTD  an d  t h e  s u b j e c t  t r an s i t i o n s  i n t o  t h e  T r e a tm en t  P e r i o d ;  
ECG s  w i l l  b e  com p l e t ed  p r e- d o s e  a n d  2  h o u r s  p o s t - d o s e .   A f t e r  t h e  l a s t  s u b j e c t  e n r o l l ed  i n  S t u d y  APD8 1 1 - 0 0 7  com p l e t e s  ap p r o x im a t e l y  6  m o n t h s  o f  t r e a tm en t  an d  a  
cum u l a t i v e  a l l - su b j e c t  d a t a  an a l y s i s  i s  p e r f o rm ed ,  a s  o u t l i n ed  i n  S e c t i o n  9 ,  ECG s  w i l l  su b s eq u en t l y  b e  co n d u c t ed  l o c a l l y  a t  t h e  d i s c r e t i o n  o f  t h e  I n v e s t i g a t o r  ( a s  c l i n i c a l l y  
i n d i c a t ed )  d u r i n g  t h e  Q3  m o n t h l y  v i s i t s .   Th e  ECG  w i l l  b e  p e r f o rm ed  a t  t h e  E n d  o f  S t u d y  V i s i t .   L o c a l l y  c o l l e c t ed  ECG  v a l u e s  f o r  RR ,  PR ,  QRS ,  QT ,  QT c ,  QT cB ,  an d  
QT cF  w i l l  b e  c o l l e c t ed  i n  t h e  S p o n so r ’ s  c l i n i c a l  d a t ab a s e . 
e C l i n i c a l  l ab o r a t o r y  t e s t s  w i l l  i n c l u d e  h em a t o l o g y ,  s e r um  c h em i s t r y , co a g u l a t i o n ,  an d  u r i n a l y s i s .   C l i n i c a l  l a b o r a t o r y  t e s t s  w i l l  b e  com p l e t ed  p r e - d o s e .   A f t e r  t h e  l a s t  s u b j e c t  
en r o l l ed  i n  S t u d y  APD 8 1 1 - 0 0 7  com p l e t e s  ap p r o x im a t e l y  6  m o n t h s  o f  t r e a tm e n t  an d  a  cum u l a t i v e  a l l - s u b j e c t  d a t a  a n a l y s i s  i s  p e r f o rm ed ,  a s  o u t l i n e d  i n  S e c t i o n  9 ,  c l i n i c a l  
l ab o r a t o r y  t e s t s  w i l l  s u b s eq u en t l y  b e  c o n d u c t ed  l o c a l l y  a t  t h e  d i s c r e t i o n  o f  t h e  I n v e s t i g a t o r  ( a s  c l i n i c a l l y  i n d i c a t ed )  d u r i n g  t h e  Q3  m o n t h l y  v i s i t s .   A  com p l e t e  c l i n i c a l  
l ab o r a t o r y  t e s t  w i l l  b e  c o n d u c t ed  l o c a l l y  a t  t h e  E n d  o f  S t u d y  V i s i t .   L o c a l l y  co l l e c t ed  l ab o r a t o r y  v a l u e s  t h a t  a r e  ab n o rm a l  an d  c l i n i c a l l y  s i g n i f i c an t  w i l l  b e  co l l e c t ed  i n  t h e  
S p o n so r ’ s  c l i n i c a l  d a t a b a s e  a l o n g  w i t h  t h e  r e f e r en c e  r an g e s .  
f  S e r um  p r eg n an cy  t e s t  w i l l  b e  com p l e t e d  p r e - d o s e  a t  e a c h  v i s i t  d u r i n g  t h e  T r e a tm e n t  P e r i o d .   A f t e r  t h e  l a s t  su b j e c t  en r o l l e d  i n  S t u d y  APD8 1 1 - 0 0 7  com p l e t e s  ap p r o x im a t e l y  
6  m o n t h s  o f  t r e a tm e n t  an d  a  cum u l a t i v e  a l l - s u b j e c t  d a t a  a n a l y s i s  i s  p e r f o rm ed ,  a s  o u t l i n e d  i n  S e c t i o n  9  (P l an n ed  S t a t i s t i c a l  M e t h o d s ) ,  p r eg n a n cy  t e s t i n g  ( e i t h e r  s e r um  o r  
u r i n e )  w i l l  su b s eq u en t l y  b e  co n d u c t e d  l o c a l l y  d u r i n g  e a c h  Q3  m o n t h l y  a n d  t h e  E n d  o f  S t u d y  V i s i t .   L o c a l l y  co l l e c t e d  p o s i t i v e  v a l u e s  f o r  hCG  w i l l  b e  c o l l e c t ed  i n  t h e  
S p o n so r ’ s  cl i n i c a l  d a t a b a s e  a l o n g  w i t h  t h e  r e f e r en c e  r an g e .  
g  V i t a l  s i g n  m e a su r em en t s  ( b l o o d  p r e s su r e ,  h e a r t  r a t e ,  r e sp i r a t i o n s ,  b o d y  t em p e r a t u r e ,  an d  p u l s e  o x im e t r y  [S pO 2] ) ,  t a k en  i n  su p i n e  p o s i t i o n  a f t e r  5  m i n u t e s  o f  r e s t )  w i l l  b e  
t ak en  a t  p r e - d o s e  o n  D ay  1 ,  a n d  p r e - d o s e  o n  t h e  f i r s t  d ay  o f  e a ch  d o s e  i n c r e a s e .   On  t h e  f i r s t  d ay  o f  e a ch  d o s e  i n c r e a s e ,  b l o o d  p r e s su r e  an d  h e a r t  r a t e  w i l l  b e  t ak en  
ap p r o x im a t e l y  ev e r y  h o u r  f o r  t h e  f i r s t  4  h o u r s  a f t e r  s t u d y  d r u g  a dm i n i s t r a t i o n .   V i t a l  s i g n s  w i l l  b e  m e a su r e d  p r i o r  t o  an y  b l o o d  d r aw  t h a t  o c cu r s  a t  t h e  s am e  t im e  p o i n t .    
h  Th e  6MWT  sh o u l d  b e  com p l e t e d  p r e - d o s e  a t  ap p r o x im a t e l y  t h e  s am e  t im e  o f  d a y  a t  e a c h  d e s i g n a t e d  v i s i t .  
i WHO /NYHA  F u n c t i o n a l  C l a s s  w i l l  b e  a s s e s s e d  p r e- d o s e  a t  a l l  v i s i t s .  
j An  a s s e s sm en t  f o r  f u r t h e r  d o s e  e s c a l a t i o n  o r  d e - e s c a l a t i o n  w i l l  b e  co n d u c t ed  d u r i n g  t h e  Q3  m o n t h s .  
k  A f t e r  t h e  l a s t  su b j e c t  en r o l l ed  i n  S t u d y  APD8 1 1 - 0 0 7  c om p l e t e s  ap p r o x im a t e l y  6  m o n t h s  o f  t r e a tm en t  an d  a  cum u l a t i v e  a l l - su b j e c t  d a t a  an a l y s i s  i s  p e r f o rm ed ,  a s  o u t l i n ed  i n  
S e c t i o n  9 ,  p r o -BNP  a n d  NT - p r oBNP  t e s t i n g  w i l l  su b s eq u e n t l y  b e  co n d u c t ed  l o c a l l y  a t  t h e  d i s c r e t i o n  o f  t h e  I n v e s t i g a t o r  ( a s  c l i n i c a l l y  i n d i c a t ed )  d u r i n g  t h e  Q3  m o n t h l y  v i s i t s .   L o c a l l y  c o l l e c t ed  v a l u e s  w i l l  b e  en t e r ed  i n t o  t h e  S p o n so r ’ s  c l i n i c a l  d a t ab a s e  a l o n g  w i t h  t h e  r e f e r e n c e  r an g e s .  
l  A t  1  y e a r  (±3  m o n t h s )  a f t e r  t h e  su b j e c t  e n r o l l s  i n t o  S t u d y  APD8 1 1 - 0 0 7 ,  an  RHC  a s s e s sm e n t  w i l l  b e  co n d u c t ed .   I f  t h e  su b j e c t  h a s  b e en  i n  S t u d y  APD8 1 1 - 0 0 7  b ey o n d  1  
y e a r  (±3  m o n t h s )  a t  t h e  t im e  o f  r eg u l a t o r y / e t h i c s  ap p r o v a l  o f  Am en dm en t  2 ,  an  RHC  a s s e s sm en t  w i l l  b e  co n d u c t ed  a t  2  y e a r s  (±3  m o n t h s )  i n s t e ad .   I f  a  su b j e c t  h a s  b e en  
en r o l l ed  i n  S t u d y  APD 8 1 1 - 0 0 7  m o r e  t h an  2  y e a r s  a t  t h e  t im e  o f  r eg u l a t o r y / e t h i c s  ap p r o v a l  o f  Am en dm en t  2 ,  an  RHC  w i l l  b e  p e r f o rm ed  a t  t h e  t im e  o f  t h o s e  ap p r o v a l s .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  3 5  4  STUDY  POPULAT ION SELECT ION 
4 .1  STUDY  POPULAT ION 
Th e  s tu d y  p o p u l a t io n  w i l l  in c lu d e  s u b j e c t s  w i th  WHO  G ro u p  1  PAH  w h o  h a v e  c omp l e t e d  
S tu d y  APD 8 1 1- 0 0 3  o r  w h o  w e r e  a s s ig n e d  to  p l a c e b o  a n d  d i s c o n t in u e d  fo r  c l in i c a l  w o r s e n in g  a n d  w h o  a r e  d e em e d  a p p ro p r i a t e  c a n d id a t e s  fo r  p a r t i c ip a t io n  in  th i s  lo n g - t e rm  e x t e n s io n  
s tu d y .  
A l l  w om e n ,  r e g a rd l e s s  o f  c h i ld b e a r in g  p o t e n t i a l ,  m u s t  h a v e  a  n e g at iv e  s e rum  h um a n  c h o r io n i c  
g o n a d o t ro p in  (hCG )  p r e g n a n c y  t e s t  a t  e a c h  v i s i t  d u r in g  th e  Tr e a tm e n t  Pe r io d  a n d  a t  W e e k  5  o f  th e  Do s e  Ti t r a t io n  Pe r io d ,  i f  a p p l i c a b l e .   M a l e s  a n d  f em a l e s  o f  c h i ld b e a r in g  p o t e n t i a l  mu s t  
u s e  a d e q u a t e  m e a n s  o f  c o n t r a c e p t io n  a n d  mu s t  a g r e e  n o t  to  p a r t i c ip a t e  in  a  c o n c e p t io n  p ro c e s s  
( i e ,  a c t iv e  a t t emp t  to  b e c om e  p r e g n a n t  o r  imp r e g n a t io n ,  s p e rm  d o n a t io n ,  in  v i t ro  f e r t i l i z a t io n )  d u r in g  th e  s tu d y  a n d  fo r  3 0  d a y s  a f t e r  th e  l a s t  d o s e  o f  s tu d y  d ru g .   E l ig ib l e  s u b j e c t s  mu s t  m e e t  a l l  e n t ry  c r i t e r i a  p r io r  to  b e in g  r a n d om i z e d  to  r e c e i v e  s tu d y  d ru g  a s  o u t l in e d  b e low .   A n y  
d e v i a t io n s  f rom  th e s e  c r i t e r i a  mu s t  b e  a p p ro v e d  b y  th e  Sp o n s o r  p r io r  to  th e  s u b j e c t  b e in g  
e n ro l l e d .  
4 .2  INCLUS ION  CR ITER IA 
E a c h  s u b j e c t mu s t  m e e t  th e  fo l low in g  c r i t e r ia  to  b e  e n ro l l e d  in to  th e  s tu d y :  
•  Ev id e n c e  o f  a  p e r s o n a l ly  s ig n e d  a n d  d a t e d  in fo rm e d  c o n s e n t  d o c um e n t 
•  I s  w i l l in g  a n d  a b l e  to  c omp ly  w i th  s c h e d u l e d  v i s i t s ,  t r e a tm e n t  p l a n ,  l a b o r a to ry  t e s t s ,  
a n d  o th e r  s tu d y  p ro c e d u r e s  a n d  i s  d e em e d  a n  a p p r o p r i a t e  c a n d id a t e  fo r  p a r t i c ip a t io n  in  
th i s  lo n g - t e rm  e x t e n s io n  s tu d y  
•  E l ig ib l e  f em a l e  s u b j e c t s  w i l l  b e : 
•  N o n p re g n a n t ,  e v id e n c e d  b y  a  n e g a t iv e  s e rum  hCG  p r e g n a n c y  t e s t  a t  B a s e l in e  
•  N o nl a c t a t in g  
•  Su rg i c a l ly  s t e r i l e  o r  p o s tm e n o p a u s a l ,  o r  a g r e e  to  c o n t in u e  to  u s e  a n  a c c e p t e d  
m e th o d  o f  b i r th  c o n t ro l  fo r  a t  l e a s t  3  mo n th s  p r io r  t o  f i r s t  d o s e ,  d u r in g ,  a n d  fo r  a t  
l e a s t  3 0  d a y s  a f t e r  l a s t  s tu d y  d ru g  a dm in i s t r a t io n  
•  A c c e p t a b l e  m e th o d s  o f  b i r th  c o n t ro l  a r e :  h o rmo n a l  c o n t r a c e p t iv e s,  d o u b l e  
b a r r i e r  m e th o d ,  in t r a u t e r in e  d e v i c e ,  s u rg i c a l  s t e r i l i t y  fo r  a t  l e a s t  6  mon th s  p r io r  
to  S c r e e n in g  fo r  tu b a l  l ig a t io n  p e r fo rm e d  l a p a ro s c o p i c a l l y ,  s u rg i c a l  s t e r i l i ty  fo r  
a t  l e a s t  6  mon th s  p r io r  to  Sc r e e n in g  b y  h y s t e r e c tomy  a n d /o r  b i l a t e r a l  
o o p h o r e c tomy ,  a n d /o r  p o s tm e n o p a u s a l  s t a tu s  (d e f i n e d  a s  a t  l e a s t  2  y e a r s  
w i th o u t  m e n s e s ).   In t e n d e d  a b s t in e n c e  i s  n o t  c o n s i d e r e d  a n  a c c e p t a b l e  m e th o d  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  3 6  o f  b i r th  c o n t ro l  fo r  th i s  s tu d y ;  s u b j e c t s  mu s t  a g r e e  t o  u s e  a n  a c c e p t a b l e  m e th o d  
o f  b i r th  c o n t ro l  s h o u ld  th e y  b e c om e  s e x u a l ly  a c t iv e  d u r in g  th e  s tu d y  o r  w i th in  
3 0  da y s  a f t e r  th e  l a s t  d o s e  o f  s tu d y  d ru g .  
•  E l ig ib l e  m a l e  s u b j e c t s  w i l l  e i th e r  b e : 
•  Su rg i c a l ly  s t e r i l e  (i e ,  v a s e c tomy )  fo r  a t  l e a s t  3  mo n th s  p r io r  to  Sc r e e n in g  
•  A g r e e  to  u s e  a  c o n d om  w i th  s p e rm i c id e  w h e n  s e x u a l ly  a c t iv e  w i th  a  f em a l e  
p a r tn e r  w h o  i s  n o t  u s in g  a n  a c c e p t a b l e  m e th o d  o f  b i r th  c o n t ro l  d u r in g  th e  s tu d y  
a n d  fo r  3 0  d a y s  a f t e r  l a s t  s tu d y  d ru g  a dm in i s t r a t io n  
•  E l ig ib l e  m a l e  a n d  f em a l e  s u b j e c t s  mu s t  a g r e e  n o t  t o  p a r t i c ip a t e  in  a  c o n c e p t io n  p ro c e s s  
( i e ,  a c t iv e  a t t emp t  to  b e c om e  p r e g n a n t  o r  imp r e g n a t io n ,  s p e rm  d o n a t io n ,  in  v i t ro  
f e r t i l i z a t io n )  d u r in g  th e  s tu d y  a n d  fo r  3 0  d a y s  a f t e r  th e  l a s t  d o s e  o f  s tu d y  d ru g  
•  Fu l f i l l e d  a l l  e l ig ib i l i ty  c r i t e r i a  fo r  S tu d y  APD 8 1 1- 0 0 3  a n d  c omp l e t e d  th e  s tu d y  a s  
p l a n n e d  
•  Su b j e c ts  w h o  w e r e  a s s ig n e d  to  p l a c e b o  in  S tu d y  APD 8 1 1 - 00 3  a n d  e x p e r i e n c e d  
c l in i c a l  w o r s e n in g  in  th a t  s tu d y  m a y  e n ro l l  in  S tu d y  APD 8 1 1- 0 0 7  a f t e r  h e / s h e  h a s  
c omp l e t e d  a l l  e n d  o f  s tu d y  p ro c e d u r e s  p e r  p ro to c o l ,  in c lu d in g  RHC,  a n d  h a v e  h a d  th e i r  in d iv id u a l  S tu d y  APD 8 1 1 -0 0 3  d a t a  lo c k e d .   
4 .3  EXCLUS ION CR ITER IA 
Su b j e c ts  w h o  m e e t  a n y  o f  th e  fo l low in g  c r i t e r i a  w i l l  b e  e x c lu d e d  f rom  th e  s tu d y :  
•  Su b j e c ts  w h o  e n ro l l e d  in  S tu d y  APD 8 1 1- 0 0 3  a n d  w e r e  w i th d r aw n  f rom  s tu d y  d ru g  
t r e a tm e n t  d u e  to  a n y  AE  o r  SAE ,  o r  s u b j e c t s  w h o  d id  n o t  c omp l e t e  S tu d y  
APD 8 1 1- 0 0 3 ,  w i th  th e  e x c e p t io n  m a d e  a s  a b o v e  fo r  p l a c e b o- t r e a t e d  s u b j e c t s  w h o  
e x p e r i e n c e d  a  c l in i c a l  w o r s e n in g  e v e n t .  
•  F em a l e  s u b j e c ts  w h o  w i s h  to  b e c om e  p r e g n a n t  
•  Sy s to l i c  BP  < 9 0  mmH g  a t  B a s e l in e 
•  O th e r  s e v e r e  a c u t e  o r  c h ro n i c  m e d i c a l  o r  l a b o r a to r y  a b n o rm a l i ty  th a t  m a y  in c r e a s e  th e  
r i s k  a s s o c i a t e d  w i th  s tu d y  p a r t i c ip a t io n  o r  in v e s t ig a t io n a l  p ro d u c t  a dm in i s t r a t io n  o r  
m a y  in t e r f e r e  w i th  th e  in t e rp r e t a t io n  o f  s tu d y  r e s u l t s  a n d ,  in  th e  ju d gm e n t  o f  th e  
In v e s t ig a to r ,  w o u ld  m a k e  th e  s u b j e c t  in a p p ro p r i a t e  fo r  e n t ry  in to  th i s  s tu d y .   
5  STUDY  TREATMENTS 
5 .1  TEST ART ICLE 
Th e  Sp o n s o r w i l l  p ro v id e  a d e q u a t e s u p p l i e s  o f  r a l i n e p a g  IR  c a p s u l e s .   R a l in e p a g w i l l  b e  
p ro v id e d  a s  1 0 ,  2 0 ,  3 0 ,  4 0 ,  a n d  1 0 0  m c g  IR  d o s e  s t r e n g th s ,  a n d  l a t e r  w i l l  b e  p ro v id e d  a s  5 0 ,  
2 5 0 ,  a n d  4 0 0  m c g  (0 .0 5 ,  0 .2 5 ,  a n d  0 .4  mg )  XR t a b l e t  d o s e  s t r e n g th s .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  3 7  5 .2  TREATMENTS ADM IN ISTERED 
Th e  r a l in e p a g IR  fo rmu l a t io n  in i t i a l ly  u s e d  in  th e  s tu d y  i s  a  l iq u id - f i l l e d ,  s i z e  4 ,  h a rd - g e l a t in  
c a p s u l e  c o n t a in in g  r a l in e p a g ,  p o ly o x y l  4 0  h y d ro g e n a t e d  c a s to r  o i l  (K o l l ip h o r® RH 4 0 )  NF ,  
b u ty l a t e d  h y d ro x y to lu e n e  NF ,  a n d  c o l lo id a l  s i l i c o n  d io x id e  NF .   Th e  r a l in e p a g XR 
fo rmu l a t io n  t a b l e t  c o n t a in s  r a l in e p a g ,  h y d ro x y p ro p y lm e th y l  c e l lu lo s e  (M e th o c e l  K 4M  P r em ium  CF  a n d  M e th o c e l  K 1 0 0  P r em ium  LVCR ) ,  m i c ro c ry s t a l l in e  c e l lu lo s e  (A v i c e l  
PH 1 0 2 ) ,  m a n n i to l  (P e a r l i to l  1 0 0  SD ) ,  s i l i c o n  d io x i d e ,  a n d  m a g n e s ium  s t e a r a t e . 
R a l in e p a g u s e d  fo r  th e  c a p s u l e s  w a s  m a n u f a c tu r e d  u n d e r  C u r r e n t  G o o d  M a n u f a c tu r in g  
P r a c t i c e s  c omp l i a n c e  b y  th e  Sp o n s o r  (o r  d e s ig n e e ) .   Th e  APD 8 1 1  c a p s u l e s  ( IR )  o r  t a b l e t s  ( XR)  w i l l  b e  m a n u f a c tu r e d  u n d e r  C u r r e n t  G o o d  M a n u f a c tu r in g  P r a c t i c e s  c omp l i a n c e  b y  th e  
Sp o n s o r  (o r  d e s ig n e e ).  
5 .3  PACKAG ING,  LABEL ING AND STORAGE 
Fo r  e a c h  IR  fo rmu l a t io n  d o s a g e  s t r e n g th ,  7 4  c a p s u l e s  w i l l  b e  b u lk  p a c k a g e d  in  4 0 - c c  
h ig h - d e n s i ty  p o ly e th y l e n e  b o t t l e s  w i th  a  h e a t  in d u c t io n  s e a l  a n d  c h i ld - r e s i s t a n t  s c r ew  c a p s .   
Th e s e  b o t t l e s  s h o u ld  b e  s to r e d  u n d e r  r e f r ig e r a t io n  a t  2° C  (3 6° F )  to  8° C  (4 6° F ) ;  th e  b o t t l e s  s h o u ld  n o t  b e  f ro z e n .  
XR t a b l e t s  a r e  p a c k a g e d  in  PERLALUX
® b l i s t e r s  (p o ly v in y l  c h lo r id e  
[ PVC] /p o ly th y l e n e / p o ly v in y l id e n e  c h lo r id e  [ PVDC] ,  2 5 0 /3 0 /9 0 ,  a n d  c o v e r  fo i l  A lu  2 0  m cm)  
in  a  1× 8  c o n f ig u r a t io n  a n d  c a rd e d  in  a n  8× 8  a r r a y ,  6 4  t a b l e t s  p e r  c a rd .   Th e  c a rd s  a r e  s to r e d  a t  
1 5 ° C  to  3 0° C  (5 9° F  to  8 6 ° F ).  
5 .4  TEST ART ICLE ACCOUNTAB IL ITY 
Th e  In v e s t ig a to r  w i l l  m a in t a in  a c c u r a t e  r e c o rd s  o f  th e  r ec e ip t  o f  a l l  s tu d y  d ru g .   In  a d d i t io n ,  
a c c u r a t e  r e c o rd s  w i l l  b e  k e p t  r e g a rd in g  w h e n  a n d  h ow  mu c h  s tu d y  d ru g  i s  d i s p e n s e d  a n d  u s e d  
b y  e a c h  s u b j e c t  in  th e  s tu d y .   R e a s o n s  fo r  d e v i a t io n  f rom  th e  e x p e c t e d  d i s p e n s in g  r e g im e n  
mu s t  a l s o  b e  r e c o rd e d.   S tu d y  d ru g w i l l  b e  r e c o n c i l e d  b y  th e  Sp o n s o r ’ s  mo n i to r  o r  c o n t r a c t e d  d e s ig n e e .   Th e  In v e s t ig a to r  a g r e e s  to  p ro v id e  s u f f i c i e n t  a c c e s s  to  s tu d y  d ru g  a s  r e q u i r e d  fo r  th e  r e c o n c i l i a t io n  p ro c e s s  to  b e  c omp l e t e d  in  a  t im e ly  f a s h io n .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  3 8  5 .5  INVEST IGAT IONAL  PRODUCT RETENT ION AT STUDY  S ITE 
A t  c omp l e t io n  o f  th e  s tu d y ,  a l l  s tu d y  d ru g w i l l  b e  r e c o n c i l e d  b y  th e  Sp o n s o r ’ s  mo n i to r  o r  
c o n t r a c t e d  d e s ig n e e  a n d  th e n  r e tu rn e d  to  e i th e r  th e  Sp o n s o r  o r  a  th i rd - p a r ty  c o n t r a c to r  to  b e  
r e t a in e d  o r  d e s t ro y e d  a c c o rd in g  t o  a p p l i c a b l e  c o u n t ry  r e g u l a t io n s  a n d  in v e s t ig a t iv e  s i t e  SOP s.   P r io r  to  a n y  a c t io n  b e in g  t a k e n  w i th  s tu d y  d ru g a f t e r  th e  s tu d y  i s  c omp l e t e d ,  th e  In v e s t ig a to r  w i l l  c o n t a c t  th e  Sp o n s o r  (o r  c o n t r a c t e d  CRO )  fo r  a p p ro v a l  o f  s u c h  a c t io n .  
5 .6  DOSAGE AND  ADM IN ISTRAT ION 
In v e s t ig a t io n a l  p ro d u c t  w i l l  b e  d i s p e n s e d  to  th e  s u b j e c t s  u n d e r  th e  s u p e rv i s io n  o f  th e  
In v e s t ig a to r  o r  h i s /h e r  d e s ig n e e .   Su b j e c ts  s h o u ld  n o t  c ru s h ,  b r e a k ,  c h ew ,  o r  d i s s o lv e  th e  
c a p s u l e s  o r  t a b l e t s .   Su b j e c ts  s h o u ld  w a s h  h a n d s  w i th  s o a p  a n d  w a t e r  a f t e r  h a n d l in g  d ru g  
p ro d u c t .  
C a p s u l e s  o r  t a b l e t s  s h o u ld  b e  t a k e n  w i th  fo o d .  
5 .6 .1 Imm ed ia t e - r e l e a s e  C ap su l e s 
5 .6 .1 .1 D o s e  T i t r a t ion  P e r iod ( S tudy  APD 8 1 1- 0 0 3  P la c ebo - t r e a t ed  Sub j e c t s )  
Su b j e c ts  w h o  w e r e  a s s ig n e d  to  p l a c e b o  t r e a tm e n t  i n  S tu d y  APD 8 1 1- 0 0 3  w i l l  u n d e rg o  a  Do s e  
Ti t r a t io n  P e r io d  o f  u p  to  9  w e e k s .   Al l  s u b j e c t s  w i l l  b e  o n  a c t iv e  t r e a tm e n t  ( r a l in e p a g )  in  th e  
o p e n - l a b e l  s tu d y ,  APD 8 1 1- 0 0 7 .  
Th e  d o s e  t i t r a t io n  s c h em e  w i l l  b e  th e  s am e  a s  c o n d u c t e d  in  S tu d y  APD 8 1 1- 0 0 3 .   Su b s e q u e n t  
d o s e  e s c a l a t io n s  w i l l  c o n t in u e  u n t i l  th e  MTD i s  d e t e rm in e d ,  w i th  a  p o s s ib l e  m a x imum  to t a l  
d a i ly  d o s e  o f  6 0 0  m c g  (3 0 0  m c g  B ID)  i f  to l e r a t e d .   Su b j e c ts  w i l l  b e  o b s e rv e d  fo r  a t  l e a s t  
4  h o u r s  a f t e r  th e  in i t i a l  d o s e  o f  r a l in e p a g ,  a n d  a t  e a c h  s u b s e q u e n t  d o s e  e s c a l a t io n .   AEs ,  BP,  a n d  h e a r t  r a t e  w i l l  b e  mo n i to r e d  d u r in g  th e  o b s e rv a t io n  p e r io d .   Th e  o b s e rv a t io n  p e r io d  m a y  b e  e x t e n d e d  b a s e d  o n  th e  ju d gm e n t  o f  th e  In v e s t ig a to r .   I f  d e em e d  n e c e s s a ry  b y  th e  
In v e s t ig a to r ,  th e  s u b j e c t  m a y  b e  mo n i to r e d  a s  a n  in p a t i e n t  fo r  th e  in i t i a l  d o s e  a n d /o r  
s u b s e q u e n t  in c r e a s e s  in  d o s e .   Th e  m e d i c a l  mo n i to r  s h o u ld  b e  n o t i f i e d  in  a n y  in s t a n c e  th a t  p ro lo n g e d  o b s e rv a t io n  a n d /o r  in p a t i e n t  mo n i to r in g  i s  a n t i c ip a t e d  o r  r e q u i r e d .    
I f  a  d o s e  i s  n o t  to l e r a t e d ,  th e  s tu d y  d ru g  s h o u ld  b e  d e c r e a s e d  to  th e  p r e v io u s  d o s e  l e v e l.   I f  th e  
in i t i a l  d o s e  o f  1 0  m c g  B ID i s  n o t  to l e r a t e d ,  d o s in g  m a y  b e  d e c r e a s e d  to  1 0  m c g  QD.  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  3 9  I f  th e  in i t i a l  d o s e  i s  to l e r a t e d  ( 1 0  m c g  B ID) ,  th e n  t h e  d o s e  w i l l  b e  in c r e a s e d  in  th e  fo l low in g  
f a s h io n  a t  s u b s e q u e n t  v i s i t s :  2 0 ,  3 0 ,  4 0 ,  6 0 ,  8 0 ,  1 0 0 ,  2 0 0 ,  a n d  3 0 0  m c g  B ID.   Th e  d o s e  m a y  b e  e s c a l a t e d  to  a  p o s s ib l e  m a x imum  to t a l  d a i ly  d o s e  o f  6 0 0  m c g  (3 0 0  m c g  B ID)  i f  to l e r a t e d .  
Su b j e c ts  m a y  b e c om e  s ymp tom a t i c  d u r in g  th e  c o u r s e  o f  d o s e  e s c a l a t io n ,  a n d  a d ju s tm e n t  u p  
a n d /o r  d ow n  m a y  b e  r e q u i r e d  to  f in d  th e  o p t im a l  d o s e  fo r  a n y  g iv e n  s u b j e c t .   O v e r  th e  9- w e e k  D o s e  Ti t r a t io n  Pe r io d ,  th e r e  a r e  o p p o r tu n i t i e s  to  c h a n g e  th e  d o s e .   I f  a  p a r t i c u l a r  d o s e  i s  n o t  to l e r a t e d ,  t r e a tm e n t  m a y  b e  r e d u c e d  to  a  p r e v io u s  d o s e  a s  d i r e c t e d  b y  th e  In v e s t ig a to r .   Th e  
d o s e  m a y  b e  d e c r e a s e d  fo r  s a f e ty / to l e r a b i l i ty  r e a s o n s  a t  a n y  t im e ,  b u t  m a y  n o t  b e  in c r e a s e d  
w i th o u t  a s s e s sm e n t  in  th e  c l in i c .   
T a b l e 3  in d i c a t e s  th e  d o s in g  r e g im e n  d u r in g  th e  Do s e  Ti t r a t io n  P e r io d .  P ro lo n g e d  d o s in g  m a y  r e s u l t  in  to l e r a n c e  to  s om e  a d v e r s e  e f f e c t s ,  s o  th a t  c o n s id e r a t io n  s h o u ld  
b e  m a d e  to  a t t emp t  d o s e  e s c a l a t io n  i f  s om e  t im e  (e g ,  > 7  d a y s )  h a s  e l a p s e d  s in c e  th e  p r io r  d o s e  
e s c a l a t io n  a t t emp t  a n d  th e  9 - w e e k  Do s e  Ti t r a t io n  Pe r io d  i s  n o t  y e t  c omp l e t e .  
In  o rd e r  to  s imp l i fy  d o s e  t i t r a t io n ,  th e  1 0  m c g  s t r e n g th  c a p s u l e  w i l l  b e  u s e d  d u r in g  th e  in i t i a l  
p o r t io n  o f  th e  d o s e  t i t r a t io n .  
I f  a  s u b j e c t  r e a c h e s  th e  h ig h e s t  d o s e  to l e r a t e d  ( s t a b l e  d o s e )  a n d  n o  fu r th e r  d o s e  e s c a l a t io n s  a r e  
p l a n n e d ,  th e  Do s e  Ti t r a t io n  Pe r io d  w i l l  b e  c o n s id e r e d  c omp l e t e d .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  4 0  T ab l e 3  Po s s ib l e  D o s ing  R e g im en  du r ing 9 - W e ek  D o s e  T i t r a t ion  P e r iod 
D o s e  (m c g ) Supp l i ed  by To t a l  da i ly  d o s e (m c g )  
1 0  QD 1  ×  1 0  m c g  QD 1 0  
1 0  B ID 1  ×  1 0  m c g  B ID 2 0  
2 0  B ID 2  ×  1 0  m c g  B ID 4 0  
3 0  B ID 3  ×  1 0  m c g  B ID 6 0  
4 0  B ID 4  ×  1 0  m c g  B ID 8 0  
6 0  B ID 3  ×  2 0  m c g B ID 1 2 0  
8 0  B ID 4  ×  2 0  m c g  B ID 1 6 0  
1 0 0  B ID 5  ×  2 0  m c g  B ID 2 0 0  
2 0 0  B ID 2  ×  1 0 0  m c g  B ID 4 0 0  
3 0 0  B ID 3  ×  1 0 0  m c g  B ID 6 0 0  
Ab b r ev i a t i o n s :  B ID ,  tw i c e  d a i l y ;  QD ,  o n c e  d a i l y 
5 .6 .1 .2 T r e a tm en t P e r iod 
Su b j e c ts  w h o  w e r e  o n  a c t iv e  t r e a tm e n t  ( r a l in e p a g )  in  S tu d y  APD 8 1 1 -0 0 3  w i l l  r em a in  o n  
c u r r e n t  d o s e  a n d  h a v e  o n s i t e  c l in i c a l  a s s e s sm e n t s  p e r fo rm e d  e v e ry  3  mo n th s  u n t i l  th e  s u b j e c t  i s  d i s c o n t in u e d  f rom  th e  s tu d y  ( s e e  T a b l e 1 ) .   Su b j e c ts  in  th e  p l a c e b o  t r e a tm e n t  g ro u p  o f  
S tu d y  APD 8 1 1- 0 0 3  w i l l  u n d e rg o  a  Do s e  Ti t r a t io n  Pe r io d  u n t i l  a  s t a b l e  MTD  i s  r e a c h e d  (u p  to  
9  w e e k s ).   A t  th e  c o n c lu s io n  o f  th e  Do s e  Ti t r a t io n  Pe r io d  a n d  w h e n  a  s u b j e c t  r e a c h e s  th e  h ig h e s t  d o s e  to l e r a t e d ,  th e  s u b j e c t  w i l l  t r a n s i t io n  d i r e c t ly  in to  th e  Tr e a tm e n t  Pe r io d  w i th  mo n th ly  a s s e s sm e n t s  fo r  th e  f i r s t  3  mo n th s  a n d  th e n  e v e ry  3  mo n th s .  
Th e  o p t im a l  d o s e  a c h i e v e d  fo r  e a c h  s u b j e c t  a t  th e  e n d  o f  th e  Do s e  Ti t r a t io n  P e r io d  c a n  b e  
m a in t a in e d  th ro u g h o u t  th e  Tr e a tm e n t  Pe r io d ;  h ow e v e r ,  in c r em e n t a l  d o s e  in c r e a s e s  w i l l  a l s o  b e  a l low e d  d u r in g  th e  T r e a tm e n t  P e r io d  a t  th e  d i s c r e t io n  o f  th e  In v e s t ig a to r  ( a s  c l in i c a l ly  in d i c a t e d )  a n d  a c c o rd in g  to  th e  s t e pw i s e  t i t r a t io n  s c h em e  o u t l in e d  in  T a b l e 4 .  
T a b l e 4  in d i c a t e s  th e  p o s s ib l e  IR  d o s in g  r e g im e n s  t o  b e  u s e d  d u r in g  th e  r em a in d e r  o f  th e  
Tr e a tm e n t  Pe r i o d  a c c o rd in g  to  e a c h  in d iv id u a l  s u b j e c t ’ s  o p t im a l ly  d e f in e d  d o s e .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  4 1  T ab l e 4  Po s s ib l e  D o s ing  R e g im en  du r ing  th e  T r e a tm en t  P e r iod 
D o s e  (mc g )  Supp l i ed  by To t a l  da i ly  d o s e (m c g )  
1 0 QD 1  ×  0 .0 1  m c g  QD 1 0 
1 0 B ID 1  ×  0 .0 1  m c g  B ID 2 0 
2 0 B ID 1  ×  0 .0 2  m c g  B ID 4 0 
3 0 B ID 1  ×  0 .0 3  m c g  B ID 6 0 
4 0 B ID 1  ×  0 .0 4  m c g  B ID 8 0 
6 0 B ID 2  ×  0 .0 3  m c g  B ID 1 2 0 
8 0 B ID 2  ×  0 .0 4  m c g  B ID 1 6 0 
1 0 0 B ID 1  ×  0 .1  m c g  B ID 2 0 0 
2 0 0 B ID 2  ×  0 .1  m c g  B ID 4 0 0 
3 0 0 B ID 3  ×  0 .1  m c g  B ID 6 0 0 
Ab b r ev i a t i o n s :  B ID ,  tw i c e  d a i l y ;  QD ,  o n c e  d a i l y  
5 .6 .2 E x t end ed- r e l e a s e  T ab l e t s 
5 .6 .2 .1 Fo rmu la t ion  Sw i t ch  and  D o s e  T i t r a t ion  P e r iod 
D u r in g  th e  s tu d y ,  a l l  s u b j e c t s  w i l l  sw i t c h  to  a n  XR fo rmu l a t io n  o f  r a l in e p a g  th a t  w i l l  b e  u s e d  
in  Ph a s e  3  s tu d i e s  o f  r a l in e p a g ,  p e r  th e  g u id a n c e  in  T a b l e  5 .   Th e  sw i t c h  to  XR r a l in e p a g  s h o u ld  o c c u r  a t  a  r e g u l a r ly  s c h e d u l e d  v i s i t ,  w i th  d o s e  t i t r a t io n  to  o c c u r ,  a s  n e e d e d ,  in  5 0 -m c g  w e e k ly  in c r em e n t s.   W e e k ly  p h o n e  c o n t a c t  w i th  th e  s u b j e c t  w i l l  b e  p e r fo rm e d  to  g u id e  XR 
d o s e  t i t r a t io n  to  th e  h ig h e s t  to l e r a t e d  d o s e .  
T ab l e  5  D o s e  Sw i t ch ing  Gu idan c e  f r om  Imm ed ia t e- r e l e a s e  to  E x t end ed - r e l e a s e  
R a l in epa g  
Cu r r en t  IR  D o s e  (mc g ;  t o t a l  da i ly )  C o r r e spond ing  XR D o se  ( m c g ) 
<3 0 5 0  EOD  
≥ 3 0  to  <12 0  5 0  
1 2 0  1 0 0  
1 6 0  1 5 0  
2 0 0  2 0 0  
4 0 0  4 0 0  
6 0 0  6 0 0  
Ab b r ev i a t i o n s :  EOD ,  ev e r y  o t h e r  d a y ;  IR ,  imm ed i a t e -r e l e a s e ;  XR ,  ex t en d ed - r e l e a s e  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  4 2  5 .6 .2 .2 T r e a tm en t  P e r iod 
A f t e r  th e  d o s e  sw i t c h  a n d  D o s e  Ti t r a t io n  P e r io d  w i th  th e  XR fo rmu l a t io n ,  s u b j e c t s  w i l l  
c o n t in u e  in to  th e  T r e a tm e n t  Pe r io d ,  in  w h i c h  s u b j e c t s  w i l l  h a v e  a n  a s s e s sm e n t  e v e ry  
3  mo n th s .   W i th  th e  e x c e p t io n  o f  th e  d i f f e r e n c e  in  r a l in e p a g  fo rmu l a t io n ,  th i s  T r e a tm e n t  P e r io d  w i l l  b e  id e n t i c a l  to  th a t  w h i c h  o c c u r r e d  w i t h  th e  IR  fo rmu l a t io n  (S e c t io n  5 .6 .1 .1 ,  S e c t io n  7 .2 .3 ) .  
Th e  o p t im a l  d o s e  a c h i e v e d  fo r  e a c h  p e r io d  d u r in g  t h e  Fo rmu l a t io n  Sw i t c h  a n d  D o s e  T i t r a t io n  
P e r io d  (S e c t io n  5 .6 .1 .1 )  c a n  b e  m a in t a in e d;  h ow e v e r ,  in c r em e n t a l  d o s e  c h a n g e s  (u p t i t r a t io n  o r  d ow n  t i t r a t io n )  w i l l  a l s o  b e  a l low e d  d u r in g  th e  T r e a tm e n t  P e r io d  a t  th e  d i s c r e t io n o f  th e  In v e s t ig a to r  ( a s  c l in i c a l ly  in d i c a t e d ) .  
5 .7  METHOD OF ASS IGN ING SUB JECTS TO TREATMENT GROUPS 
A l l  s u b j e c t s  w i l l  r e c e iv e  r a l in e p a g  in  th i s  s tu d y .   S u b j e c t s  r a n d om i z e d  to  p l a c e b o  d u r in g  S tu d y  
APD 8 1 1- 0 0 3  w i l l  b e g in  a  Do s e  Ti t r a t io n  Pe r io d  u n t i l  a  s t a b l e  d o s e  i s  r e a c h e d .   S u b j e c t s  
r a n d om i z e d  to  r a l in e p a g  d u r in g  S tu d y  APD 8 1 1 - 0 0 3  w i l l  s t a r t  o n  th e  f in a l  d o s e  a c h i e v e d  
d u r in g  th a t  s tu d y .   Su bj e c t s  w h o  r em a in  o n  r a l in e p a g  a t  s tu d y  t e rm in a t io n  a n d  m e e t  a l l  e l ig ib i l i ty  c r i t e r i a  a r e  e l ig ib l e  to  ro l l  in to  th e  o p e n - l a b e l  e x t e n s io n  s tu d y  (ROR - PH- 3 0 3 ) .  
5 .8  RANDOM IZAT ION AND  BL IND ING 
N o t  a p p l i c a b l e.   Th i s  i s  a n  o p e n- l a b e l  s tu d y .  
N o  r e- r a n d om i z a t io n  p ro c e s s  i s  to  t a k e  p l a c e  fo r  th i s  s tu d y ;  s u b j e c t s  w i l l  r e t a in  th e  
s u b j e c t / r a n d om i z a t io n  n umb e r s  a s s ig n e d  in  S tu d y  APD 8 1 1- 0 0 3  a s  s u b j e c t  id e n t i f i e r s  in  th i s  
s tu d y .  
6  STUDY PROCEDURES 
Da t a  r e s u l t in g  f rom  p ro c e d u r e s  c o l l e c t e d  a s  p a r t  o f  th e  s u b j e c t ’ s  s t a n d a rd  o f  c a r e  m a y  b e  
c o l l e c t e d  in  a d d i t io n  to  th e  p ro c e d u r e s  o u t l in e d  in  t h i s  s e c t io n .   Th i s  w i l l  b e  o u t l in e d  
a c c o rd in g l y  in  th e  s u b j e c t  in fo rm e d  c o n s e n t  d o c um e n t  a n d  in c lu d e s  th e  c o l l e c t io n  o f  d a t a  r e s u l t in g  f rom  p e r fo rm a n c e  o f  RHC s p e r fo rm e d  a s  s t a n d a rd  o f  c a r e .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  4 3  6 .1  INFORMED  CONSENT 
Th e  In v e s t ig a to r  w i l l  o b t a in  a n d  d o c um e n t  th e  in fo rm e d  c o n s e n t  fo r  e a c h  s u b j e c t  s c r e e n e d  fo r  
t h i s  s tu d y .   A l l  s u b j e c t s  w i l l  b e  in fo rm e d  in  w r i t in g  o f  th e  n a tu r e  o f  th e  p ro to c o l  a n d  
in v e s t ig a t io n a l  th e r a p y ,  i t s  p o s s ib l e  h a z a rd s ,  a n d  th e i r  r ig h t  to  w i th d r aw  a t  a n y  t im e ,  a n d  w i l l  s ig n  a  fo rm  in d i c a t in g  th e i r  c o n s e n t  to  p a r t i c ip a t e  p r io r  to  th e  in i t i a t io n  o f  s tu d y  p ro c e d u r e s .   Th e  s u b j e c t’ s  m e d i c a l  r e c o rd  s h o u ld  c o n t a in  w r i t t e n  d o c um e n t a t io n  in d i c a t in g  th a t  in f o rm e d  
c o n s e n t  w a s  o b t a in e d .   Th e  In fo rm e d  C o n s e n t  F o rm  (ICF )  mu s t  b e  r e v i ew e d  a n d  a p p ro v e d  b y  
th e  In v e s t ig a to r ’ s  d e s ig n a t e d  IRB / IEC  a n d  b y  th e  Sp o n s o r .   Th e  ICF  s h o u ld  in c lu d e  a l l  th e  e l em e n t s  a s  o u t l in e d  in  ICH  G u id e l in e  E6.  
6 .2  MED ICAL AND  SOC IAL  H ISTORY 
A t  B a s e l in e,  e v a lu a t io n s  w i l l  in c lu d e  a  m e d i c a l  a n d  s o c i a l  h i s to ry  u p d a t e ,  to  in c lu d e  to b a c c o ,  
a l c o h o l ,  a n d  c a f f e in e  u s e .   C o n c om i t a n t  m e d i c a t io n s a n d  c o n c om i t a n t  n o n d ru g  t r e a tm e n t s  w i l l  a l s o  b e  r e c o rd e d .  
6 .3  PHYS ICAL EXAM INAT ION 
Ph y s i c a l  e x am in a t io n s  w i l l  b e  c o n d u c t e d  a s  p e r  s t a n d a rd  c l in i c a l  p r a c t i c e  a n d  s h o u ld  in c lu d e  
a n  a s s e s sm e n t  o f  e a c h  b o d y  s y s t em ,  h e ig h t ,  a n d  w e ig h t .   Ph y s i c a l  e x am in a t io n s  s h o u ld  b e  
p e r fo rm e d  in  a  m a n n e r  th a t  i s  r e a s o n a b ly  c o n s i s t e n t  f rom  v i s i t  to  v i s i t.   Th e  p h y s i c a l  
e x am in a t io n  p e r fo rm e d  a t  th e  W e e k  2 5  V i s i t  o f  St u d y  APD 8 1 1 - 0 0 3  w i l l  s e rv e  a s  th e  B a s e l in e  Vi s i t  fo r  S tu d y  APD 8 1 1- 0 0 7 .  
6 .4  V ITAL  S IGNS 
Su p in e  BP,  h e a r t  r a t e ,  b o d y  t emp e r a tu r e ,  r e s p i r a to r y  r a t e  (RR )  a n d  p u l s e  o x im e t ry  w i l l  b e  
m e a s u r e d  a f t e r  th e  s u b j e c t  h a s  b e e n  r e s t in g  fo r  5  m inu t e s ,  a c c o rd in g  to  T a b l e 1  a n d  T a b l e 2 ,  o r  fo l low in g  e a r ly  t e rm in a t io n  o f  th e  s tu d y .   V i t a l  s ig n s  w i l l  b e  m e a s u r e d  p r io r  to  a n y  b lo o d  d r aw  
th a t  o c c u r s  a t  th e  s am e  t im e  p o in t .  
P ro p e r  t e c h n iq u e  s h o u ld  b e  u t i l i z e d  d u r in g  th e  m e a s u r em e n t  o f  BP  to  in c lu d e  th e  fo l low in g : 
•  Su b j e c t s  s h o u ld  b e  a l low e d  a  5- m in u t e  r e s t  p e r io d  b e fo r e  e a c h  a s s e s sm e n t.    
•  R e a d in g s  s h o u ld  b e  t a k e n  o n  th e  s u b j e c t ’ s  n o n d om in a n t  a rm  c o n s i s t e n t ly  th ro u g h o u t  
th e  s tu d y .   
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  4 4  •  Th e  s u b j e c t ’ s  a rm  s h o u ld  b e  b a r e  a n d  s u p p o r t e d  a t  h e a r t  l e v e l .  
•  A n  a p p ro p r i a t e ly  s i z e d  c u f f  ( c u f f  b l a d d e r  e n c i r c l in g  a t  l e a s t  8 0%  o f  th e  a rm )  s h o u ld  b e  
u t i l i z e d .  
•  Th e  s u b j e c t ’ s  l e g s  s h o u ld  n o t  b e  c ro s s e d  d u r in g  th e  e v a lu a t io n .   
In  a d d i t io n ,  s u b j e c t s  s h o u ld  b e  q u e r i e d  c o n c e rn in g  c a f f e in e  o r  to b a c c o  u s e ,  n e i th e r  o f  w h i c h  i s  
p e rm i t t e d  w i th in  3 0  m inu t e s  p r io r  to  BP  m e a s u r em e n t s . 
I t  i s  a l s o  c r i t i c a l  th a t  s t a n d a rd ,  c o n s i s t e n t  d e f in i t io n s  o f  s y s to l i c  BP  a n d  d i a s to l i c  BP  b e  
u t i l i z e d .   Sy s to l i c  BP  i s  th e  p o in t  a t  w h i c h  th e  f i r s t  o f  2  o r  mo r e  s o u n d s  a r e  h e a rd.   D i a s to l i c  
BP  i s  th e  p o in t  b e fo r e  th e  d i s a p p e a r a n c e  o f  s o u n d s.   Th e  r e s u l t s  o f  th e  m e a s u r em e n t  o f  
s y s to l i c  BP  a n d  di a s to l i c  BP  s h o u ld  n o t  b e  ro u n d e d . 
6 .5  ELECTROCARD IOGRAPHY 
6 .5 .1 ECG  Equ ipm en t 
S a f e ty  ECG s  w i l l  b e  r e c o rd e d  f rom  a n  ECG  m a c h i n e  (1 2- l e a d ) .   S a f e ty  ECG s  w i l l  b e  p r in t e d  
a n d  r e v i ew e d  o n  s i t e  b y  th e  In v e s t ig a to r  o r  d e s ig n e e .   S a f e ty  ECG s  w i l l  b e  c a p tu r e d ,  r e c o rd e d ,  
a n d  a n a ly z e d  a c c o rd in g  to  th e  C e n t r a l i z e d  ECG  P r o c e d u r e  M a n u a l  fo r  v i s i t s  th a t  r e q u i r e  
c e n t r a l i z e d  ECG  c o l l e c t io n  ( s e e  T a b l e 1  a n d  T a b l e 2 ) .    
6 .5 .2 ECG  A cqu i s i t ion  
C e n t r a l:  Th e  s a f e ty  ECG  e q u ipm e n t  w i l l  b e  s e t  a c c o rd in g  to  th e  p ro c e d u r e  m a n u a l.   Th e  o p e r a to r  w i l l  e n t e r  c e r t a in  s u b j e c t  d emo g r a p h i c  in f o rm a t io n  p r io r  to  o b t a in in g  th e  ECG .   Ev e ry  a t t emp t  w i l l  b e  m a d e  to  e n s u r e  th a t  s u b j e c t  ECG  r e a d in g s  th ro u g h o u t  th e  s tu d y  w i l l  b e  o b t a in e d  f rom  th e  s am e  m a c h in e .   Th e  fo l low in g  s u b j e c t  in fo rm a t io n  w i l l  b e  e n t e r e d  in to  th e  
m a c h in e :   
•  Su b j e c t in i t i a l s  ( e x amp l e :  XYZ  o r  X - Z ) 
•  Su b j e c t n umb e r  ( e n t e r  th e  r a n d om i z a t io n  n umb e r )  
•  Su b j e c t s e x  •  Su b j e c t d a t e  o f  b i r th  (DDMMMYYYY )  
•  S tu d y  d a y  a n d  t im e 
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  4 5  ECG s  w i l l  b e  r e c o rd e d  w i th  s u b j e c t s  in  th e  r e c umb e n t  p o s i t io n  a n d  r e s t in g .   Su b j e c ts  w i l l  
h a v e  b e e n  in  th i s  r e s t in g  p o s i t io n  fo r  1 0  m inu t e s  p r io r  to  ECG  r e c o rd in g ,  a n d  th e  ECG  w i l l  b e  p e r fo rm e d  p r io r  to  a n y  b lo o d  d raw  th a t  o c c u r s  a t  th e  s am e  t im e  p o in t .  
In  c a s e  o f  b a s e l in e  t r emo r ,  m e a s u r e s  w i l l  b e  t a k e n  to  e l im in a t e  th i s  a s  i t  m a y  in t e r f e r e  
s ig n i f i c a n t ly  w i th  th e  q u a l i ty  o f  th e  in t e rp r e t a t io n .   P r io r  to  e l e c t ro d e  p l a c em e n t ,  th e a n a tom i c a l  s i t e s  w i l l  b e  p r e p a r e d  to  a l low  fo r  p ro p e r  s k in / e l e c t ro d e  in t e r f a c e .   Su b j e c ts  w i th  e x c e s s iv e  h a i r  w i l l  b e  d ry  s h a v e n ,  a s  n e e d e d .  
In t e rv a l s  to  b e  p ro v id e d  o n  th e  c o n f i rm e d  r e a d  fo r  e a c h  s a f e ty  ECG  a r e :  RR ,  PR ,  QRS ,  QT ,  
QT c ,  QT  in t e rv a l  c o r r e c t e d  fo r  B a z e t t ’ s  fo rmu l a  (QT cB) ,  a n d  QT cF .  
L o c a l:  A f t e r  th e  l a s t  s u b j e c t  e n ro l l e d  in  APD 8 1 1 - 0 0 7  c omp l e t e s  a p p ro x im a t e ly  6  mo n th s  o f  
t r e a tm e n t  a n d  a  c umu l a t iv e  a l l - s u b j e c t  d a t a  a n a ly s i s  i s  p e r fo rm e d ,  a s  o u t l in e d  in  S e c t io n 9 ,  
ECG s  w i l l  s u b s e q u e n t ly  b e  c o n d u c t e d  lo c a l ly  a t  th e  d i s c r e t io n  o f  th e  In v e s t ig a to r  ( a s  c l in i c a l ly  
in d i c a t e d )  d u r in g  th e  e v e ry  3  ( Q 3)  mo n th ly  v i s i t s.  
6 .5 .3 ECG  As s e s sm en t  
B a s e l in e ECG s  w i l l  b e  c omp a r e d  w i th th e  f in a l  ECG . 
Th e  In v e s t ig a to r  w i l l  b e  r e s p o n s ib l e  fo r  th e  r e v i ew  a n d  in t e rp r e t a t io n  o f  s a f e ty  ECG s  o n  s i t e  
a n d  d e t e rm in in g  i f  th e  ECG  i s  n o rm a l ,  a b n o rm a l  c l in i c a l ly  in s ig n i f i c a n t ,  o r  a b n o rm a l  c l in i c a l ly  s ig n i f i c a n t .   F in d in g s  w i l l  b e  d o c um e n t e d  in  th e  C a s e  R e p o r t  Fo rm  (CRF) .   Th i s  
in fo rm a t io n  w i l l  b e  u s e d  in  th e  o n g o in g  s a f e ty  r e v i ew  d u r in g  th e  c o n d u c t  o f  th e  s tu d y .  
6 .6  6 -M INUTE WALK TEST 
Th e  6 - M in u t e  W a lk  T e s t  (6MWT)  s h o u ld  b e  c o n d u c t e d  a c c o rd in g  to  th e  g u id e l in e s  in  
A p p e n d ix  1,  w h i c h  h a v e  b e e n  a d a p t e d  f rom  th e  g u i d e l in e s  i s s u e d  b y  th e  Am e r i c a n  Th o r a c i c  
So c i e ty , ATS  S ta t em e n t :  G u id e l in e s  fo r  th e  S i x- m in u t e  Wa l k  T e s t.
16  T e c h n i c i a n s  p e r fo rm in g  
th e  t e s t  w i l l  b e  t r a in e d  a c c o rd in g  to  p u b l i s h e d  p ro c e d u r e s  (A p p e n d ix  1 ) .   T e s t s  w i l l  b e  p e r fo rm e d  a t  a p p ro x im a t e ly  th e  s am e  t im e  o f  d a y  f o r  e a c h  t e s t  in  o rd e r  to  m in im i z e  in t r a - d a y  
v a r i a b i l i ty .   Th e  6MWT  p e r fo rm e d  a t th e  W e e k  2 5  Vi s i t  o f  Stu d y  APD 8 1 1 - 0 0 3  w i l l  s e rv e  a s  
th e  B a s e l in e  a s s e s sm e n t  fo r  S tu d y  APD 8 1 1- 0 0 7 .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  4 6  6 .7  WHO /NYHA FUNCT IONAL  CLASS ASSESSMENT 
Su b j e c t s  w i l l  b e  c l a s s i f i e d  a c c o rd in g  to  a  s y s t em  o r ig in a l ly  d e v e lo p e d  fo r  h e a r t  f a i lu r e  b y  th e  
NYHA  a n d  th e n  mo d i f i e d  b y  th e  WHO  fo r  s u b j e c t s  w i th  PAH .17  Th e  s e v e r i ty  o f  PAH  w i l l  b e  
g r a d e d  a c c o rd in g  to  th e  fu n c t io n a l  s t a tu s  o f  th e  s u b j e c t  a n d  a s s e s s e d  a t  e v e ry  v i s i t .   Th e  g r a d e s  
r a n g e  f rom  FC  I ,  w h e r e  th e  s u b j e c t ' s  d i s e a s e  d o e s  n o t  a f f e c t  th e i r  d a y - to - d a y  a c t iv i t i e s ,  to  FC  IV ,  w h e r e  s u b j e c t s  a r e  s e v e r e ly  fu n c t io n a l ly  imp a i r e d ,  e v e n  a t  r e s t  ( s e e  A p p e n d ix  2) .  
6 .8  R IGHT  HEART CATHETER IZAT ION 
A t  1  y e a r  (±3  mo n th s )  a f t e r  th e  s u b j e c t  e n ro l l s  in to  APD 8 1 1 - 0 0 7 ,  a n  RHC  a s s e s sm e n t  w i l l  b e  
c o n d u c t e d .   I f  th e  s u b j e c t  h a s  b e e n  in  th e  APD 8 1 1 - 0 0 7  s tu d y  b e y o n d  1  y e a r  (±3  mo n th s )  a t  
th e  t im e  o f  r e g u l a to ry / e th i c s  a p p ro v a l  o f  A m e n dm e n t  2,  a n  RHC  a s s e s sm e n t  w i l l  b e  
c o n d u c t e d  a t  2  y e a r s  ( ± 3  mo n th s )  in s t e a d.   I f  a  s u b j e c t  h a s  b e e n  e n ro l l e d  in  APD 8 1 1 - 0 0 7  fo r  mo r e  th a n  2 y e a r s  a t  th e  t im e  o f  r e g u l a to ry / e th i c s  a p p ro v a l  o f  Am e n dm e n t  2,  a n  RHC  w i l l  b e  p e r fo rm e d  a t  th e  t im e  o f  th o s e  a p p ro v a l s .   I t  i s  r e c omm e n d e d  th a t  e v e ry  e f fo r t  s h o u ld  b e  m a d e  
to  t a k e  th e  m e a s u r em e n t s  a p p ro x im a t e ly  4 h o u r s  a f t e r  th e  l a s t  d o s e  o f  s tu d y  d ru g .   A n  RHC  
s h o u ld  b e  p e r fo rm e d  w h e n  a  s u b j e c t  t e rm in a t e s  f rom  th e  s tu d y  e a r ly  i f  a n  RHC  h a s  n o t  b e e n  c o n d u c t e d  w i th in  th e  p r e v io u s  y e a r .  
Th e  fo l low in g  v a lu e s  w i l l  b e  o b t a in e d  a n d  r e c o rd e d :  PAP  ( s y s to l i c ,  d i a s to l i c ,  a n d  m e a n ) , h e a r t  
r a t e ,  r ig h t  a t r i a l  p r e s s u r e ,  PCWP  r ig h t  v e n t r i c u l a r  p r e s s u r e  a n d  c a rd i a c  o u tp u t ,  PVR , a r t e r i a l  
a n d  m ix e d  v e n o u s  o x y g e n  s a tu r a t io n  ( i f  a p p l i c a b l e ) .   Sy s t em i c  v a s c u l a r r e s i s t a n c e  (SVR )  w i l l  b e  e s t im a t e d  f rom  BP m e a s u r em e n t s.   Fu r th e r  s p e c i f i c a t io n s w i l l  b e  p ro v id e d  in  a  s e p a r a t e  s tu d y  m a n u a l .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  4 7  6 .9  ASSESSMENT  OF  CL IN ICAL WORSEN ING 
Th e  In v e s t ig a to r  w i l l  e v a lu a t e  th e  s u b j e c t  fo r  p o t e n t i a l  c l in i c a l  w o r s e n in g  th ro u g h o u t  th e  
s tu d y .   I f  c l in i c a l  w o r s e n in g  i s  s u s p e c t e d ,  a d d i t io n a l  c l in i c  e v a lu a t io n s  m a y  b e  r e q u i r e d  to  
m a k e  a  f in a l  d e t e rm in a t io n  a s  to  w h e th e r  c l in i c a l  w o r s e n in g  h a s  b e e n  m e t.   C l in i c a l  w o r s e n in g  i s  d e f in e d  a s  fu l f i l lm e n t  o f  a n y  1  o f  th e  fo l low in g  c r i t e r i a  ( a s  a s s e s s e d  b y  c h a n g e  f rom  b a s e l in e  in  S tu d y  APD 8 1 1- 0 0 3 :  
•  D e a th ,  o r  o n s e t  o f  t r e a tm e n t- em e rg e n t  AE  (TEAE )  w i th  a  f a t a l  o u t c om e  o c c u r r in g  l e s s  
th a n  o r  e q u a l  to  1 4  d a y s  a f t e r  s tu d y  t r e a tm e n t  d i s c o n t in u a t io n  
•  H o s p i t a l i z a t io n  fo r  w o r s e n in g  PAH,  h e a r t- lu n g  o r  l u n g  t r a n s p l a n t ,  o r  a t r i a l  s e p to s tomy  
•  Th e  s u b j e c t r e q u i r e s  th e  a d d i t io n  (o r  c h a n g e  in  d o s e  i f  a p p l i c a b l e )  o f  a n y  o f  th e  
fo l low in g  PAH  s p e c i f i c  m e d i c a t io n s :  •  P ro s t a c y c l in /p ro s t a c y c l in  a n a lo g u e  (IV ,  SC,  o r a l ,  o r  in h a l e d )   
•  PDE5- I  o r  sGC  •  ERA 
•  Th e  c omb in e d  o c c u r r e n c e  o f  th e  e v e n t s  l i s t e d  b e low:   
•  A  d e c r e a s e  in  6MWD  b y  a t  l e a s t  2 0%  f rom  b a s e l in e ,  c o n f i rm e d  o n  tw o  6MWT s  o n  
d i f f e r e n t  d a y s  
•  In c r e a s e  (w o r s e n in g )  in  WHO /NYHA  FC  f rom  b a s e l in e  
•  A p p e a r a n c e  o f  o r  w o r s e n in g  o f  s ig n s / s ymp tom s  o f  r ig h t  h e a r t  f a i lu r e  th a t  d id  n o t  
r e s p o n d  to  o p t im i z e d  o r a l  d iu r e t i c  th e r a p y  
In  c a s e s  o f  c l in i c a l  d e t e r io r a t io n ,  th e  In v e s t ig a to r  mu s t  a s s e s s  c a r e fu l ly  i f  th e  d e t e r io r a t io n  o f  
th e  s u b j e c t ’ s  c o n d i t io n  ( e g ,  w o r s e n in g  FC)  i s  r e l a t e d  to  th e  u n d e r ly in g  PH o r  c a n  b e  e x p l a in e d  
b y  a n  a l t e rn a t iv e  c a u s e  (e g ,  t r a n s i e n t  in f e c t io n ,  mu s c u lo s k e l e t a l  d i s e a s e ,  s u rg i c a l  o r  m e d i c a l  
in t e rv e n t io n  o th e r  th a n  PH  r e l a t e d ,  e x a c e rb a t io n  o f  a  c o n c om i t a n t  lu n g  d i s e a s e ,  l a c k in g  c omp l i a n c e  o f  m e d i c a t io n  in t a k e ) .   O n ly  p e r s i s t e n t  c l in i c a l  d e t e r io r a t io n s  c a u s e d  b y  th e  u n d e r ly in g  PAH a n d  c o n f i rm e d  a s  p e r  th e  a b o v e  c r i t e r i a  w i l l  b e  c o n s id e r e d  c l in i c a l  w o r s e n in g .  
6 .1 0  CL IN ICAL  LABORATORY TESTS 
A l l  d e t a i l s  r e g a rd in g  c l in i c a l  l a b o r a to ry  s amp l e  c o l l e c t io n ,  p r e p ar a t io n ,  a n d  s h ipm e n t  a r e  
in c lu d e d  in  th e  l a b o r a to ry  m a n u a l  p ro v id e d  b y  th e  c e n t r a l  l a b o r a to ry  fo r  v i s i t s  th a t  r e q u i r e  
c e n t r a l i z e d  l a b  c o l l e c t io n  ( s e e  T a b l e 1  a n d  T a b l e 2 ) .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  4 8  In  th e  e v e n t  o f  a b n o rm a l  c l in i c a l  l a b o r a to ry  v a lu e s ,  th e  p h y s i c i a n  w i l l  m a k e  a  ju d gm e n t  
w h e th e r  o r  n o t  th e  a b n o rm a l i ty  i s  c l in i c a l ly  s ig n i f i c a n t . 
A f t e r  th e  l a s t  s u b j e c t  e n ro l l e d  in  APD 8 1 1 - 0 0 7  c om p l e t e s  a p p ro x im a t e ly  6  mo n th s  o f  
t r e a tm e n t  a n d  a  c umu l a t iv e  a l l - s u b j e c t  d a t a  a n a ly s i s  i s  p e r fo rm e d ,  a s  o u t l in e d  in  S e c t io n  9 ,  
c l in i c a l  l a b o r a to ry  t e s t s  w i l l  s u b s e q u e n t ly  b e  c o n d u c t e d  lo c a l ly  a t  th e  d i s c r e t io n  o f  th e  In v e s t ig a to r  ( a s  c l in i c a l ly  in d i c a t e d )  d u r in g  th e  Q 3  mo n th ly  v i s i t s .   L o c a l ly  c o l l e c t e d  l a b o r a to ry  v a lu e s  th a t  a r e  a b n o rm a l  a n d  c l in i c a l ly  s ig n i f i c a n t  w i l l  b e  c o l l e c t e d  in  Sp o n s o r’ s  
c l in i c a l  d a t a b a s e  a lo n g  w i th  th e  r e f e r e n c e  r a n g e s .  
6 .1 0 .1 L abo r a to r y  Pa r am e t e r s 
C l in i c a l  l a b o r a to ry  t e s t s  w i l l  in c lu d e  th e  fo l low in g :   
S e rum  Ch em i s t r y 
A lb um in  (ALB ) 
A lk a l in e  p h o s p h a t a s e  (ALK- P ) 
A l a n in e  am in o t r a n s f e r a s e  (ALT ;  SGPT ) Amy l a s e 
A s p a r t a t e  am in o t r a n s f e r as e  (AST ;  SGOT )  
B i c a rb o n a t e   B lo o d  u r e a  n i t ro g e n  (BUN ) 
C a l c ium  (C a ) 
C h lo r id e  (C l ) C r e a t in in e   
C r e a t in e  k in a s e  a n d  MB  s u b ty p e  ( i f  
e l e v a t e d )  
G amm a- g lu t amy l  t r a n s f e r a s e  (GGT )  
G lu c o s e  L a c t a t e  d e h y d ro g e n a s e  (LDH ) 
L ip a s e 
M a g n e s ium  Ph o s p h a t e   
Po t a s s ium  (K ) 
So d ium  (N a ) To t a l  b i l i ru b in 
To t a l  c h o l e s t e ro l   
To t a l  p ro t e in T r ig ly c e r id e s H ema to lo g y  H em a to c r i t  (H c t ) 
H emo g lo b in  (H b ) 
M e a n  c o rp u s c u l a r  h emo g lo b in  (MCH ) M e a n  c o rp u s c u l a r  v o lum e  (MCV ) 
P l a t e l e t  c o u n t 
R e d  b lo o d  c e l l  c o u n t  (RBC ) 
W h i t e  b lo o d  c e l l  c o u n t  (WBC )  wi th  
d i f f e r e n t i a l   
 
C o a gu la t ion  
P ro th romb in  t im e  (PT ) 
A c t iv a t e d  p a r t i a l  th romb o p l a s t in  t im e  
(PTT )  
In t e rn a t io n a l  n o rm a l i z e d  r a t io n  ( INR )   
Add i t iona l  t e s t s  S e rum  h um a n  c h o r io n i c  g o n a d o t ro p in  
(hCG )  *  
Br a in  n a t r iu r e t i c  p e p t id e  (BNP )*   
N -t e rm in a l  p ro - b r a in  n a t riu r e t i c  p e p t id e  
(NT - p roBNP )  l e v e l s *  
 
*  T e s t s  p e r f o rm ed  a t  W e ek  2 5 V i s i t  o f  S t u d y  APD8 1 1 -0 0 3  w i l l  s e r v e  a s  b a s e l i n e  f o r  S t u d y  APD8 1 1 - 0 0 7 .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  4 9  6 .1 0 .2 U r ina ly s i s 
U r in a ly s i s  p a r am e t e r s  fo r  c l in i c a l  l a b o r a to ry  t e s t s  i n c lu d e  th e  fo l low in g : 
Ap p e a r a n c e Oc c u l t  b lo o d  
Bi l i ru b in  pH  
Co lo r Pro t e in  
Glu c o s e  Sp e c i f i c  g r a v i ty  
Ke to n e s  Uro b i l in o g e n  
Le u k o c y t e  e s t e r a s e   
 
6 .1 0 .3 Samp l e  C o l l e c t ion,  S to r a g e ,  and  Sh ipp ing  
B lo o d  s amp l e s  fo r  h em a to lo g y ,  c o a g u l a t io n  p a r am e t e r s ,  s e rum  c h em i s t ry ,  h um a n  
immu n o d e f i c i e n c y  v i ru s  a n d  h e p a t i t i s  s c r e e n s ,  a n d  s e rum  hCG  w i l l  b e  c o l l e c t e d  a c c o rd in g  to  th e  l a b o r a to ry  m a n u a l  p ro v id e d  b y  th e  lo c a l  o r  c e n t r a l  l a b o r a to ry  a n d  a c c o rd in g  to  th e  
s c h e d u l e  o f  e v e n t s  p r e s e n t e d  in  T a b l e 1  a n d  T a b l e 2 .  
6 .1 1  BNP /NT- PROBNP 
A s  m e a n  PAP in c r e a s e s ,  s o  d o e s  th e  b r a in  n a t r iu r e t i c  p e p t id e  ( BNP) /N - t e rm in a l  p ro - b r a in  
n a t r iu r e t i c  p e p t id e  (NT- p roBNP )  l e v e l  a s  lo n g  a s  v e n t r i c u l a r  fu n c t io n  i s  in t a c t .   In  id io p a th i c  
PAH,  th e  BNP /NT - p roBNP  l e v e l  i s  r e l a t e d  to  fu n c t io n a l  imp a i rm e n t .  
A s  BNP /NT- p roBNP  m a y  b e  a f f e c t e d  b y  r e c e n t  e x e r c i s e ,  s u b j e c t s  mu s t  b e  a l low e d  to  r e s t  fo r  
a  m in imum  p e r io d  o f  1  hou r fo l low in g  a r r iv a l  a t  t h e  c l in i c ,  p r io r  to  o b t a in in g  th i s  b lo o d  
s amp l e .   S im i l a r ly ,  th i s  s amp l e  mu s t  b e  t a k e n  p r io r  to  th e  6MWT.   Th i s  s amp l e  s h o u ld  b e  
t a k e n  w i th  th e  s u b j e c t  in  th e  s am e  p o s i t io n  a t  a l l  a p p ro p r i a t e  v i s i t s ,  e g ,  s i t t in g  o r  s em i - r e c umb e n t .   D e t a i l e d  in s t ru c t io n s  a b o u t  s amp l e  c o l l e c t io n  w i l l  b e  p ro v id e d  in  a  s e p a r a t e  s amp l e  c o l l e c t io n  m a n u a l .  
A f t e r  th e  l a s t  s u b j e c t  e n ro l l e d  in  APD 8 1 1 - 0 0 7  c om p l e t e s  a p p ro x im a t e ly  6  mo n th s  o f  
t r e a tm e n t  a n d  a  c umu l a t iv e  a l l - s u b j e c t  d a t a  a n a ly s i s  i s  p e r fo rm e d ,  a s  o u t l in e d  in  S e c t io n  9 ,  p ro - BNP  a n d  NT- p roBNP  t e s t in g  w i l l  s u b s e q u e n t ly  b e  c o n d u c t e d  lo c a l ly  a t  th e  d i s c r e t io n  o f  th e  In v e s t ig a to r  ( a s  c l in i c a l ly  in d i c a t e d )  d u r in g  th e  Q 3  mo n th ly  v i s i t s .   L o c a l ly  c o l l e c t e d  v a lu e s  w i l l  b e  e n t e r e d  in to  th e  Sp o n s o r’ s  c l in i c a l  d a t a b a s e  a lo n g  w i th  th e  r e f e r e n c e  r a n g e s .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  5 0  6 .1 2  ADVERSE EVENTS ASSESSMENTS 
AE s  w i l l  b e  r e c o rd e d  a n d  r e p o r t e d  in  a c c o rd a n c e  w i th  ICH  G u id e l in e  E6 ,  G o o d  C l in i c a l  
P r a c t i c e :  C o n s o l id a t e d  G u id a n c e (1 9 9 6 ) .   De f in i t i o n s  o f  AE s  a n d  SAE s  w i l l  b e  th e  s am e  a s  
th o s e  p r e s e n t e d  in  ICH  G u id e l in e  E2A .  
6 .1 2 .1 Adv e r s e  E v en t  R epo r t ing 
Su b j e c ts  w i l l  b e  in s t ru c t e d  th a t  th e y  m a y  r e p o r t  AE s  a t  a n y  t im e .   A l l  e v e n t s  r e p o r t e d  fo l low in g  s tu d y  d ru g  a dm in i s t r a t io n  w i l l  b e  r e c o rd e d  a s  TEAEs .  
M o n i to r in g  o f  AE s  w i l l  b e  c o n t in u e d  u p  to  3 0  d a y s  a f t e r c e s s a t io n  o f  s tu d y  d ru g  
a dm in i s t r a t io n .   In  th e  e v e n t  th a t  a n  AE  i s  n o t  r e s o l v e d  o r  s t a b i l i z e d  b y  th i s  t im e ,  th e  Sp o n s o r  
in  c o n s u l t a t io n  w i th  th e  In v e s t ig a to r  w i l l  d e c id e  w h e th e r  to  c o n t in u e  to  mo n i to r  th e  AE  o r  
c lo s e - o u t  th e  e v e n t  in  th e  d a t a b a s e  i f  n o  fu r th e r  fo l l ow - u p  i s  n e c e s s a ry . 
Fo r  th i s  s tu d y ,  a n  AE  i s  d e f in e d  a s :  “A n y  u n tow a r d  m e d i c a l  o c c u r r e n c e  in  a  s tu d y  s u b j e c t  
a dm in i s t e r e d  a n y  d o s e  o f  r a l in e p a g  a n d  w h i c h  d o e s  n o t  n e c e s s a r i ly  h a v e  to  h a v e  a  c a u s a l  
r e l a t io n s h ip  w i th  th i s  t r e a tm e n t . ”   A n  AE  c a n  th e r e fo r e  b e  a n y  u n f a v o r a b l e  a n d  u n in t e n d e d  
s ig n  ( in c lu d in g  a n  a b n o rm a l  l a b o r a to ry  f in d in g ) ,  s ymp tom ,  o r  d i s e a s e  t emp o r a l ly  a s s o c i a t e d  w i th  th e  u s e  of  th e  s tu d y  d ru g ,  w h e th e r  o r  n o t  r e l a t e d  to  th e  p ro d u c t .  
AE s  c a n  b e  a n y  o f  th e  fo l low in g : 
•  U n f a v o r a b l e  c h a n g e s  in  g e n e r a l  c o n d i t io n 
•  Su b j e c t iv e  o r  o b j e c t iv e  s ig n s / s ymp tom s 
•  C o n c om i t a n t  d i s e a s e  o r  a c c id e n t s 
•  C l in i c a l ly  r e l e v a n t  a d v e r s e  c h a n g e s  in  l a b o r a to ry  p a r am e t e r s  o b s e rv e d  in  a  s u b j e c t  in  
th e  c o u r s e  o f  a  c l in i c a l  s tu d y  
•  P r e- e x i s t in g  c o n d i t io n s  w h i c h  w o r s e n  in  s e v e r i ty  o r  f r e q u e n c y  o r  w h i c h  h a v e  n ew  
s ig n s / s ymp tom s  a s s o c i a t e d  w i th  th em  
AEs  w i l l  b e  e l i c i t e d  a t  th e  t im e  in d i c a t e d  in  th e  s c h e d u l e  b y  a s k in g  th e  q u e s t io n ,  “S in c e  y o u  
w e r e  l a s t  a s k e d ,  h a v e  y o u  f e l t  u nw e l l  o r  d i f f e r e n t  f rom  u s u a l  in  a n y  w a y ? ”   A n y  a d v e r s e  o r  
u n e x p e c t e d  e v e n t s ,  s ig n s ,  a n d  s ymp tom s  w i l l  b e  fu l ly  r e c o rd e d  o n  th e  AE Fo rm,  in c lu d in g  
d e t a i l s  o f  in t e n s i ty ,  o n s e t ,  d u r a t io n ,  o u t c om e ,  a n d  r e l a t io n s h ip  to  th e  d ru g  a s  d e t e rm in e d  b y  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  5 1  th e  In v e s t ig a to r .   W h e n e v e r  p o s s ib l e ,  a  c o n s t e l l a t io n  o f  s ig n s  a n d  s ymp tom s  s h o u ld  b e  
r e c o rd e d  a s  a  u n i fy in g  d i a g n o s i s  ( e g ,  s e l f - l im i t e d  f e v e r ,  ru n n y  n o s e ,  c o u g h ,  a n d  s c r a t c h y  th ro a t  s h o u ld  b e  c a p tu r e d  a s  a n  u p p e r  r e s p i r a to ry  i n f e c t io n  r a th e r  th a n  b y  th e  in d iv id u a l  s ig n s  
a n d  s ymp tom s ) .   AE s  m a y  a l s o  b e  r e p o r t e d  a t  a n y  t im e.   Th e  ty p e  a n d  d u r a t io n  o f  fo l low- u p  
o f  s u b j e c t s  a f t e r  AE s  w i l l  b e  d o c um e n t e d .  
6 .1 2 .2 S e r iou s Adv e r s e  E v en t s  and  E xp ed i t ed  R epo r t ing  o f  Adv e r s e  E v en t s 
SAE s  w i ll  b e  c a p tu r e d  f rom  t h e  S tu d y  APD 8 1 1- 0 0 7  B a s e l in e  V i s i t  (W e e k  2 5  o f  S tu d y  APD 8 1 1- 0 0 3 )  to  3 0  d a y s  a f t e r  th e  l a s t  d o s e  o f  s tu d y  d ru g  a n d  w i l l  b e  mo n i to r e d  u n t i l  r e s o lu t io n  o r  s t a b i l i z a t io n .  
A n  SAE  i s  a n y  u n tow a rd  m e d i c a l  o c c u r r e n c e  th a t  a t  a n y  d o s e  r e s u l t s  in  th e  fo l low in g  
o u t c om e s :  
•  D e a th 
•  I s  l i f e - t h r e a t e n in g  
•  R e q u i r e d /p ro lo n g e d  ho s p i t a l i z a t io n  •  D i s a b i l i ty /i n c a p a c i ty  
•  C o n g e n i t a l  a n om a ly /bi r th  d e f e c t  
•  Imp o r t a n t  m e d i c a l  e v e n t  ( s e e  b e low )  
A n  imp o r t a n t  m e d i c a l  e v e n t  th a t  m a y  n o t  r e s u l t  in  d e a th ,  b e  l i f e- th r e a t e n in g ,  o r  r e q u i r e  
h o s p i t a l i z a t io n  m a y  b e  c o n s id e r e d  a n  SAE  w h e n ,  b a s e d  u p o n  a p p ro p r i a t e  m e d i c a l  ju d gm e n t ,  i t  m a y  j e o p a rd i z e  th e  s u b j e c t  a n d  m a y  r e q u i r e  m e d i c a l  o r  s u rg i c a l  in t e rv e n t io n  to  p r e v e n t  1  o f  
th e  o u t c om e s  l i s t e d  in  th i s  d e f in i t io n .   Ex amp l e s  o f  s u c h  a  m e d i c a l  e v e n t  in c lu d e s  a l l e rg i c  
b ro n c h o s p a sm  r e q u i r in g  in t e n s iv e  t r e a tm e n t  in  a n  em e rg e n c y  ro om  o r  a t  h om e ,  b lo o d  d y s c r a s i a s ,  o r  c o n v u l s io n s  th a t  d o  n o t  r e s u l t  in  fo rm a l  h o s p i t a l i z a t io n .  
Th e  fol low in g  a r e  n o t  c o n s id e r e d  SAE s  d e s p i t e  r e q u i r in g  h o s p i t a l i z a t io n :  
•  P r e- e x i s t in g  c o n d i t io n s  th a t ,  in  th e  o p in io n  o f  th e  i n v e s t ig a to r ,  d id  n o t  w o r s e n  o r  
p ro g r e s s  d u r in g  s tu d y  p a r t i c ip a t io n   
•  R o u t in e ly  s c h e d u l e d  p ro c e d u r e s  o r  t r e a tm e n t  ( e g,  r o u t in e  RHC )  
•  E l e c t iv e  p ro c e d u r e s  th a t  w e r e  s c h e d u l e d  p r io r  to  s t u d y  p a r t i c ip a t io n  ( i e ,  s ig n in g  o f  th e  
in fo rm e d  c o n s e n t  d o c um e n t )  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  5 2  A l l  SAE s ,  w h e th e r  o r  n o t  c o n s id e r e d  r e l a t e d  to  s tu d y  t r e a tm e n t ,  mu s t  b e  r e p o r t e d  to th e  
Sp o n s o r  c o n t a c t w i th in  2 4  h o u r s  o f  b e c om in g  aw a r e  o f  th e  e v e n t.   In  a d d i t io n ,  a  c omp l e t e d  r e p o r t  u s in g  th e  Sp o n s o r ’ s  SAE  R e p o r t  fo rm  mu s t  b e  s u bm i t t e d  w i th in  2 4  h o u r s  o f  
n o t i f i c a t io n  to :  
U n i t e d  Th e r a p e u t i c s  G lo b a l  D ru g  S a f e ty 
G lo b a l  F a x:    
em a i l :   
O th e r  s i tu a t io n s  a s  d e f in e d  in  ICH  G u id e l in e  E2A ,  C l in i c a l  S a f e t y  D a ta  Ma n a g em e n t :  D e f in i t io n s  a n d  S ta n d a r d s  fo r  E x p e d i t e d  R e p o r t in g (1 9 9 4 ) ,  2 1  C o d e  o f  F e d e r a l  R e g u l a t io n s  
S e c t io n 3 1 2 .3 2 ,  a n d  EU  V o lum e  1 0  a l s o  q u a l i fy  fo r  e x p e d i t e d  r e p o r t in g .   In  th e  fo l low in g  s i tu a t io n s ,  th e  p ro c e s s  w i l l  b e  a s  d e t a i l e d  fo r  SAE s  a b o v e :  
•  SAEs  w h i c h  c o u ld  b e  a s s o c i a t e d  w i th  th e  s tu d y  p r o c e d u r e s  
•  SAEs  a n d  AEs  o f  s p e c i a l  in t e r e s t  th a t  c o u ld  m a t e r i a l ly  in f lu e n c e  th e  b e n e f i t - r i s k  
a s s e s sm e n t  o f  a  m e d i c in a l  p ro d u c t ,  s u c h  a s  a  c l in i c a l ly  imp o r t a n t  in c r e a s e  in  th e  r a t e  o f  
a  s e r io u s  s u s p e c t e d  a d v e r s e  r e a c t io n  o v e r  th a t  l i s t e d  in  th e  In v e s t ig a to r ’ s  B ro c h u r e  
6 .1 2 .3 P r e gnan c y 
I f  a  s tu d y  s u b j e c t  b e c om e s  p r e g n a n t  d u r in g  p a r t i c i p a t io n  in  th i s  c l in i c a l  s tu d y ,  s i t e  s t a f f  mu s t  
n o t i fy  th e  s p o n s o r  w i th in  2 4  h o u r s  o f  l e a rn in g  o f  th e  p r e g n a n c y .   Su b j e c t s  w h o  b e c om e  p r e g n a n t  d u r in g  th e  s tu d y  w i l l  b e  d i s c o n t in u e d  f rom  r a l in e p a g  imm e d i a t e ly .   A l th o u g h  n o t  c o n s id e r e d  a n  SAE  o r  AE ,  p r e g n a n c i e s  o c c u r r in g  d u r in g  th e  p e r io d  o f  r a l in e p a g  
a dm in i s t r a t io n  u n t i l  3 0  d a y s  a f t e r  th e  l a s t  d o s e  o f  r a l in e p a g  s h o u ld  b e  r e p o r t e d  to  th e  Sp o n s o r  
a n d  IRB / IEC  in  th e  s am e  m a n n e r  a s  a n  SAE ,  u s in g  a  p r e g n a n c y  n o t i f ic a t io n  fo rm .  
Th e  p r e g n a n c y  mu s t  b e  fo l low e d  u p  to  d e t e rm in e  o u t c om e  ( in c lu d in g  p r em a tu r e  t e rm in a t io n )  
a n d  s t a tu s  o f  mo th e r  a n d  c h i ld .   P r e g n a n c y  c omp l i c a t io n s  a n d  e l e c t iv e  t e rm in a t io n s  fo r  
m e d i c a l  r e a s o n s  mu s t  b e  r e p o r t e d  a s  a n  AE  o r  SAE .   Sp o n t a n e o u s  a b o r t io n s  mu s t  b e  r e p o r t e d  
a s  a n  SAE .   P r e g n a n c i e s  w i l l  b e  fo l low e d  e v e ry  t r im e s t e r  th ro u g h  th e  f i r s t  w e l l  b a b y  v i s i t .   
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  5 3  Fo r  f em a l e  p a r tn e r s  w h o  b e c om e  p r e g n a n t  b y  m a l e  s tu d y  s u b j e c t s  d u r in g  th e  c o u r s e  o f  th e  
s tu d y ,  r e a s o n a b l e  e f fo r t s  w i l l  b e  m a d e  to  c o l l e c t  in fo rm a t io n  o n  th e  p a r tn e r ’ s  p r e g n a n c y  th ro u g h  th e  f i r s t  w e l l  b a b y  v i s i t  a s  p ro v id e d  b y  th e  m a l e  s tu d y  s u b j e c t .  
6 .1 2 .4 A s s e s sm en t o f  Adv e r s e  E v en t  S e v e r i ty  
Th e  s e v e r i ty  o f  e a c h  AE  w i l l  b e  a s s e s s e d  a t  o n s e t  b y  a  n u r s e  a n d /o r  p h y s i c i a n .  W h e n  r e c o rd in g  th e  o u t c om e  o f  th e  AE ,  th e  m a x imum  s e v e r i ty  o f  th e  AE  e x p e r i e n c e d  w i l l  a l s o  b e  
r e c o rd e d .   Th e  s e v e r i ty  o f  th e  AE  w i l l  b e  g r a d e d  a c c o rd in g  to  th e  C ommo n  T e rm in o lo g y  
C r i t e r i a  fo r  A d v e r s e  Ev e n t s v .  4 .0 3
2 0 d e f in i t io n s  l i s t e d  b e low : 
G r a d e  1 :  M i ld ;  a s ymp tom a t i c  o r  m i ld  s ymp tom s ;  c l in i c a l  o r  d i a g n o s t i c  o b s e rv a t io n s  o n ly ;  
in t e rv e n t io n  n o t  in d i c a t e d .  
G r a d e  2 :   M o d e r a t e ;  m in im a l ,  lo c a l  o r  n o n in v a s iv e  in t e rv e n t io n  in d i c a t e d ;  l im i t i n g  a g e-
a p p ro p r i a t e  in s t rum e n t a l  A c t iv i t i e s  o f  D a i ly  L iv in g  (ADL )* .  
G r a d e  3 :   S e v e r e  o r  m e d i c a l ly  s ig n i f i c a n t  b u t  n o t  imm e d i a t e ly  l i f e- th r e a t e n in g ;  
h o s p i t a l i z a t io n  o r  p ro lo n g a t io n  o f  h o s p i t a l i z a t io n  i n d i c a t e d ;  d i s a b l in g ;  l im i t in g  s e l f-
c a r e  ADL * * .  
G r a d e  4 :   L i f e- th r e a t e n in g  c o n s e q u e n c e s ;  u rg e n t  in t e rv e n t io n  in d i c a t e d .  
G r a d e  5 :   D e a th  r e l a t e d  to  AE . 
*   I n s t r um e n t a l  ADL  r e f e r  t o  p r ep a r i n g  m e a l s ,  sh o p p i n g  f o r  g r o c e r i e s  o r  c l o t h e s ,  u s i n g  t h e  t e l e p h o n e ,  m a n ag i n g  
m o n ey ,  e t c . 
* *  S e l f- c a r e  ADL  r e f e r  t o  b a t h i n g ,  d r e s s i n g  an d  u n d r e s s i n g ,  f e ed i n g  s e l f ,  u s i n g  t h e  t o i l e t ,  t ak i n g  m ed i c a t i o n s ,  an d  n o t  
b ed r i d d en .  
6 .1 2 .5 A s s e s sm en t o f  Adv e r s e  E v en t  R e la t ion sh ip  to  S tudy  D rug  
Th e  r e l a t io n s h ip  o f  a n  AE  to  in v e s t ig a t io n a l  p ro d uc t ( s )  w i l l  b e  c l a s s i f i e d  u s in g  mo d i f i e d  
WHO  c r i t e r i a  (Edw a rd s  a n d  B i r i e l l ,  W o r ld  H e a l th  O rg a n i z a t io n  C o l l a b o r a t in g  C e n t r e  fo r  In t e rn a t io n a l  D ru g  M o n i to r in g  1 9 9 4 )  a s  fo l low s .  
R e la t ed:   a  c l in i c a l  e v e n t ,  in c lu d in g  l a b o r a to ry  t e s t  a b n o rm a l i ty ,  w i th  a  r e a s o n a b l e  t im e  
s e q u e n c e  to  a dm in i s t r a t io n  o f  th e  d ru g ,  u n l ik e ly  to  b e  a t t r ib u t e d  to  c o n c u r r e n t  d i s e a s e  
o r  o th e r  d ru g s  o r  c h em i c a l s ,  a n d  w h i c h  fo l low s  a  c l in i c a l ly  r e a s o n a b l e  r e s p o n s e  o n  
w i th d r aw a l  (d e c h a l l e n g e ) .   R e c h a l l e n g e  in fo rm a t io n  i s  n o t  r e q u i r e d  to  fu l f i l l th i s  
d e f in i t io n ;  o r  a n  e v e n t  th a t  c o u ld  a l s o  b e  e x p l a in e d  b y  c o n c u r r e n t  d i s e a s e  o r  o th e r  
d ru g s  o r  c h em i c a l s  w h e r e  in fo rm a t io n  o n  d ru g  w i t h d r aw a l  m a y  b e  l a c k in g  o r  u n c l e a r .  
N o t  r e la t ed:   a  c l in i c a l  e v e n t ,  in c lu d in g  l a b o r a to ry  t e s t  a b n o rm a l i ty ,  w i th  s u f f i c i e n t  
e v id e n c e  to  a c c e p t  th a t  th e r e  i s  n o  c a u s a l  r e l a t io n s h ip  to  d ru g  a dm in i s t r a t io n  ( e g ,  n o  
t emp o r a l  r e l a t io n s h ip  to  d ru g  a dm in i s t r a t io n ,  b e c a u s e  th e  d ru g  w a s  a dm in i s t e r e d  a f t e r  
o n s e t  o f  e v e n t ;  in v e s t ig a t io n  s h ow s  th a t  th e  d ru g  w a s  n o t  a dm in i s t e r e d ;  p ro o f  o f  o th e r  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  5 4  c a u s e ;  e t c ) ;  o r  a n  e v e n t  w i th  a  t emp o r a l  r e l a t io n s h ip  to  d ru g  a dm in i s t r a t io n  w h i c h  
m a k e s  a  c a u s a l  r e l a t io n s h ip  imp ro b a b l e ,  a n d  in  w h i c h  o th e r  d ru g s ,  c h em i c a l s  o r  
u n d e r ly in g  d i s e a s e  p ro v id e  p l a u s ib l e  e x p l a n a t io n s .  
6 .1 2 .6 A s s e s sm en t o f  Adv e r s e  E v en t  Ou t c om e  
O u t c om e  o f  AE s  w i l l  b e  d e f in e d  a c c o rd in g  to  ICH  G u id e l in e  E2B .  
•  R e c o v e r e d /R e s o lv e d 
•  R e c o v e r in g /R e s o lv in g  
•  N o t  R e c o v e r e d /N o t  R e s o lv e d 
•  R e c o v e r e d /R e s o lv e d  w i th  S e q u e l a e •  F a t a l 
•  U n k n ow n  
6 .1 2 .7 A c t ion T ak en fo r  Adv e r s e  E v en t  
A c t io n  t a k e n  fo r  AE s  w i l l  b e  d o c um e n te d  a c c o rd in g  to  th e  fo l low in g :  
•  C o n c om i t a n t  m e d i c a t io n  o r  o th e r  t r e a tm e n t 
•  W i th d r aw a l  f rom  th e  s tu d y 
6 .1 2 .7 .1 A c t ion T ak en  fo r  S tudy  D rug 
A n y  a c t io n  t a k e n w i th  s tu d y  d ru g w i l l  b e  d e f in e d  a c c o rd in g  to  ICH  G u id e l in e  E2B ,  D a ta  
E l em e n t s  fo r  T r a n sm i s s io n  o f  In d i v id u a l  C a s e  S a f e t y  R e p o r t s (1 9 9 8 )  a n d  d o c um e n t e d  in  th e  
CRF  a c c o rd in g  to  th e  fo l low in g : 
•  D ru g  W i th d r aw n 
•  D o s e  R e d u c e d 
•  D o s e  In c r e a s e d •  N o n e  (n o t  c h a n g e d )  
•  D o s e  In t e r ru p t e d 
•  U n kn ow n  
•  N o t  A p p l i c a b l e 
6 .1 2 .8 C o l l e c t ion o f  E x t r a  L abo r a to r y  Samp l e s / Inv e s t ig a t ion s  
In  th e  e v e n t  o f  a  c l in i c a l ly  imp o r t a n t  AE ,  a  s u i t a b l e  s amp l e  m a y  b e  c o l l e c t e d  fo r  d ru g  a s s a y  o r  
fo r  a d d i t io n a l  l a b o r a to ry  t e s t s .   Th e  In v e s t ig a to r  m u s t  e n s u r e  th a t  th e  s amp l e  i s  p ro pe r ly  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  5 5  l a b e l e d  a n d  s to r e d .   Th e  In v e s t ig a to r  a n d  o th e r s  r e s p o n s ib l e  fo r  th e  c a r e  o f  th e  s u b j e c t s  s h o u ld  
in s t i tu t e  a n y  s u p p l em e n t a ry  in v e s t ig a t io n s  o f  s ig n i f i c a n t  AE s  b a s e d  o n  th e  c l in i c a l  ju d gm e n t  o f  th e  l ik e ly  c a u s a t iv e  f a c to r.   Th i s  m a y  in c lu d e  s e e k in g  a  fu r th e r  o p in io n  f rom  a  s p e c i a l i s t  in  
th e  f i e ld  o f  th e  AE .   Th e  c omp a n y  m a y  s u g g e s t  s p e c i a l  t e s t s  b a s e d  o n  e x p e r t  a d v i c e . 
6 .1 2 .9 Fo l low -up  o f  Adv e r s e  E v en t s  P r e s en t  a t  L a s t  S ch edu l ed  S tudy  V i s i t 
Th e  AEs  p r e s e n t  a t  th e  l a s t  s tu d y  d a y  (En d  o f  S tu d y )  th a t  r e q u i r e  fo l low  u p  o r  a  r e p e a t  l a b o r a to ry  t e s t  w i l l  b e  fo l low e d  u p  in i t i a l ly  fo r  3 0  d a y s  a c c o rd in g  to  th e  Sp o n s o r ’ s .   AE s  th a t  
h a v e  n o t  r e s o lv e d  o r  s t a b i l i z e d  a t  3 0  d a y s  a f t e r  th e  l a s t  s u b j e c t ’ s  l a s t  s tu d y  d o s e  w i l l  b e  r e v i ew e d  o n  a n  in d iv id u a l  b a s i s  to  d e t e rm in e  w h e th e r  th e  d a t a b a s e  w i l l  b e  lo c k e d  a n d  s u b s e q u e n t ly  u p d a t e d  o n c e  th e  e v e n t s  o f  o n g o in g  AE s  a r e  r e s o lv e d  o r  w h e th e r  d a t a b a s e  lo c k  
w i l l  b e  h e ld . 
6 .1 3  CONCOM ITANT MED ICAT ION ASSESSMENTS 
A l l  c o n c om i t a n t  m e d i c a t io n s  (o v e r - th e - c o u n t e r  a n d  p r e s c r ib e d )  t a k e n  b y  s u b j e c t s  w i l l  b e  
r e c o rd e d  in  th e  CRF  w i th  in d i c a t io n ,  s t a r t  d a t e / t im e ,  a n d  s to p  d a t e / t im e ,  i f  k n ow n .  
Su b j e c ts  a r e  p e rm i t t e d  o r a l  d i s e a s e - s p e c i f i c  PAH  t h e r a p y  c o n s i s t in g  o f  a n  ERA  a n d /o r  a  
PDE5 - I  o r  sGC  s t imu l a to r ,  b u t  n o t  a l l  3 .   Th e  o n- s tu d y  a d d i t io n / s u b s t i tu t io n  o f  a n  ERA ,  PDE5 - I  o r  sGC  s t imu l a to r ,  i f  o n  a  s in g l e  s u c h  a g e n t  a t  B a s e l in e,  o r  d o s a g e  in c r e a s e  fo r  s u c h  
a g e n t s  i s  p e rm i t t e d .   In  a d d i t io n  to  r a l in e p a g ,  s u b j e c t s  c a n  b e  p r e s c r ib e d  n o  mo r e  th a n  1  a g e n t  
f rom  th e  ERA  c l a s s  a n d  1  f rom  th e  PDE5 - I / sGC  s t imu l a to r  c l a s s  a t  a n y  1  t im e .   Su b s t i tu t io n  a n d  d o s e  a d ju s tm e n t  w i th in  e a c h  o f  th e s e  c l a s s e s  i s  p e rm i t t e d .   Su b j e c ts  s h o u ld  b e  e v a lu a t e d  fo r  th e  p r e s e n c e  o f  c l in i c a l  w o r s e n in g  i f  a d d i t io n a l  th e r a p y  o r  d o s e  a d ju s tm e n t s  o f  c u r r e n t  
th e r a p i e s  a r e  r e q u i r e d .  
In  a d d i t io n ,  th e  fo l low in g  th e r a p i e s ,  w h i c h  m a y  a f f e c t  PAH ,  a r e  p e rm i t t e d  a n d  m a y  b e  
a d ju s t e d  in  d o s e  a s  n e e d e d :    
•  Va s o d i l a to r s  ( in c lu d in g  c a l c ium  c h a n n e l  b lo c k e r s )  
•  D ig o x in  
•  Sp i ro n o l a c to n e  
•  L -A rg in in e  s u p p l em e n t a t io n 
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  5 6  D iu r e t i c s m a y  b e  d o s e d  a s  c l in i c a l ly  in d i c a t e d  th ro u g h o u t  th e  s tu d y . 
Su b j e c t s  w h o  r e q u i r e  t r e a tm e n t  w i th  a  p ro s t a c y c l in /p ro s t a c y c l in  a n a lo g u e  ( IV ,  SC ,  o r a l ,  o r  
in h a l e d ) ,  e x c e p t  fo r  a c u t e  v a s o d i l a to r  t e s t in g  d u r in g  c a rd i a c  c a th e t e r i z a t io n ,  w i l l  b e  
d i s c o n t in u e d  f rom  th e  s tu d y .  
6 .1 4  REMOVAL OF SUB JECTS FROM THE STUDY OR STUDY DRUG 
Su b j e c ts  w i l l  b e  a l low e d  to  r em a in  o n  s tu d y  d ru g  u n t i l  m a rk e t in g  a p p ro v a l  o f  r a l in e p a g  i s  
g r a n t e d  o r  u n t i l  th e  Sp o n s o r  d i s c o n t in u e s  th e  s tu d y .   Th e  s tu d y  w i l l  b e  t e rm in a t e d  e a r ly  i f ,  in  
th e  o p in io n  o f  th e  Sp o n s o r ,  In v e s t ig a to r ,  o r  IRB / IEC ,  a n  u n a c c e p t a b l e  r i s k  to  th e  s a f e ty  a n d  w e l f a r e  o f  s u b j e c t s  i s  p o s e d  b y  th e  c o n t in u a t io n  o f  th e  s tu d y  in  l ig h t  o f  r e v i ew  o f  th e  k e y  s a f e ty  d a t a .  
Su b j e c ts  w i l l  b e  in fo rm e d  th a t  th e y  a r e  f r e e  to  w i th d r aw  f rom  th e  s tu d y  a t  a n y  t im e  fo r  a n y  
r e a s o n  s h o u ld  th e y  s o  w i s h .   Th e  In v e s t ig a to r  m a y  r emo v e  a  s u b j e c t  i f ,  in  h i s /h e r  o p in io n ,  i t  i s  in  th e  b e s t  in t e r e s t  o f  th e  s u b j e c t .   A  s u b j e c t  m a y  b e  w i th d r aw n  f rom  th e  s tu d y  fo r  a n y  o f  th e  fo l low in g  r e a s o n s :  
•  C l in i c a l  w o r s e nin g ,  a s  d e f in e d  in  S e c t io n  6 .9  
•  D e v i a t io n /n o n c omp l i a n c e  w i th  th e  p ro to c o l 
•  A  s e r io u s  o r  in to l e r a b l e  AE  o c c u r s 
•  Th e  Sp o n s o r  o r  In v e s t ig a to r  t e rm in a t e s  th e  stu d y  
•  W i th d r aw a l  o f  c o n s e n t  -  a n y  s u b j e c t  m a y  w i th d r aw  h i s /h e r  c o n s e n t  f rom  th e  s tu d y  a t  
a n y  t im e .   Th e  In v e s t ig a to r  s h o u ld  m a k e  a  r e a s o n a b l e  a t t emp t  to  d o c um e n t  th e  s p e c i f i c  
r e a s o n  w h y  c o n s e n t  i s  w i th d r aw n .  
6 .1 4 .1 Hand l ing  o f  W i thd r aw a l s 
A l th o u g h  a  s u b j e c t  i s  n o t  o b l ig e d  to  g iv e  h i s /h e r  r e a s o n  fo r  w i th d r aw in g  p r em a tu r e ly ,  th e  
In v e s t ig a to r  w i l l  m a k e  a  r e a s o n a b l e  e f fo r t  to  o b t a in  th e  r e a s o n  w h i l e  fu l ly  r e s p e c t in g  th e  s u b j e c t ’ s  r ig h t s .   I f  th e r e  i s  a  m e d i c a l  r e a s o n  fo r  d i s c o n t in u a t io n ,  th e  s u b j e c t  w i l l  r em a in  u n d e r  th e  s u p e rv i s io n  o f  th e  s tu d y  p h y s i c i a n  u n t i l  in  s a t i s f a c to ry  h e a l th .   R e a s o n a b l e  e f fo r t s  w i l l  b e  
m a d e  to  c o n t a c t  a  s u b j e c t  w h o  f a i l s  to  a t t e n d  a n y  f o l low- u p  a p p o in tm e n t s ,  in  o rd e r  to  e n s u r e  
th a t  h e / s h e  i s  in  s a t i s f a c to ry  h e a l th .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  5 7  I f  a  s u b j e c t  i s  p r em a tu r e ly  d i s c o n t in u e d  f rom  th i s  s tu d y ,  e v e ry  a t t emp t  w i l l  b e  m a d e  to  fo l low  
th e  En d  o f  S tu d y P ro c e d u r e s  d e s c r ib e d  in  S e c t io n  7 .  
In  a d d i t io n ,  a l l  s u b j e c t s  w i l l  b e  c o n t a c t e d  a t  th e  t im e  o f  S tu d y  APD 8 1 1 - 0 0 7  c lo s u r e  to  a s s e s s  
v i t a l  (mo r t a l i ty )  s t a tu s .   Th e  v i t a l  s t a tu s  fo l low - u p  c o n t a c t  o f  s u b j e c t s  w i l l  d e p e n d  o n  lo c a l  
r e g u l a t io n s  o r  s p e c i f i c  a g r e em e n t  w i th  th e  s u b j e c t  a n d  In v e s t ig a to r .  
6 .1 5  ALLOWABLE V IS IT AND PROCEDURE W INDOWS 
A  ±3 - d a y  w in d ow  i s  a l low e d  fo r  s tu d y  v i s i t s  a n d  p ro c e d u r e s  d u r in g  th e  Do s e  Ti t r a t io n  Pe r io d ,  
Tr e a tm e n t  Pe r io d ,  a n d  En d  o f  Stu d y  a n d  Fo l low -u p  Vi s i t s ,  w i th  th e  e x c e p t io n  o f  th e  Q 3  M o n th  Vi s i t s  d u r in g  th e  Tr e a tm e n t  Pe r io d ,  w h i c h  a r e  a l low e d  a  ±5 - d a y  w in d ow .  
7  STUDY ACT IV IT IES 
7 .1  SCREEN ING V IS IT 
G iv e n  th a t  th i s  s tu d y  s e rv e s  a s  a n  e x t e n s io n  to  S tu d y APD 8 1 1- 0 0 3 ,  a n  in d e p e n d e n t  S c r e e n in g  
V i s i t  i s  n o t  r e q u i r e d.   In  o rd e r  fo r  s u b j e c t s  to  b e  e l i g ib l e  fo r  th i s  s tu d y ,  th e y  mu s t  h a v e  c omp l e t e d  S tu d y  APD 8 1 1- 0 0 3  a s  p l a n n e d  o r  h a v e  b e e n  a s s ig n e d  to  p l a c e b o  a n d  d i s c o n t in u e d  fo r  c l in i c a l  w o r s e n in g  a n d  f u l f i l l  th e  e l ig ib i l i ty  c r i t e r i a  o u t l in e d  in  S e c t io n  4 .  
Su b j e c ts  w h o  h a v e  a n  in t e r e s t  in  p a r t i c ip a t in g  in  th i s  s tu d y  s h o u ld  b e  p ro p e r ly  c o n s e n t e d  p r io r  
to  c omp l e t in g  th e  W e e k  2 5  V i s i t  in  S tu d y  APD 8 1 1- 0 0 3 .   Th i s  i s  to  in c lu d e  a  d e t a i l e d  o r a l  p r e s e n t a t io n  o f  th e  n a tu r e ,  p u rp o s e ,  r i s k s ,  a n d  r e q u i r em e n t s  o f  th e  s tu d y  in  a d d i t io n  to  r e c e iv in g  d e t a i l e d  w r i t t e n  in fo rm a t io n .   E a c h  s u b j e c t s h o u ld  h a v e  a d e q u a t e  o p p o r tu n i ty  to  a s k  
th e  a p p ro p r i a t e  p e r s o n  o f  th e  c l in i c a l  s t a f f  ( i e ,  In v e s t ig a to r  o r  d e s ig n e e )  p r e s e n t in g  th e  s tu d y  
a b o u t  a n y  a s p e c t  o f  th e  s tu d y .   O n c e  th e  s u b j e c t  i s  s a t i s f i e d  th a t  h e / s h e  i s  w i l l in g  to  p a r t i c ip a t e  in  th e  s tu d y ,  h e / s h e  w i l l  b e  a s k e d  to  s ig n  th e  s tu d y  ICF .   Th e  c l in i c a l  p e r s o n n e l  o b t a in in g  w r i t t e n  c o n s e n t  f rom  th e  s u b j e c t  w i l l  a l s o  s ig n  th e  fo rm  to  c o n f i rm  c o n s e n t  h a s  b e e n  o b t a in e d.   
O n c e  s ig n e d ,  th e In v e s t ig a to r  w i l l  r e t a in  th e  o r ig in a l  fo r  th e  s u b j e c t ’ s  s tu d y  r e c o rd s  a n d  
p ro v id e  th e  s u b j e c t  w i th  a  s ig n e d  c o p y.   Th e  In v e s t ig a to r  w i l l  v e r i fy  th a t  in fo rm e d  c o n s e n t  h a s  b e e n  o b t a in e d  f rom  e a c h  s u b j e c t  p r io r  to  a dm i s s io n  in to  th e  s tu d y  a n d  p r io r  to  th e  s u b j e c t u n d e rg o in g  a n y  s tu d y - r e l a t e d  p ro c e d u r e s .   I f  i t  i s  s t a n d a rd  p r a c t i c e  a t  th e  s i t e  to  c o n d u c t  a  f ew  
g e n e r a l  n o n in v a s iv e  s tu d y  p ro c e d u r e s  ( i e ,  m e d i c a l / s o c i a l  h i s to ry ,  c o l l e c t io n  o f  c o n c om i t a n t  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  5 8  m e d i c a t io n s ,  e t c )  b e fo r e  a  s u b j e c t  c a n  b e  c o n s id e r e d  fo r  a  s p e c i f i c  s tu d y ,  th e  s tu d y  c e n t e r  mu s t  
h a v e  a  w r i t t e n  SOP  d e t a i l in g  th e  p r o c e d u r e ,  a n d  a l s o  e n s u r e  th a t  e a c h  s u b j e c t  s ig n s  a  g e n e r a l  c o n s e n t  p r io r  to  u n d e rg o in g  th e  g e n e r a l  p ro c e d u r e s .  
7 .2  STUDY PROCEDURES 
7 .2 .1 B a s e l in e S tudy  P r o c edu r e s –  A l l  Sub j e c ts   
Su b j e c ts  w h o  m e e t  a l l  th e  e n t ry  c r i t e r i a  a n d  a r e  e l i g ib l e  fo r  th e  s tu d y  w i l l  r e p o r t  to  th e  c l in i c a l  
s tu d y  u n i t  to  c o n f i rm  e l ig ib i l i ty  fo r  th e  s tu d y  a n d  c omp l e t e  a l l  B a s e l in e p ro c e d u r e s  a n d  r e c e iv e  s tu d y  d ru g  a n d  in s t ru c t io n s .   Th e  s tu d y  d ru g  w i l l  b e  g iv e n  in  th e  mo rn in g a t  th e  s tu d y  s i t e  d u r in g  th e  B a s e l in e V i s i t .   
7 .2 .1 .1 P r e-b a s e l in e  P r o c edu r es  
A l l  W e e k  2 5  m e a s u r em e n t s f rom  Stu d y  APD 8 1 1 - 0 0 3  w i l l  s e rv e  a s  B a s e l in e a s s e s sm e n t s  fo r  Stu d y  APD 8 1 1 - 0 0 7 .   
P l a c e b o- t r e a t e d  s u b j e c t s  w h o  d i s c o n t in u e d  p r em a tu r e ly  f rom  S tu d y  APD 8 1 1- 0 0 3  d u e  to  
c l in i c a l  w o r s e n in g  a r e  p e rm i t t e d  to  e n ro l l  in  APD 8 1 1 - 0 0 7  p ro v id e d  th a t  a l l  e n d  o f  s tu d y  p ro c e d u r e s  a r e  p e r fo rm e d  p e r  th e  ADP8 1 1 - 0 0 3  p ro to c o l .   Fo r  th e s e  s u b j e c t s ,  th e  t im e  o f  th e  c l in i c a l  w o r s e n in g  e v e n t  th a t  l e d  to  e a r ly  t e rm in a t i o n  in  S tu d y  APD 8 1 1- 0 0 3  w i l l  s e rv e  a s  th e  
B a s e l in e t im e  p o in t  fo r  c l in i c a l  w o r s e n in g  in  APD 8 1 1 - 0 0 7 .  
A n y  u n r e s o lv e d  AE  f rom  Stu d y  APD 8 1 1 - 0 0 3  w i l l  b e  c a r r i e d  fo rw a rd  a n d  r e c o rd e d . 
7 .2 .1 .2 B a s e l in e P r o c edu r e s 
•  M e d i c a l  h i s to ry  (p a r t i a l  h i s to ry ,  to  u p d a t e  f in d in g s  f rom  Stu d y  APD 8 1 1 - 0 0 3 )   
•  Ph y s i c a l  e x am1 
•  1 2 - l e a d  ECG1 
•  C l in i c a l  l a b o r a to ry  t e s t s  ( to  in c lu d e  h em a to lo g y ,  c o a g u l a t io n  p a r am e t e r s ,  s e rum  
c h em i s t ry ,  a n d  u r in a ly s i s )1 
•  S e rum  p r e g n a n c y  t e s t  (w om e n  o n ly )1 
•  V i t a l  s ig n s1 
•  6MWT1 
•  BNP /NT- p roBNP1 
•  A s s e s sm e n t  o f  c l in i c a l  w o r s e n in g  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  5 9  •  WHO /NYHA  FC a s s e s sm e n t1 
•  R e c o rd  AEs1 
•  R e c o rd  c o n c om i t a n t  m e d i c a t io n s1 
1 T ak en  f r om  W e ek  2 5  V i s i t  i n  S t u d y  APD 8 1 1 - 0 0 3  
7 .2 .2 S tudy  P r o c edu r e s  –  fo r  Imm ed ia t e - r e l e a s e  D o s e  T i t r a t ion  P e r iod  (S tudy  
APD 8 1 1-0 0 3  P la c ebo Sub j e c ts )  
V i s i t s  a f t e r  B a s e l in e s h o u ld  o c c u r  w e e k ly  fo r  e a c h  e s c a l a t io n  o f  s tu d y  d ru g  d o s e .   Th e r e  
s h o u ld  b e  1  s tu d y  v i s i t  p e r  w e e k  d u r in g  th e  Do s e  Ti t r a t io n  Pe r io d .   B e y o n d  the  w e e k ly  v i s i t ,  
a n y  a d d i t io n a l  v i s i t  d u r in g  th e  Do s e  Ti t r a t io n  Pe r io d  w i l l  b e  d o c um e n t e d  a s  a n  ‘u n s c h e d u l e d ’  
v i s i t . 
I f  a  s u b j e c t  r e a c h e s  a  s t a b l e  MTD  a n d  n o  fu r th e r  d o s e  e s c a l a t io n s  a r e  p l a n n e d ,  th e  Do s e  
Ti t r a t io n  Pe r io d  w i l l  b e  c o n s id e r e d  c omp l e t e d  a n d  w i l l  b e  fo l low e d  b y  mo n th ly  a s s e s sm e n t s  
fo r  th e  f i r s t  3  mo n th s  a n d  th e n  e v e ry  3  mo n th s  u n t i l  th e  s u b j e c t  i s  d i s c o n t in u e d  f rom  th e  s tu d y ,  
Sp o n s o r  t e rm in a t io n  o f  th e  s tu d y ,  o r  th e  l a s t  s u b j e c t  e n ro l l e d  c omp l e t e s  a p p ro x im a t e ly  6  mo n th s  o f  t r e a tm e n t  w i th  r a l in e p a g .  
7 .2 .2 .1 P r e- do s e  P r o c edu r e s  fo r  D o s e  T i t r a t ion  P e r iod  V i s i t s  ( S tudy  APD 8 1 1-0 0 3  
P la c ebo  Sub j e c ts )  
•  V i t a l  s ig n s a c c o rd in g  to  T a b l e 2  
•  S a f e ty  ECG  a t  W e e ks  1  to  9  a c c o rd in g  to  T a b l e 2  •  As s e s sm e n t  o f  c l in i c a l  w o r s e n in g  
•  WHO /NYHA  FC a s s e s sm e n t   
•  C l in i c a l  l a b o r a to ry  t e s t s  ( to  in c lu d e  h em a to lo g y ,  c o a g u l a t io n  p a r am e t e r s ,  s e rum  
c h em i s t ry ,  a n d  u r in a ly s i s )  a t  W e e k s  2 ,  5 ,  a n d  9  
•  S e rum  hCG  p r e g n a n c y  t e s t  ( f em a l e s  o n ly )  a t  W e e k  5  
•  R e c o rd  AEs  
•  R e c o rd  c o n c om i t a n t  m e d i c a t io n s 
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  6 0  7 .2 .2 .2 Po s t- do s e  P r o c edu r e s fo r  D o s e  T i t r a t ion  P e r iod  V i s i t s ( S tudy  APD 8 1 1-0 0 3  
P la c ebo  Sub j e c ts )  
•  S tu d y  d ru g  a dm in i s t r a t io n   
•  V i t a l  s ig n s:  e v e ry  h o u r  th ro u g h  th e  f i r s t  4  h o u r s  
•  S a f e ty  ECG  2  h o u r s  p o s t - d o s e  a t  W e e k s  1  to  9  a c c o rd in g  to  T a b l e 2  
•  R e c o rd  AEs  
•  R e c o rd  c o n c om i t a n t  m e d i c a t io n s 
7 .2 .3 S tudy  P r o c edu r e s  fo r  th e  T r e a tm en t  Pe r iod  –  A l l  Sub j e c ts  (Fo r  B o th  
Imm ed ia t e - r e l e a s e  and  E x t end ed - r e l e a s e  Fo rmu la t ion s )  
7 .2 .3 .1 S tudy  P r o c edu r e s  M 1- M 3 ( S tudy APD 8 1 1-0 0 3 :  P la c ebo - t r e a t ed  Sub j e c ts )  Q3  
M on th s  (S tudy APD 8 1 1 -0 0 3 :  P la c ebo -  and  R a l in epa g -t r e a t ed  Sub j e c ts ;  
Sub j e c ts  who  Sw i t ch ed  to  th e  XR Fo rmu la t ion )  
•  S a f e ty  ECG  a c c o rd in g  to  Se c t io n  6 .5 .2  a n d  T a b l e 1  a n d  T a b l e 2 .  •  C l in i c a l  l a b o r a to ry  t e s t s  ( to  in c lu d e  h em a to lo g y ,  c o a g u l a t io n  p a r am e t e r s ,  s e rum  
c h em i s t ry ,  a n d  u r in a ly s i s )  a c c o rd in g  to  Se c t io n  6 .1 0  a n d  T a b l e 1  a n d  T a b l e 2 .  
•  S e rum  hCG  p r e g n a n c y  t e s t  ( f em a l e s  o n ly ) a c c o rd i n g  to  Se c t io n  6 .1 0  a n d  T a b l e 1  a n d  
T a b l e 2  
•  V i t a l  s ig n s •  S tu d y  d ru g  a dm in i s t r a t io n 
•  6MWT 
•  BNP /NT- p roBNP  a c c o rd in g  to  Se c t io n  6 .1 0  a n d  T a b l e 1  a n d  T a b l e 2  
•  A s s e s sm e n t  o f  c l in i c a l  w o r s e n in g •  WHO /NYHA FC a s s e s sm e n t  
•  D o s e  e s c a l a t io n  a s s e s sm e n t  a c c o rd in g  to  a c c o rd in g  to  T a b l e 1  a n d  T a b l e 2  
•  R e c o rd  AEs  
•  R e c o rd  c o n c om i t a n t  m e d i c a t io n s 
7 .2 .3 .2 S tudy  P r o c edu r e s -  Y e a r  1  o r  Y e a r  2 
•  RHC –  a c c o rd in g  to  T a b l e 1  a n d  T a b l e 2  ( s e e  s tu d y  RHC  m a n u a l )  
7 .2 .3 .3 Sw i t ch to  XR R a l in epa g  and  D o s e  T i t r a t ion 
A t  1  o f  th e  r e g u l a r  q u a r t e r ly  v i s i t s ,  a s  o u t l in e d  in  S e c t io n  7 .2 .3 .1 ,  i n  a d d i t io n  to  th e  r e g u l a r ly  
s c h e d u l e d  p ro c e d u r e s ,  s u b j e c t s  w i l l  b e  g iv e n  n ew  d o s in g  c a rd s  w i th  a n  XR fo rmu l a t io n  o f  
r a l in e p a g .   D o s e- sw i t c h in g  w i l l  o c c u r  a s  o u t l in e d  i n  T a b l e  5 ,  a n d  t i t r a t io n  w i l l  o c c u r  a s  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  6 1  d e s c r ib e d  in  S e c t io n  5 .6 .2 .1  v i a  w e e k ly  t e l e p h o n e  c a l l s  u n t i l  th e  n e x t  r e g u l a r ly  s c h e d u l e d  
q u a r t e r ly  v i s i t ,  a t  w h i c h  t im e  th e  s u b j e c t  w i l l  r e s um e  p ro c e d u r e s  d e s c r ib e d  in  S e c t io n  7 .2 .3 .1 .  
7 .2 .4 End  o f  S tudy V i s i t –  A l l  Sub j e c ts  
•  Ph y s i c a l  e x am   
•  S a f e ty  ECG a c c o rd in g  to  S e c t io n  6 .5 .2  a n d  T a b l e 1  a n d  T a b l e 2  
•  C l in i c a l  l a b o r a to ry  t e s t s  ( to  in c lu d e  h em a to lo g y ,  c o a g u l a t io n  p a r am e t e r s ,  s e rum  
c h em i s t ry ,  a n d  u r in a ly s i s )  a c c o rd in g  to  Se c t io n  6 .1 0  a n d  T a b l e 1  a n d  T a b l e 2  
•  S e rum  hCG  p r e g n a n c y  t e s t  ( f em a l e s  o n ly ) 
•  V i t a l  s ig n s   
•  6MWT 
•  A s s e s sm e n t  o f  c l in i c a l  w o r s e n in g •  WHO /NYHA FC a s s e s sm e n t   
•  R e c o rd  AEs  
•  R e c o rd  c o n c om i t a n t  m e d i c a t io n s 
7 .2 .5 2 8 -da y  Fo l low -up –  A l l  Sub j e c ts  
•  WHO /NYHA FC a s s e s sm e n t   •  A s s e s sm e n t  o f  c l in i c a l  w o r s e n in g 
•  R e c o rd  AEs  
•  R e c o rd  c o n c om i t a n t  m e d i c a t io n s 
8  DATA MANAGEMENT 
8 .1  DATA COLLECT ION 
A l l  d a t a  (ECG s ,  c l in i c a l  l a b o r a to ry  d a t a ,  a n d  a l l  o t h e r  s tu d y - r e l a t e d  d a t a )  w i l l  b e  c o l l e c t e d  
a c c o rd in g  to  th e  Sp o n s o r  o r  CRO ’ s  SOP s .  
U p o n  d a t a b a s e  lo c k ,  to  in c lu d e  r e s o lu t io n  o f  a l l  q u e r i e s ,  th e  CRO  ( i f  a p p l i c a b l e )  w i l l  p ro v id e  
s t a t i s t i c a l  a n a ly s i s  s o f tw a r e  t r a n s f e r  d a t a s e t s  to  t h e  Sp o n s o r  a n d  b io s t a t i s t i c i a n  fo r  a n a ly s i s  u s in g  s e c u r e  e l e c t ro n i c  d a t a  t r a n s f e r  p e r  th e  Sp o n s o r ’ s  s p e c i f i c a t io n s . 
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  6 2  8 .2  DATA COD ING 
8 .2 .1 Adv e r s e E v en t s 
AEs  w i l l  b e  c o d e d  u s in g  th e  M e dDRA  a n d  t a b u l a t e d ,  in c lu d in g  c a t e g o r i c a l  in fo rm a t io n  o f  
in t e r e s t ,  s u c h  a s  o n s e t  a n d  r e s o lu t io n  t im e s ,  t im e  o f  o n s e t  r e l a t iv e  to  d o s e ,  s e v e r i ty  a t  o n s e t ,  m a x imum  s e v e r i ty ,  c a u s a l  r e l a t io n s h ip  to  s tu d y  d ru g ,  a n d  a c t io n  t a k e n .   W h e n e v e r  p o s s ib l e ,  a  
c o n s t e l l a t io n  o f  s ig n s  a n d  s ymp tom s  s h o u ld  b e  r e c o rd e d  a s  a  u n i fy in g  d i a g n o s i s  ( e g ,  
s e l f - l im i t e d  f e v e r ,  ru n n y  n o s e ,  c o u g h ,  a n d  s c r a t c h y  th ro a t  s h o u ld  b e  c a p tu r e d  a s  a n  u p p e r  r e s p i r a to ry  in f e c t io n  r a th e r  th a n  b y  th e  in d iv id u a l  s ig n s  a n d  s ymp tom s ) .   A s  th e r e  i s  n o  Sc r e e n in g  Pe r io d  in  th i s  s tu d y  a n d  s u b j e c t s  w i l l  e n t e r  th e  s tu d y  o n  a c t iv e  t r e a tm e n t ,  a l l  AE s  
th a t  o c c u r  a f t e r  th e  f i r s t  d o s e  o f  s tu d y  d ru g  w i l l  b e  c o n s id e r e d  t r e a tm e n t em e rg e n t .  
8 .2 .2 C on c om i tan t  M ed i c a t ion s 
D u e  to  th e  v a r i a b i l i ty  in  h ow  m e d i c a t io n s  a r e  r e c o r d e d ,  a  s t a n d a rd  n am in g  c o n v e n t io n  i s  r e q u i r e d  in  o rd e r  to  t a b u l a t e  th e s e  d a t a  e f f e c t iv e ly .   A  c ommo n  m e th o d  o f  s t a n d a rd i z a t io n  i s  to  
c a t e g o r i z e  m e d i c a t io n s  b y  th e i r  P r e f e r r e d  T e rm .   I n  o rd e r  to  d o  th i s ,  m e d i c a t io n s  w i l l  b e  c o d e d  u s in g  th e  WHO  D ru g  D i c t io n a ry .   
9  PLANNED STAT IST ICAL  METHODS 
A f t e r  th e  la s t  s u b j e c t  e n ro l l e d  in  APD 8 1 1 - 0 0 7  c om p l e t e s  a p p ro x im a t e ly  6  mo n th s  o f  
t r e a tm e n t ,  a  c umu l a t iv e  a l l - s u b j e c t  d a t a  a n a ly s i s  w i l l  b e p e r fo rm e d .  
Th e  s t a t i s t i c a l  a n a ly s i s  o f  th e  d a t a  o b t a in e d  f rom  th i s  s tu d y  w i l l  b e  th e  r e s p o n s ib i l i ty  o f  th e  
Sp o n s o r.   D e t a i l s  o f th e  s t a t i s t i c a l  a n a ly s e s  w i l l  b e  in c lu d e d  in  a  s e p a r a t e  S t a t i s t i c a l  A n a ly s i s  
Pl a n ,  w h i c h  w i l l  b e  f in a l i z e d  b e fo r e  d a t a b a s e  lo c k.   I f ,  a f t e r  th e  d a t a b a s e  h a s  b e e n  lo c k e d ,  c h a n g e s  a r e  m a d e  to  th e  p r e - s p e c i f i e d  St a t i s t i c a l  An a ly s i s  Pl a n ,  th e  c h a n g e s  w i l l  b e  l i s t e d  a lo n g  w i th  a n  e x p l a n a t io n  a s  to  w h y  th e y  o c c u r r e d  in  th e  C l in i c a l  S tu d y  R e p o r t .
 
9 .1  ANALYS IS POPULAT IONS 
S a f e ty  Po p u l a t io n:  
Th i s  p o p u l a t io n  w i l l  in c lu d e  a l l  s u b j e c t s  w h o  r e c e i v e d  a t  l e a s t  1  d o s e  o f  th e  s tu d y  d ru g  in  th i s  
e x t e n s io n  s tu d y .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  6 3  M o d i f i e d  In te n t - to - t r e a t  Po p u l a t io n :  
Th e  a n a ly s e s  o f  a l l  e f f i c a c y  v a r i a b l e s  w i l l  u s e  th e  M o d i f i e d  In t e n t -to -T r e a t  Po p u l a t io n .   Th i s  
p o p u l a t io n  c o n s i s t s  o f  a l l  s u b j e c t s  r a n d om i z e d  w h o  r e c e iv e d  a t  l e a s t  1  d o s e  o f  s tu d y  d ru g  in  
th e  e x t e n s io n  s tu d y ,  h a v e  a  b a s e l in e  m e a s u r em e n t ,  a n d  h a v e  a t  l e a s t  1  m e a s u r em e n t  a f t e r e n t ry  in to  th e  e x t e n s io n  s tu d y .   Th e  L a s t  O b s e rv a t io n  C a r r i e d  Fo rw a rd  a p p ro a c h  w i l l  b e  u s e d  to  imp u t e  m i s s in g  v a lu e s .   
9 .2  STAT IST ICAL METHODS 
9 .2 .1 Sa f e ty  Ana ly s i s 
Sa f e ty  i s  th e  p r im a ry  a n a ly s i s  fo r  th i s  e x t e n s io n  s tu d y .   A l l  s u b j e c t s  w h o  r e c e iv e  s tu d y  d ru g  in  
th e  e x t e n s io n  s tu d y  w i l l  b e  e v a lu a t e d  fo r  s a f e ty.   L o n g -t e rm  s a f e ty  a n d  to l e r a b i l i ty  o f  r a l in e p a g  w i l l  b e  a s s e s s e d  b y  c l in i c a l  a n d  s t a t i s t i c a l  r e v i ew  o f  a l l  r e l e v a n t  s a f e ty  p a r am e t e r s,  in c lu d in g  AEs ,  l a b o r a to ry  v a lu e s ,  v i t a l  s ig n s ,  a n d  ECG  f in d in g s .  
9 .2 .1 .1 D emo g r aph i c s and  B a s e l in e  Cha r a c t e r i s t i c s  
A l l  b a s e l in e  s u b j e c t  c h a r a c t e r i s t i c s  fo r  d emo g r a p h i c  d a t a  ( a g e ,  h e ig h t ,  w e ig h t ,  r a c e ) ,  m e d i c a l  h i s to ry  ( a b n o rm a l i t i e s  o n ly ) ,  p h y s i c a l  e x am in a t io n  ( a b n o rm a l i t i e s  o n ly ) ,  a n d  c o n c om i t a n t  
m e d i c a t io n s  a t  e n t ry  in  S tu d y  APD 8 1 1- 0 0 3  a n d  a l s o  a t  e n t ry  in  th i s  e x t e n s io n  s tu d y  w i l l  b e  
l i s t e d  fo r  a l l  s u b j e c t s .   D emo g r a p h i c  d a t a  w i l l  b e  s umm a r i z e d  a n d  t a b u l a t e d.   C o n t in u o u s  v a r i a b l e s  w i l l  b e  s umm a r i z e d  u s in g  n umb e r  o f  o b s e rv a t io n s ,  m e a n ,  s t a n d a rd  d e v i a t io n ,  m e d i a n ,  m in imum ,  a n d  m a x imum.   F r e q u e n c i e s  a n d  p e r c e n t a g e s  w i l l  b e  r e p o r t e d  fo r  a l l  
c a t e g o r i c a l  d a t a .  
9 .2 .1 .2 Adv e r s e E v en t s 
Th e  AEs  w i l l  b e  c o d e d  u s in g  th e  mo s t  c u r r e n t  M e dDRA  a n d  t a b u l a t e d ,  in c lu d in g  c a t e g o r i c a l  in fo rm a t io n  o f  in t e r e s t ,  s u c h  a s  o n s e t  a n d  r e s o lu t io n  t im e s ,  t im e  o f  o n s e t  r e l a t iv e  to  d o s e ,  
s e v e r i ty  a t  o n s e t ,  m a x imum  s e v e r i ty ,  c a u s a l  r e l a t io n s h ip  to  s tu d y  d ru g ,  a n d  a c t io n  t a k e n .   
A l l  AE s  w i l l  b e  l i s t e d  b y s u b j e c t  a n d  w i l l  b e  s umm a r i z e d  a n d  e x p r e s s e d  in  t e rm s  o f  m a x imum  
s e v e r i ty  a n d  r e l a t io n s h ip  to  s tu d y  d ru g .  
9 .2 .1 .3 Phy s i c a l  E x am ina t ion s  
Ph y s i c a l  e x am in a t io n  r e s u l t s  ( a b n o rm a l i t i e s  o n ly )  w i l l  b e  c o l l e c t e d .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  6 4  9 .2 .1 .4 V ita l  S ign s 
In d iv id u a l  v i t a l  s ig n  m e a s u r em e n t s  w i l l  b e  l i s t e d  b y  m e a s u r em e n t  t im e  a n d  s umm a r i z e d  u s in g  
d e s c r ip t iv e  s t a t i s t i c s .   Summ a ry  s t a t i s t i c s  w i l l  a l s o  b e  p ro v id e d  fo r  c h a n g e  f rom  b a s e l in e  in  
v i t a l  s ig n  m e a s u r em e n t s .   
9 .2 .1 .5 C l in i c a l L abo r a to r y  V a lu e s 
In d iv id u a l  l a b o r a to ry  v a lu e s  w i l l  b e  l i s t e d  b y  v i s i t  a n d  s umm a r i z e d  u s in g  d e s c r ip t iv e  s t a t i s t i c s .   Summ a ry  s t a t i s t i c s  w i l l  a l s o  b e  p ro v id e d  fo r  c h a n g e  f rom  B a s e l in e in  l a b o r a to ry  v a lu e s .   Sh i f t  t a b l e s  f rom  b a s e l in e  to  th e  l a s t  e x t e n s io n  s tu d y  v i s i t  w i l l  a l s o  b e  p ro d u c e d  fo r  th e  l a b o r a to ry  a s s e s sm e n t s  b a s e d  o n  th e  c a t e g o r i e s  o f  L ow ,  N o rm a l ,  a n d  H ig h .   A  c l in i c a l ly  s ig n i f i c a n t  
c h a n g e  f rom  b a s e l in e  m a y  b e  r e c o rd e d  a s  a n  AE  i f  d e em e d  a p p ro p r i a t e  b y  th e  In v e s t ig a to r  o r  
Sp o n s o r .  
9 .2 .1 .6 Sa f e ty ECG s 
In d iv id u a l  ECG  v a lu e s  w i l l  b e  l i s t e d  b y  v i s i t  a n d  s umm a r i z e d  u s in g  d e s c r ip t iv e  s t a t i s t i c s .   In t e rv a l s  to  b e  p ro v id e d  fo r  e a c h  ECG  a r e  RR ,  PR ,  QRS ,  QT ,  QT c ,  QT cB ,  a n d  QT cF .   ECG s  w i l l  b e  c omp a r e d  w i th  th e  b a s e l in e  ECG.   A n y  c l in i c a l ly  s ig n i f i c a n t  c h a n g e  f rom  b a s e l i n e  m a y  b e  r e c o rd e d  a s  a n  AE  i f  d e em e d  a p p ro p r i a t e  b y  th e  In v e s t ig a to r  o r  Sp o n s o r .  
9 .2 .2 S ta t i s t i c a l Ana ly s e s  o f  E f f i c a c y  M e a su r em en t s 
E f f i c a c y  a n a ly s e s  a r e  c o n s id e r e d  a s  s e c o n d a ry  fo r  t h i s  e x t e n s io n  s tu d y .   Th e  t im e  to  c l in i c a l w o r s e n in g  w i l l  b e  s umm a r i z e d.   E s t im a t io n  a n d  9 5%  c o n f id e n c e  in t e rv a l s  fo r  
w i th in- t r e a tm e n t  c h a n g e  f rom  b a s e l in e  in  6MWD ,  WHO /NYHA  FC  a s s es sm e n t ,  a n d  m a in  
h emo d y n am i c  p a r am e t e r s  w i l l  a l s o  b e  p e r fo rm e d.   B a s e l in e  i s  d e f in e d  a s  th e  D a y  1  p r e- d o s e  m e a s u r em e n ts  f rom  S tu d y  APD 8 1 1- 0 0 3 .   A  s e co n d a ry  a n a ly s i s  u s in g  a  d e f in i t io n  o f  B a s e l in e a s  D a y  1  o f  S tu d y  APD 8 1 1 - 0 0 7  w i l l  a l s o  b e  p e r fo rm e d . 
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  6 5  1 0  REGULATORY REQU IREMENTS 
1 0 .1  PRE- STUDY DOCUMENTAT ION 
Th e  Sp o n s o r  mu s t  r e c e iv e  th e  fo l low in g  d o c um e n t a t io n  p r io r  to  in i t i a t io n  o f  th e  s tu d y :  
•  P ro to c o l  s ig n a tu r e  p a g e  s ig n e d  b y  th e  In v e s t ig a to r  
•  FDA  fo rm  1 5 7 2  s ig n e d  b y  th e  In v e s t ig a to r  
•  C u r r i c u lum  v i t a e  o f  th e  In v e s t ig a to r ,  u p d a t e d  w i th i n  2  y e a r s  
•  C u r r e n t  m e d i c a l  l i c e n s e s  fo r  th e  In v e s t ig a to r  •  C o p y  o f  th e  IRB/ IEC  a p p ro v a l  l e t t e r  fo r  th e  s tu d y  a n d  a p p ro v e d  ICF  
•  IRB / IEC  M emb e r s h ip  L i s t 
A d d i t io n a l  c o u n t ry- s p e c i f i c  d o c um e n t a t io n  m a y  b e  r e q u i r e d  p e r  in t e rn a t io n a l  r e g u l a to ry  
a u th o r i t i e s .   D o c um e n t s  s h o u ld  b e  s e n t  to  th e  Sp o n s o r  a t  th e  fo l low in g  a d d r e s s :  
U n i t e d  Th e r a p e u t i c s  C o rp o r a t io n   
5 5  T .W .  A l e x a n d e r  D r iv e   
R e s e a r c h  T r i a n g l e  P a rk ,  NC  2 7 7 0 9,  USA 
 
1 0 .2  INVEST IGATOR  OBL IGAT IONS 
Th e  In v e s t ig a to r  i s  r e s p o n s ib l e  fo r  e n s u r in g  th a t  a l l  s tu d y  s i t e  p e r s o n n e l  a n d  o th e r  s tu d y  s t a f f  
m emb e r s  a d h e r e  to  a l l  a p p l i c a b l e  FDA  a n d /o r  a p p l i c a b l e c o u n t ry  r e g u l a t io n s  a n d  g u id e l in e s  r e g a rd in g  c l in i c a l  s tu d i e s ,  in c lu d in g  g u id e l in e s  fo r  GCP  ( in c lu d in g  th e  a r c h iv in g  o f  e s s e n t i a l  d o c um e n t s ) ,  b o th  d u r in g  a n d  a f t e r  s tu d y  c omp l e t io n .   Th e  In v e s t ig a to r  w i l l  b e  r e s p o n s ib l e  fo r  
th e  s u b j e c t ’ s  c omp l i a n c e  to  th e  s tu d y  p ro to c o l .   Th e  In v e s t ig a to r  i s  r e s p o n s ib l e  fo r  p ro v id in g  
th e  Sp o n s o r  a n  a d e q u a t e  f in a l  r e p o r t  s h o r t ly  a f t e r  h e / s h e  c omp l e t e s  p a r t i c ip a t io n  in  th e  s tu d y ,  in  a c c o rd a n c e  w i th  ICH  G u id e l in e s  E6 ,  E2A ,  a n d  E8 .  
1 0 .3  SUB JECT CONF IDENT IAL ITY 
A l l  in fo rm a t io n  o b t a in e d  d u r in g  th e  c o n d u c t  o f  th e  s tu d y  w i th  r e s p e c t  to  th e  s u b j e c t s ’  s t a t e  o f  
h e a l th  w i l l  b e  r e g a rd e d  a s  c o n f id e n t i a l .   Th i s  i s  d e t a i l e d  in  th e  w r i t t e n  in fo rm a t io n  p ro v id e d  to  th e  s u b j e c t .   A n  a g r e em e n t  fo r  d i s c lo s u r e  o f  a n y  s u c h  in fo rm a tio n  w i l l  b e  o b t a in e d  in  w r i t in g  
a n d  i s  in c lu d e d  in  b o th  c o p i e s  o f  th e  ICF  s ig n e d  b y  th e  s u b j e c t .   Th e  s tu d y  d a t a  s h a l l  n o t  b e  
d i s c lo s e d  to  a  th i rd  p a r ty  w i th o u t  th e  w r i t t e n  c o n s e n t  o f  th e  Sp o n s o r .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  6 6  1 0 .4  INFORMED  CONSENT 
A c c o rd in g  to  ICH  G u id e l in e  E6 ,  G o o d  C l in i c a l  P r a c t i c e :  C o n s o l id a t e d  G u id a n c e (1 9 9 6 ) ,  th e  
In v e s t ig a to r  w i l l  o b t a in  a n d  d o c um e n t  in fo rm e d  c o n s e n t  fo r  e a c h  s u b j e c t  s c r e e n e d  fo r  th i s  
s tu d y .   A l l  s u b j e c t s  w i l l  b e  in fo rm e d  in  w r i t in g  o f  t h e  n a tu r e  o f  th e  p ro to c o l  a n d  in v e s t ig a t io n a l  th e r a p y ,  i t s  p o s s ib l e  h a z a rd s ,  a n d  th e i r  r ig h t  to  w i th d r aw  a t  a n y  t im e ,  a n d  w i l l  s ig n  a  fo rm  in d i c a t in g  th e i r  c o n s e n t  to  p a r t i c ip a t e  p r io r  to  th e  in i t i a t io n  o f  s tu d y  p ro c e d u r e s .   
Th e  s u b j e c t’ s  m e d i c a l  r e c o rd  s h o u ld  c o n t a in  w r i t t e n  d o c um e n t a t io n  in d i c a t in g  th a t  in f o rm e d  
c o n s e n t  w a s  o b t a in e d .   Th e  ICF  mu s t  b e  r e v i ew e d  a n d  a p p ro v e d  b y  th e  In v e s t ig a to r ’ s  d e s ig n a t e d  IRB / IEC  a n d  b y  th e  Sp o n s o r .   Th e  ICF  s h o u ld  in c lu d e  a l l  th e  e l em e n t s  a s  o u t l in e d  in  S e c t io n  4 .8 .1 0  o f  ICH  G u id e l in e  E6 .  
1 0 .5  INST ITUT IONAL  REV IEW BOARD 
Th i s  p ro to c o l  a n d  r e l e v a n t  s u p p o r t i n g  d a t a  a r e  to  b e  s u bm i t t e d  to  th e  a p p ro p r i a t e  IRB/ IEC  fo r  
r e v i ew  a n d  a p p ro v a l  b e fo r e  th e  s tu d y  c a n  b e  in i t i a t e d .   Am e n dm e n t s  to  th e  p ro to c o l  w i l l  a l s o  
b e  s u bm i t t e d  to  th e  IRB / IEC  p r io r  to  imp l em e n t a t i o n  o f  th e  c h a n g e .   Th e  Sp o n s o r  mu s t  
r e c e i v e  a  l e t t e r  d o c um e n t in g  th e  IRB / IEC  a p p ro v a l  p r io r  to  in i t i a t io n  o f  th e  s tu d y .   Th e  In v e s t ig a to r  i s  a l s o  r e s p o n s ib l e  fo r  in fo rm in g  th e  IRB / IEC  o f  th e  p ro g r e s s  o f  th e  s tu d y  a n d  fo r  o b t a in in g  a n n u a l  IRB / IEC  r e n ew a l .   Th e  IRB/ IEC  mu s t  b e  in fo rm e d  a t  th e  t im e  o f  c omp l e t io n  
o f  th e  s tu d y  a n d  s h o u ld  b e  p ro v id e d  w i th  a  s umm a ry  o f  th e  r e s u l t s  o f  th e  s tu d y  b y  th e  
In v e s t ig a to r .   Th e  In v e s t ig a to r  mu s t  n o t i fy  th e  IRB / IEC  in  w r i t in g  o f  a n y  SAE  o r  a n y  u n e x p e c t e d  AE  a c c o rd in g  to  ICH  g u id e l in e s .  
1 1  PROTOCOL MANAGEMENT  AND  ADM IN ISTRAT IVE  CONS IDERAT IONS 
1 1 .1  STUDY DOCUMENTAT ION 
Th e  In v e s t ig a to r  h a s  th e  r e s p o n s ib i l i ty  o f  m a in t a in i n g  a  c omp r e h e n s iv e  a n d  c e n t r a l i z e d  f i l in g  
s y s t em  c o n t a in in g  a l l  s tu d y - r e l a t e d  d o c um e n t a t io n .   Th e s e  f i l e s  mu s t  b e  a v a i l a b l e  fo r  
in s p e c t io n  b y  th e  Sp o n s o r ,  r e p r e s e n t a t iv e s  o f  th e  S p o n s o r ,  th e  IRB / IEC ,  a n d  r e g u l a to ry  a u th o r i t i e s  ( i e ,  FDA  o r  in t e rn a t io n a l  r e g u l a to ry  a u t h o r i t i e s )  a t  a n y  t im e ,  a n d  s h o u ld  c o n s i s t  o f  th e  fo l low in g  e l em e n t s :  
•  Su b j e c t f i l e s ,  c o n t a in in g  th e  c omp l e t e d  CRF s ,  s u p p o r t in g  s o u r c e  d o c um e n t a t io n  f rom  
th e  m e d i c a l  r e c o rd s ,  in c lu d in g  l a b o r a to ry  d a t a  a n d  th e  ICF  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  6 7  •  R e g u l a to ry  f i l e s ,  c o n t a in in g  th e  p ro to c o l  w i th  a l l  am e n dm e n t s  a n d  In v e s t ig a to r 
s ig n a tu r e  p a g e s ,  c o p i e s  o f  a l l  o th e r  r e g u l a to ry  d o c um e n t a t io n ,  a n d  a l l  c o r r e s p o n d e n c e  
b e tw e e n  th e  s i t e  a n d  th e  IRB / IEC  a n d  Sp o n s o r ;  a n d  d ru g  a c c o u n t a b i l i ty  f i l e s ,  in c lu d in g  a  c omp l e t e  a c c o u n t  o f  th e  r e c e ip t  a n d  d i s p o s i t io n  o f  th e  s tu d y  d ru g .  
R e c o rd s  a r e  to  b e  a v a i l a b l e  fo r  2  y e a r s  a f t e r  m a rk e t in g  a p p l i c a t io n  a p p ro v a l ,  o r  i f  th e  
a p p l i c a t io n  i s  n o t  a p p ro v e d  o r  n e v e r  s u bm i t t e d ,  2  y e a r s  a f t e r  th e  l a s t  s h ipm e n t  a n d  d e l iv e ry  o f  th e  m a t e r i a l  a n d  th e  a p p ro p r i a t e  c omp e t e n t  r e g u l a t o ry  a u th o r i t i e s  a r e  n o t i f i e d .   Th e  Sp o n s o r  w i l l  p ro v id e  w r i t t e n  n o t i f i c a t io n  w h e n  i t  i s  a p p ro p r i a t e  fo r  th e  In v e s t ig a to r  to  d i s c a rd  th e  
s tu d y - s p e c i f i c  d o c um e n t s  r e f e r e n c e d  a b o v e .  
1 1 .2  PROTOCOL INTERPRETAT ION  AND COMPL IANCE 
To  e n s u r e  a c c u r a t e  in t e rp r e t a t io n  a n d  imp l em e n t a t i o n  o f  th e  s tu d y ,  th e  p ro c e d u r e s  a n d  
e n d p o in t s  d e f in e d  in  th e  p ro to c o l  w i l l  b e  c a r e fu l ly  r e v i ew e d  b y  th e  In v e s t ig a to r  p r io r  to  th e  
t im e  o f  s tu d y  in i t i a t io n .   Th e  Sp o n s o r  a n d  In v e s t ig a to r  w i l l  fo l low  a l l  r e a s o n a b l e  m e a n s  to  r e s o lv e  a n y  d i f f e r e n c e s  o f  o p in io n  o f  m a t t e r s  o f  e l i g ib i l i ty ,  to x i c i ty ,  a n d  o th e r  e n d p o in t s .   In  th e  e v e n t  th a t  a  r e s o lu t io n  c a n n o t  b e  r e a c h e d ,  1  o r  b o th  p a r t i e s  m a y  s e e k  to  t e rm in a t e  th e  s tu d y  fo l low in g  th e  p ro v i s io n s  o u t l in e d  in  th e  C l in i c a l  T r i a l s  A g r e em e n t .  
1 1 .3  STUDY MON ITOR ING 
Th e  Sp o n s o r  o r  a  c o n t r a c t e d  mo n i to r  w i l l  v i s i t  th e  s tu d y  c e n t e r  p e r io d i c a l ly  to  mo n i to r  
a d h e r e n c e  to  th e  p ro to c o l ,  c omp l i a n c e  w i th  ICH  g u id e l in e s ,  a d h e r e n c e  to  a p p l i c a b l e  FDA  
a n d /o r  a p p l i c a b l e  c o u n t ry  r e g u l a t io n s ,  a n d  th e  m a i n t e n a n c e  o f  a d e q u a t e  a n d  a c c u r a t e  c l in i c a l  
r e c o rd s .   CRF s w i l l  b e  r e v i ew e d  to  e n s u r e  th a t  k e y  s a f e ty  a n d  e f f i c a c y  d a t a  a r e  c o l l e c t e d  a n d  r e c o rd e d  a s  s p e c i f i e d  b y  th e  p ro to c o l .   Th e  mo n i to r  w i l l  b e  p e rm i t t e d  to  a c c e s s  s u b j e c t s ’  c omp l e t e  m e d i c a l  r e c o rd s ,  l a b o r a to ry  d a t a ,  a n d  o th e r  s o u r c e  d o c um e n t a t io n  a s  n e e d e d  to  
mo n i to r  th e  s tu d y  a p p ro p r i a t e ly .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  6 8  1 2  REFERENCE L IST 
1 . H a t a  AN ,  B r e y e r  RM.   Ph a rm a c o lo g y  a n d  s ig n a l in g  o f  p ro s t a g l a n d in  r e c e p to r s :  
mu l t ip l e  ro l e s  in  in f l amm a t io n  a n d  immu n e  mo d u l a t io n.   Ph a rm a c o l  Th e r.   
2 0 0 4 ;1 0 3 (2 ) :1 4 7 - 1 6 6 .  
2 . M cL a u g h l in  VV ,  Sh i l l in g to n  A ,  R i c h  S.   Su rv iv a l  i n  p r im a ry  p u lmo n a ry  h y p e r t e n s io n :  
th e  imp a c t  o f  e p o p ro s t e n o l  th e r a p y .   C i r c ul a t io n .   2 0 0 2  S e p t emb e r  1 7 ;1 0 6 (1 2 ) :1 4 7 7 -
1 4 8 2 .  
3 . M cG o o n  MD , M i l l e r DP.   REVEAL:  a  c o n t emp o r a ry  US  p u lm o n a ry  a r t e r i a l  
h y p e r t e n s io n  r e g i s t ry .   Eu r  R e s p i r  R e v.   2 0 1 2 ;2 1 ( 1 2 3 ) : 8 - 1 8 .  
4 . A r c h e r  SL ,  W e i r  EK ,  W i lk i n s  MR.   B a s i c  s c i e n c e  o f  p u lmo n a ry  a r t e r i a l  h y p e r t e n s io n  
fo r  c l in i c i a n s :  n ew  c o n c e p t s  a n d  e x p e r im e n t a l  t h e r a p i e s .   C i r c u l a t io n.   
2 0 1 0 ;1 2 1 (1 8 ) ;2 0 4 5 - 2 0 6 6 .  
5 . Eu ro p e a n  M e d i c in e s  A g e n c y  (EMEA ).   G u id e l in e  o n  th e  C l in i c a l  In v e s t ig a t io n s  o f  
M e d i c in a l  P ro d u c t s  fo r  th e  T r e a tm e n t  o f  Pu lmo n a r y  A r t e r i a l  H y p e r t e n s io n  (D o c .  R e f .  
EMEA /CHMP /EWP /3 5 6 9 5 4 /2 0 0 8 )  L o n d o n ,  2 2  O c to b e r  2 0 0 9 . 
6 . Tu d e r  RM ,  C o o l  CD ,  G e r a c i  MW,  e t  a l .   P ro s t a c y c l in  s y n th a s e  e x p r e s s io n  i s  d e c r e a s e d  
in  lu n g s  f rom  p a t i e n t s  w i th  s e v e r e  p u lmo n a ry  h y p e r t e n s io n .   Am  J  R e s p i r  C r i t  C a r e  
M e d.   1 9 9 9 ;1 5 9 (6 ) :1 9 2 5 - 3 2 .  
7 . B a r s t  R J ,  R u b in  L J ,  L o n g  WA ,  e t  a l.   A  c omp a r i s o n  o f  c o n t in u o u s  in t r a v e n o u s  
e p o p ro s t e n o l  (p ro s t a c y c l in )  w i th  c o n v e n t io n a l  th e r a p y  fo r  p r im a ry  p u lmo n a ry  h y p e r t e n s io n .   Th e  P r im a ry  Pu lmo n a ry  H y p e r t e n s io n  S tu d y  G ro u p.   N  En g l  J  M e d.   1 9 9 6 ;3 3 4 (5 ) :2 9 6 - 3 0 2 .  
8 . Simo n n e a u  G ,  R o b b in s  IM ,  B e g h e t t i  M ,  e t  a l .   U p d a t e d  c l in i c a l  c l a s s i f i c a t io n  o f  
p u lmo n a ry  h y p e r t e n s io n .   J  Am  C o l l  C a rd io l .   2 0 0 9 ;5 4 (1  Su p p l ) :S4 3 -S5 4 .  
9 . H umb e r t  M ,  S i tb o n  O ,  C h a o u a t  A ,  e t  a l.   Pu lmo n a r y  a r t e r i a l  h y p e r t e n s io n  in  F r a n c e :  
r e s u l t s  f rom  a  n a t io n a l  r e g i s t ry .   Am  J  R e s p i r  C r i t  C a r e  M e d.   2 0 0 6 ;1 7 3 (9 ) :1 0 2 3 - 1 0 3 0 .  
1 0 . P e a c o c k  A J ,  M u rp h y  NF ,  M cM u r r a y  J J ,  e t  a l .   A n  e p id em io lo g i c a l  s tu d y  o f  p u lmo n a ry  
a r t e r i a l  h y p e r t e n s io n .   Eu r  R e s p i r  J.   2 0 0 7 ;3 0 (1 ) :1 0 4 - 1 0 9 .  
1 1 . B a d e s c h  DB ,  R a s k o b  GE ,  E l l io t t  CG,  e t  a l .   Pu lmo n a ry  a r t e r i a l  h y p e r t e n s io n :  b a s e l in e  
c h a r a c t e r i s t i c s  f rom  th e  REVEAL  R e g i s t ry .   C h e s t.   2 0 1 0 ;1 3 7 (2 ) :3 7 6 - 8 7 .   
1 2 . G a l i è  N ,  C o r i r s  PA ,  F ro s t  A ,  e t  a l.   U p d a t e d  t r e a tm e n t  a lg o r i thm  o f  p u lmo n a ry  a r t e r i a l  
h y p e r t e n s io n .   J  Am  C o l l  C a rd io l .   2 0 1 3 ;6 2 (2 5 ,  Su p p l  D ) :6 0 - 7 2 .  
1 3 . Or e n i t r am
® [ P r e s c r ib in g  In fo rm a t io n] ,  R e s e a r c h  T r i a n g l e  P a rk ,  NC :  U n i t e d  
Th e r a p e u t i c s  C o rp . ;  D e c emb e r  2 0 1 3 . 
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  6 9  1 4 . Ty v a s o® [ P r e s c r ib in g  In fo rm a t io n] ,  R e s e a r c h  T r i a n g l e  P a rk ,  NC :  U n i t e d  Th e r a p e u t i c s  
C o rp . ;  J u ly  2 0 0 9 . 
1 5 . M cL a u g h l in  VV ,  A r c h e r  SL ,  B a d e s c h  DB ,  e t a l .   ACCF /AHA  2 0 0 9  e x p e r t  c o n s e n s u s  
d o c um e n t  o n  p u lmo n a ry  h y p e r t e n s io n  a  r e p o r t  o f  t h e  Am e r i c a n  C o l l e g e  o f  C a rd io lo g y  
Fo u n d a t io n  T a s k  Fo r c e  o n  Ex p e r t  C o n s e n s u s  D o c um e n t s  a n d  th e  Am e r i c a n  H e a r t  
A s s o c i a t io n  d e v e lo p e d  in  c o l l a b o r a t io n  w i th  th e  Am e r i c a n  C o l l e g e  o f  C h e s t  
Ph y s i c i a n s ;  Am e r i c a n  Th o r a c i c  So c i e ty ,  In c . ;  a n d  t h e  Pu lmo n a ry  H y p e r t e n s io n  A s s o c i a t io n.   J  Am  C o l l  C a rd io l .   2 0 0 9 ;5 3 (1 7 ) :1 5 7 3 - 1 6 1 9 .  
1 6 . ATS  C omm i t t e e  o n  P ro f i c i e n c y  S t a n d a rd s  fo r  C l in i c a l  Pu lmo n a ry  Fu n c t io n  
L a b o r a to r i e s .   ATS  St a t em e n t :  G u id e l in e s  fo r  th e  S ix - M in u t e  W a lk  T e s t .   Am  J  R e s p i r  
C r i t  C a r e  M e d .   2 0 0 2 ;1 6 6 (1 ) :1 1 1- 1 1 7 .  
1 7 . G a l i è  N ,  H o e p e r  MM ,  H umb e r t  M,  e t  a l .   G u id e l in e s  fo r  th e  d i a g n o s i s  a n d  t r e a tm e n t  o f  
p u lmo n a ry  h y p e r t e n s io n .   Eu r  H e a r t  J.   2 0 0 9 ;3 0 :2 4 9 3 - 5 3 7 .  
1 8 . F i j a lk ow s k a  A ,  K u r z y n a  M ,  To rb i c ki  A ,  e t  a l .   S e r um  N- t e rm in a l  b r a in  n a t r iu r e t i c  
p e p t id e  a s  a  p ro g n o s t i c  p a r am e t e r  in  p a t i e n t s  w i th  p u lmo n a ry  h y p e r t e n s io n .   C h e s t.   
2 0 0 6 ;1 2 9 :1 3 1 3 - 2 1 .  
1 9 . H a b ib  G ,  To rb i c k i  A .   Th e  ro l e  o f  e c h o c a rd io g r a p h y  in  th e  d i a g n o s i s  a n d  m a n a g em e n t  
o f  p a t i e n t s  w i th  p u lmo n a ry  h y p e r t e n s io n .   Eu r  R e s p i r  R e v.   2 0 1 0 ;1 9 (1 1 8 ) :1 - 1 2 .  
2 0 . C ommo n  T e rm in o lo g y  C r i t e r i a  fo r  A d v e r s e  Ev e n t s  v 4 .0 3  (CTCAE ) .  Pu b l i s h  D a t e :  
J u n e  1 4 ,  2 0 1 0 .  A c c e s s e d  O c to b e r  2 0 1 0 .  h t tp : / / e v s .n c i .n ih .g o v / f tp 1 /CTCAE /CTCAE_ 4 .0 3 _ 2 0 1 0 - 0 6 -1 4 _Q u i c kR e f e r e n c e _ 5 x 7 .p d f  
 
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  7 0  App end ix  1 Gu id e l in e s  fo r  6- M inu t e  W a lk  T e s t 
(A d a p t e d  f rom  Am e r i c a n  Th o r a c i c  So c i e ty  (ATS )  S t a t em e n t :  G u id e l in e s  fo r  th e  S ix -M in u t e  
W a lk  T e s t .  [ATS  S t a tem e n t  2 0 0 2 ] )  
L o c a t ion  
Th e  6MWT  s h o u ld  b e  p e r fo rm e d  in d o o r s  p r e f e r a b l y ,  a lo n g  a  lo n g ,  f l a t ,  s t r a ig h t ,  h a l lw a y  w i th  a  h a rd  s u r f a c e  th a t  i s  s e ld om  t r a v e l e d .   Th e  w a lk in g  c ou r s e  mu s t  b e  1 5 to  5 0  m e t e r s  in  
l eng th .   Tu rn a ro u n d  p o in t s  s h o u ld  b e  m a rk e d  w i th  a  b r ig h t ly  c o lo r e d  c o n e .   A  s t a r t in g  l in e ,  
w h i c h  m a rk s  th e  b e g in n in g  a n d  e n d  o f  e a c h  l a p ,  s h o u ld  b e  m a rk e d  o n  th e  f lo o r  w i th  b r ig h t ly  c o lo r e d  t a p e .   I f  p o s s ib l e ,  th e  s u b j e c t  s h o u ld  u s e  th e  s am e  6MWT  lo c a t io n  fo r  e a c h  t e s t  a n d  s am e  p a i r  o f  s h o e s .  
Sa f e ty  I s su e s 
1 . T e s t in g  s h o u ld  b e  p e r fo rm e d  in  a  lo c a t io n  w h e r e  a  r a p id ,  a p p ro p r i a t e  r e s p o n s e  to  a n  
em e rg e n c y  i s  p o s s ib l e .   Th e  a p p ro p r i a t e  lo c a t io n  o f  a  c r a s h  c a r t  s h o u ld  b e  d e t e rm in e d  
b y  th e  p h y s i c i a n  s u p e rv i s in g  th e  f a c i l i ty .  
2 . Su p p l i e s  th a t  s h o u ld  b e  a v a i l a b l e  in c lu d e  o x y g e n ,  s u b l in g u a l  n i t ro gly c e r in e ,  a s p i r in ,  
a n d  a lb u t e ro l  ( e g ,  a  b e t a  a g o n i s t  b y  m e t e r e d  d o s e  i n h a l e r  o r  n e b u l i z e r ) .   A  t e l e p h o n e  o r  o th e r  m e a n s  s h o u ld  b e  in  p l a c e  to  e n a b l e  a  c a l l  fo r  h e lp . 
3 . Th e  t e c h n i c i a n  s h o u ld  b e  c e r t i f i e d  in  c a rd io p u lmo n a ry  r e s u s c i t a t io n  w i th  a  m in imum  
o f  B a s ic  L i f e  Su p p o r t  a n d  Am e r i c a n  H e a l th  A s s o c i a t io n - a p p ro v e d  c a rd io p u lmo n a ry  
r e s u s c i t a t io n  c o u r s e  (o r  e q u iv a l e n t ) .   A d v a n c e d  c a r d i a c  l i f e  s u p p o r t  c e r t i f i c a t io n  i s  
d e s i r a b l e .   T r a in in g ,  e x p e r i e n c e ,  a n d  c e r t i f i c a t io n  i n  r e l a t e d  h e a l th  c a r e  f i e ld s  
( r e g i s t e r e d  n u r s e ,  r e g i s t e r e d  r e s p i r a to ry  th e r a p i s t ,  c e r t i f i e d  p u lmo n a ry  fu n c t io n  
t e c h n i c i a n ,  e t c )  a r e  a l s o  d e s i r a b l e .   A  c e r t i f i e d  in d i v id u a l  s h o u ld  b e  r e a d i ly  a v a i l a b l e  to  
r e s p o n d  i f  n e e d e d .  
4 . Ph y s i c i a n s  a r e  n o t  r e q u i r e d  to  b e  p r e s e n t  d u r in g  a l l  t e s t s .   Th e  p h y s i c i a n  o rd e r in g  th e  
t e s t  o r  s u p e rv i s in g  a  l a b o r a to ry  p h y s i c i a n  m a y  d e c id e  w h e th e r  p h y s i c i a n  a t t e n d a n c e  a t  a  s p e c i f i c  t e s t  i s  r e q u i r e d .  
R e a s o n s  fo r  imm e d i a t e ly  s to p p in g  a  6MWT  in c lu d e  th e  fo l low in g :  (1 )  c h e s t  p a in ,  (2 )  
in to l e r a b l e  d y s p n e a ,  (3 )  l e g  c r amp s ,  (4 )  s t a g g e r in g ,  (5 )  d i a p h o r e s i s ,  a n d  (6 )  p a l e  o r  a s h e n  
a p p e a r a n c e .  
T e c h n i c i a n s  mu s t  b e  t r a in e d  to  r e c o g n i z e  th e s e  p ro b l em s  a n d  th e  a p p ro p r i a t e  r e s p o n s e s .   I f  a  
t e s t  i s  s to p p e d  fo r  a n y  o f  th e s e  r e a s o n s ,  th e  s u b j e c t  s h o u ld  s i t  o r  l i e  s u p in e  a s  a p p ro p r i a t e  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  7 1  d e p e n d in g  o n  th e  s e v e r i ty  o r  th e  e v e n t  a n d  th e  t e c h n i c i a n ’ s  a s s e s sm e n t  o f  th e  s e v e r i ty  o f  th e  
e v e n t  a n d  th e  r i s k  o f  s y n c o p e .  
Equ ipm en t  in  th e  V i c in i ty 
1 . O2 s a tu r a t io n  e q u ipm e n t  +  fo r e h e a d  p ro b e s .  
2 . C o u n td ow n  t im e r  o r  s to pw a t c h . 
3 . M e c h a n i c a l  l a p  c o u n t e r . 4 . Tw o  sm a l l  c o n e s  to  m a rk  th e  tu rn a ro u n d  p o in t s . 5 . A  c h a i r  th a t  c a n  b e  e a s i ly  mo v e d  a lo n g  th e  w a lk in g  c o u r s e . 6 . W o rk s h e e t s . 7 . A  s o u r c e  o f  o x y g e n . 8 . T e l e p h o n e .  9 . A u tom a t e d  e l e c t ro n i c  d e f ib r i l l a to r . 
Sub j e c t  P r epa r a t ion 
1 . C om fo r t a b l e  c lo th in g  s h o u ld  b e  w o rn . 2 . A p p ro p r i a t e  s h o e s  fo r  w a lk in g  s h ou ld  b e  w o rn  p r e f e r a b ly  th e  s am e  p a i r  fo r  e a c h  t e s t .  3 . A  s u b j e c t  s h o u ld  u s e  h i s  o r  h e r  u s u a l  w a lk in g  a id s  d u r in g  th e  t e s t  ( c a n e ,  w a lk e r ,  e t c ) . 
4 . Th e  s u b j e c t ’ s  u s u a l  m e d i c a l  r e g im e n  s h o u ld  b e  c o n t in u e d  a n d  s tu d y  d ru g  t a k e n  in  th e  
mo rn in g  b e fo r e  th e  c omm e n c em e n t  o f  th e  6MWT .  
5 . A  l ig h t  m e a l  i s  a c c e p t a b l e  b e fo r e  e a r ly  mo rn in g  o r  e a r ly  a f t e rn o o n  t e s t s . 
6 . Su b j e c t s  s h o u ld  n o t  h a v e  e x e r c i s e d  v ig o ro u s ly  w i t h in  2  h o u r s  o f  b e g in n in g  th e  t e s t .  
M e a su r em en t s 
1 . R e p e a t  t e s t in g  s h o u ld  b e  p e r fo rm e d  a b o u t  th e  s am e  t im e  o f  da y  to  m in im i z e  in t r a - d a y  
v a r i a b i l i ty .  
2 . A  “w a rm- u p ”  p e r io d  b e fo r e  th e  t e s t  s h o u ld  n o t  b e  p e r fo rm e d .  
3 . Th e  s u b j e c t  s h o u ld  s i t  a t  r e s t  in  a  c h a i r ,  lo c a t e d  n e a r  th e  s t a r t in g  p o s i t io n ,  fo r  a t  l e a s t  
1 0  m inu t e s  b e fo r e  th e  t e s t  s t a r t s .   D u r in g  th i s  t im e ,  c h e c k  fo r  c o n t r a in d i c a t io n s  a n d  
m a k e  s u r e  th a t  c lo th in g  a n d  s h o e s  a r e  a p p ro p r i a t e .   R e c o rd  a l l  p e r t in e n t  in fo rm a t io n  
s u r ro u n d in g  th e  t e s t  ( i e ,  s t a r t in g  lo c a t io n ,  l e n g th  o f  h a l lw a y ,  d i r e c t io n  th e  s u b j e c t  w i l l  
b e  w a lk in g ,  t im e  o f  t e s t ,  s u b j e c t ’ s  g e n e r a l  c o n d i t io n / f e e l in g  o n  th e  d a y  o f  th e  t e s t ,  a n d  
a n y  o th e r  p h y s i c a l  o r  m e d i c a l  in fo rm a t io n  th a t  m a y  p o t e n t i a l ly  in f lu e n c e  th e  r e s u l t s  o f  th e  t e s t ) .  
4 . Su b j e c t s  w h o  r e q u i r e  s u p p l em e n t a l  o x y g e n  mu s t  b r e a th e  a  s t a b l e  o x y g e n  d o s e  fo r  a t  
l e a s t  1 5  m inu t e s  p r io r  to  th e  m e a s u r em e n t  o f  SpO
2 a n d  u n t i l  th e  e n d  o f  th e  6MWT  ( s e e  
b e low  fo r  SpO 2  r e q u i r em e n t s ) .   I t  i s  c r i t i c a l  th a t  i f  o x y g e n  w a s  u t i l i z e d  d u r in g  th e  
s c r e e n in g  6MWT s ,  th a t  i t  b e  u t i l i z e d  d u r in g  a l l  s u b s e q u e n t  o n - s tu d y  t e s t s  a n d  th a t  i t  i s  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  7 2  d e l iv e r e d  in  th e  s am e  m a n n e r  w i th  th e  s am e  f low .   N o t e  w h e th e r  th e  o x im e t e r  s ig n a l  
q u a l i ty  i s  a c c e p t a b l e . 
5 . S e t  th e  l a p  c o u n t e r  to  0  a n d  th e  t im e  to  6 m inu t e s .   A s s emb l e  a l l  n e c e s s a ry  e q u ipm e n t  
( l a p  c o u n t e r ,  t im e r ,  w o rk s h e e t s ,  e t c . )  a n d  mo v e  to  t h e  s t a r t in g  p o in t .  
6 . In s t ru c t  th e  s u b j e c t  a s  fo l low s :  
The  o b j e c t  o f  th i s  t e s t  i s  to  w a l k  a s  fa r  a s  p o s s ib l e  f o r  6  m in u t e s .   Yo u  w i l l  w a l k  b a c k  a n d  
fo r th  in  th i s  h a l lw a y .   S i x  m in u t e s  i s  a  lo n g  t im e  to  w a l k ,  s o  y o u  w i l l  b e  e x e r t in g  y o u r s e l f .   
Yo u  w i l l  p r o b a b l y  g e t  o u t  o f  b r e a th  o r  b e c om e  e x h a u s t e d .   Yo u  a r e  p e rmi t t e d  to  s low  d ow n ,  to  s to p ,  a n d  to  r e s t  a s  n e c e s s a r y .   Yo u  m a y  l e a n  a g a in s t  th e  w a l l  w h i l e  r e s t in g ,  b u t  r e s um e  w a l k in g  a s  s o o n  a s  y o u  a r e  a b l e .  
Yo u  w i l l  b e  w a l k in g  b a c k  a n d  fo r th  a r o u n d  th e  c o n e s .   Yo u  s h o u ld  p i v o t  b r i s k l y  a r o u n d  th e  
c o n e s  a n d  c o n t in u e  b a c k  th e  o th e r  w a y  w i th o u t  h e s i ta t io n .   N ow  I ’m  g o in g  to  s h ow  y o u .   P l e a s e  w a t c h  th e  w a y  I  tu r n  w i th o u t  h e s i ta t io n . 
D emo n s t r a t e  b y  w a lk in g  o n e  l a p  y o u r s e l f .   W a lk  a n d  p iv o t  a ro u n d  a  c o n e  b r i s k ly . 
A r e  y o u  r e a d y  to  d o  th a t?  I  am  g o in g  to  u s e  th i s  c o u n t e r  to  k e e p  t r a c k  o f  th e  n um b e r  o f  la p s  y o u  c om p l e t e .   I  w i l l  c l i c k  i t  e a c h  t im e  y o u  tu r n  a r o u n d  a t  th i s  s ta r t in g  l in e .   R em em b e r  th a t  th e  o b j e c t  i s  to  w a l k  AS  FAR  AS  PO S S IBLE  fo r  6 m in u t e s ,  b u t  d o n ’ t  r u n  o r  jo g .  
S ta r t  n ow  o r  w h e n e v e r  y o u  a r e  r e a d y . 
7 . Po s i t io n  th e  s u b j e c t  a t  th e  s t a r t in g  l in e .   Y o u  s h o u l d  a l s o  s t a n d  n e a r  th e  s t a r t in g  l in e  
d u r in g  th e  t e s t .   D o  n o t  w a lk  w i th  th e  s u b j e c t .   A s  s o o n  a s  th e  s u b j e c t  s t a r t s  to  w a lk ,  
s t a r t  th e  t im e r .  
8 . D o  n o t  t a lk  to  a n y o n e  d u r in g  th e  w a lk .   U s e  a n  e v e n  to n e  o f  v o i c e  w h e n  u s in g  th e  
s t a n d a rd  p h r a s e s  o f  e n c o u r a g em e n t .   W a t c h  th e  s u b j e c t .   D o  n o t  g e t  d i s t r a c t e d  a n d  lo s e  
c o u n t  o f  th e  l a p s .   E a c h  t im e  th e  p a r t i c ip a n t  r e tu rn s  to  th e  s t a r t in g  l in e ,  c l i c k  th e  l a p  
c o u n t e r  o n c e  (o r  m a rk  th e  l a p  o n  th e  w o rk s h e e t ) .   L e t  th e  p a r t i c ip a n t  s e e  y o u  d o  i t .  
Ex a g g e r a t e  th e  c l i c k  u s in g  b o d y  l a n g u a g e ,  l ik e  u s i n g  a  s to pw a t c h  a t  a  r a c e . 
A f t e r  th e  f i r s t  m in u t e ,  t e l l  th e  s u b j e c t  th e  fo l low in g  ( in  e v e n  to n e s ) :  Yo u  a r e  d o in g  w e l l .   Yo u  
h a v e  5  m in u t e s  to  g o . 
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  7 3  W h e n  th e  t im e r  s h ow s  4 m inu t e s  r em a i n in g ,  t e l l  th e  s u b j e c t  th e  fo l low in g :  K e e p  u p  th e  g o o d  
w o r k .   Yo u  h a v e  4 m in u t e s  to  g o . 
W h e n  th e  t im e r  s h ow s  3 m inu t e s  r em a in in g ,  t e l l  th e  s u b j e c t  th e  fo l low in g :  Yo u  a r e  d o in g  w e l l .   
Yo u  a r e  h a l fw a y  d o n e . 
W h e n  th e  t im e r  s h ow s  2 m inu t e s  r em a in in g ,  t e l l  th e  s u b j e c t  th e  fo l low in g :  K e e p  u p  th e  g o o d  
w o r k .   Yo u  h a v e  o n l y  2 m in u t e s  l e f t . 
W h e n  th e  t im e r  s h ow s  1 m inu t e  r em a in in g ,  t e l l  th e  s u b j e c t :  Yo u  a r e  d o in g  w e l l .   Yo u  h a v e  
o n l y  1  m in u t e  to  g o . 
D o  n o t  u s e  o th e r  w o rd s  o f  e n c o u r a g em e n t  (o r  b o d y  l a n g u a g e )  to  s p e e d  th e  s u b j e c t  u p . I f  th e  s u b j e c t  s to p s  w a lk in g  d u r in g  th e  t e s t  a n d  n e e d s  a  r e s t ,  s a y  th i s :  Yo u  c a n  l e a n  a g a in s t  th e  
w a l l  i f  y o u  w o u ld  l i k e :  th e n  c o n t in u e  w a l k in g  w h e n e v e r  y o u  f e e l  a b l e .  D o  n o t  s to p  th e  t im e r .   
I f  th e  s u b j e c t  s to p s  b e fo r e  th e  6  m inu t e s  a r e  u p  a n d  r e fu s e s  to  c o n t in u e  (o r  y o u  d e c id e  th a t  
th e y  s h o u ld  n o t  c o n t in u e ) ,  w h e e l  th e  c h a i r  o v e r  fo r  th e  s u b j e c t  to  s i t  o n ,  d i s c o n t in u e  th e  w a lk  a n d  n o t e  o n  th e  w o rk s h e e t  th e  d i s t a n c e ,  th e  t im e  s t o p p e d ,  a n d  th e  r e a s o n  fo r  s to p p in g  p r em a tu r e ly .  
W h e n  th e  t im e r  i s  1 5  s e c o n d s  f rom  c omp l e t io n ,  s a y  th i s :  In  a  mom e n t  I ’m  g o in g  to  t e l l  y o u  to  
s to p .   W h e n  I  d o ,  ju s t  s to p  r ig h t  w h e r e  y o u  a r e  a n d  I  w i l l  c om e  to  y o u . 
W h e n  th e  t im e  r in g s  (o r  b u z z e s ) ,  s a y  th i s :  S to p !   W a lk  o v e r  to  th e  s u b j e c t .  C o n s id e r  t a k in g  
th e  c h a i r  i f  th e y  lo o k  e x h a u s t e d .   M a rk  th e  s p o t  w h e r e  th e y  s to p p e d  b y  p l a c in g  a  b e a n  b a g  o r  a  
p i e c e  o f  t a p e  o n  th e  f lo o r .  
9 . R e c o rd  th e  n umb e r  o f  l a p s  f rom  th e  c o u n t e r  (o r  t i c k  m a rk s  o n  th e  w o rk s h e e t ) . 
1 0 . R e c o rd  th e  a d d i t io n a l  d i s t a n c e  c o v e r e d  ( th e  n umb e r  o f  m e t e r s  in th e  f in a l  p a r t i a l  l a p )  
u s in g  th e  m a rk e r s  o n  th e  w a l l  a s  d i s t a n c e  g u id e s  (o r  u s e  a  t a p e  m e a s u r e ) .  C a l c u l a t e  th e  
to t a l  d i s t a n c e  w a lk e d ,  ro u n d in g  to  th e  n e a r e s t  m e t e r ,  a n d  r e c o rd  i t  o n  th e  w o rk s h e e t .  
1 1 . C o n g r a tu l a t e  th e  s u b j e c t  o n  g o o d  e f fo r t  a n d  o f f e r  a  d r in k o f  w a t e r .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  7 4  CONTRA IND ICAT IONS   
A b s o lu t e  c o n t r a in d i c a t io n s  fo r  th e  6MWT  in c lu d e  th e  fo l low in g :  u n s t a b l e  a n g in a  d u r in g  th e  p r e v io u s  mo n th  a n d  my o c a rd i a l  in f a r c t io n  d u r in g  t h e  p r e v io u s  mo n th .   R e l a t iv e  
c o n t r a in d i c a t io n s  in c lu d e  a  r e s t in g  h e a r t  r a t e  o f  mo r e  th a n  1 2 0 ,  a  s y s to l i c  BP  o f  mo r e  th a n  
1 8 0  mmH g ,  a n d  a  di a s to l i c  BP  o f  mo r e  th a n  1 0 0  mmH g .   
Su b j e c t s  w i th  a n y  o f  th e s e  f in d in g s  s h o u ld  b e  r e f e r r e d  to  th e  p h y s i c i a n  o rd e r in g  o r  s u p e rv i s in g  
th e  t e s t  fo r  in d iv id u a l  c l in i c a l  a s s e s sm e n t  a n d  a  d e c i s io n  a b o u t  th e  c o n d u c t  o f  th e  t e s t .   Th e  
r e s u l t s  f rom  a  r e s t in g  e l e c t ro c a rd io g r am  d o n e  d u r i n g  th e  p r e v io u s  6  mo n th s  s h o u ld  a l s o  b e  
r e v i ew e d  b e fo r e  t e s t in g .   S t a b l e  e x e r t io n a l  a n g in a  i s  n o t  a n  a b s o lu t e  c o n t r a in d i c a t io n  fo r  a  6MWT ,  b u t  s u b j e c t s  w i th  th e s e  s ymp tom s  s h o u ld  p e r fo rm  th e  t e s t  a f t e r  u s in g  th e i r  a n t i a n g in a  m e d i c a t io n ,  a n d  r e s c u e  n i t r a t e  m e d i c a t io n  s h o u ld  b e  r e a d i ly  a v a i l a b l e .   
R a t iona l e  
Su b j e c t s  w i th  th e  p r e v io u s ly  m e n t io n e d  r i s k  f a c to r s  m a y  b e  a t  in c r e a s e d  r i s k  fo r  a r rh y thm i a s  o r  c a rd io v a s c u l a r  c o l l a p s e  d u r in g  t e s t in g .   H ow e v e r ,  e a c h  s u b j e c t  d e t e rm in e s  th e  in t e n s i ty  o f  th e i r  e x e r c i s e ,  a n d  th e  t e s t  (w i th o u t  e l e c t ro c a rd io g r am  mo n i to r in g )  h a s  b e e n  p e r fo rm e d  in  
th o u s a n d s  o f  o ld e r  p e r s o n s  a n d  th o u s a n d s  o f  s u b j e c t s  w i th  h e a r t  f a i lu r e  o r  c a rd iomy o p a th y  
w i th o u t  SAEs .   Th e  c o n t r a in d i c a t io n s  l i s t e d  p r e v io u s ly  h e r e  w e r e  u s e d  b y  s tu d y  In v e s t ig a to r s  b a s e d  o n  th e i r  imp r e s s io n s  o f  th e  g e n e r a l  s a f e ty  o f  th e  6MWT  a n d  th e i r  d e s i r e  to  b e  p ru d e n t ,  b u t  i t  i s  u n k n ow n  w h e th e r  AEs  w o u ld  o c c u r  i f  s u c h  s u b j e c t s  p e r fo rm e d  a  6MWT ;  th e y  a r e ,  
t h e r e fo r e ,  l i s t e d  a s  r e l a t iv e  c o n t r a in d i c a t io n s .  
Un i t ed  Th e r ap eu t i c s  C o rpo r a t ion   ADP8 1 1- 0 0 7  P r o to c o l  Am endm en t  4  
 R a l in epa g  
V e r s ion  D a t e  1 5  M a y  2 0 1 9 C on f id en t ia l Pa g e  7 5  App end ix  2 Fun c t iona l  C la s s i f i c a t ion  o f  Pu lmona r y  Hyp e r t en s ion  M od i f i ed  A f t e r  Th e  
N ew  Y o rk  H e a r t  A s s o c ia t ion  Fun c t iona l  C la s s i f i c a t ion  A c c o rd ing  to  th e  
WHO  1 9 9 8 
W o r ld  H e a l th  O r g an i z a t ion  fun c t iona l  a s s e s sm en t  c la s s i f i c at ion   
C la s s  I :  Su b j e c ts  w i th  p u lmo n a ry  h y p e r t e n s io n  (PH )  b u t  w i th o u t  r e s u l t in g  l im i t a t io n  o f  
p h y s i c a l  a c t iv i ty .   O rd in a ry  p h y s i c a l  a c t iv i ty  d o e s  n o t  c a u s e  u n d u e  d y s p n e a  o r  
f a t ig u e ,  c h e s t  p a in ,  o r  n e a r  s y n c o p e .  
C la s s  I I :  Su b j e c ts  w i th  PH  r e s u l t in g  in  s l ig h t  l im i t a t io n  o f  p h y s i c a l  a c t iv i ty .   Th e y  a r e  
c om fo r t a b l e  a t  r e s t .   O rd in a ry  p h y s i c a l  a c t iv i ty  c a u s e s  u n d u e  d y s p n e a  o r  
f a t ig u e ,  c h e s t  p a in ,  o r  n e a r  s y n c o p e .  
C la s s  I I I :  Su b j e c ts  w i th  PH  r e s u l t in g  in  m a rk e d  l im i t a t io n  o f  p h y s i c a l  a c t iv i ty .   Th e y  a r e  
c om fo r t a b l e  a t  r e s t .   L e s s  th a n  o rd in a ry  a c t iv i ty  c a u s e s  u n d u e  d y s p n e a  o r  f a t ig u e ,  c h e s t  p a in ,  o r  n e a r  s y n c o p e .  
C la s s  IV :  Su b j e c ts  w i th  PH  w i th  in a b i l i ty  to  c a r ry  o u t  a n y  p h y s i c a l  a c t iv i ty  w i th o u t  
s ymp tom s .   Th e s e  s u b j e c ts  m a n i f e s t  s ig n s  o f  r ig h t - h e a r t  f a i lu r e .   D y s p n e a  
a n d /o r  f a t ig u e  m a y  e v e n  b e  p r e s e n t  a t  r e s t .   D i s c om fo r t  i s  in c r e a s e d  b y  a n y  
p h y s i c a l  a c t iv i ty . 
Ad ap t ed  f r om  g u i d e l i n e s  f o r  t h e  d i ag n o s i s  a n d  t r e a tm en t  o f  p u lm o n a r y  h y p e r t en s i o n1 7  
 